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1.  Colon tuMour develoPMent
1.1.  A roadmap of cancer
Despite the huge heterogeneity of cancer, even 
between tumours from the same histological 
subtype, it has been proposed that there are 
only six general features any cell needs to 
acquire in order to become a cancer cell [1]. Like 
a roadmap that includes inevitable roadblocks. 
These features or roadblocks are: insensitivity to 
anti-growth signals, self-sufficiency in growth 
signals, evading apoptosis, limitless replicative 
potential, sustained angiogenesis, and tissue 
invasion and metastasis.
The roadmap does go with a manual. There 
are many different ways in disrupting cell signal-
ling pathways in order to get to the same point; 
some are shortcuts, others require multiple 
steps just to cross one roadblock (see figure 1). 
Which steps may be taken will be explained in 
paragraph 1.2. And there is no necessary order 
of the roadblocks to be taken. The final course 
is tumour specific and probably depends on the 
cell’s constitutive biology as well as its micro-
environment. For details, see also paragraph 1.3.
For colorectal cancer, one possible route 
which partly contains the roadblocks men-
tioned above has already been mapped (see 
figure 1) [2]. This route parallels the develop-
ment of distinct histological features of the 
majority of colon tumours: the progression from 
normal epithelium - to aberrant crypt foci - to 
polyps (early, intermediate and late adenoma) 
- to carcinoma. That unique feature makes colon 
cancer nearly an in vivo cancer model of its own, 
which is probably why the route of colon cancer 
has been studied so well.
Many of the roadblocks were originally iden-
tified by in vitro cell culture experiments and 
animal models. Meanwhile most have been 
confirmed in human tumour tissues. However, 
the roadmap still has its blind spots, for instance 
on micro-environment interactions, and future 
research likely will identify other roadblocks to 
be cleared by developing tumours including 
those of the colon. In this thesis we focus on the 
need for tumour cells to evade recognition and 
destruction by the immune system.
1.2.  Genetic instability and clonal 
selection: how to cross roadblocks?
Tumours may be described as accumulations 
of cells exhibiting acquired disruptions of cell 
signalling pathways leading to loss of (normal) 
growth control. Both qualitative as well as quan-
titative changes in the protein components may 
account for the compromised functionality of 
signal transduction pathways in cancer cells. 
These changes may result from alterations at the 
genomic, transcriptional, translational or post-
translational level. We will focus on those at the 
genomic and transcriptional level.
Genomic alterations comprise various types 
of irreversible changes in the content and orga-
nization of the genetic information of cells. For 
instance numerical and structural chromosome 
The accumulation of genetic defects is a hallmark of cancer, and its detailed characterization has 
illuminated potential therapeutic targets and will keep on providing those. Yet, the identification 
of distinct colon tumour entities makes it necessary to adjust therapeutic strategies. One promising 
therapeutic strategy is the employment of the adaptive immune system in eradicating host tumour 
cells. However, its feasibility in eradicating human cancer is not well known as tumour escape mecha-
nisms have not been studied in detail. In this chapter, current concepts of colon tumour develop-
ment and tumour immunology are discussed and an outline of this thesis is given.
Jan-Willem Dierssen BW druk 3.indd   8 08-09-10   10:17
General Introduction 9
alterations have been describes almost a cen-
tury ago. Only much later alterations at the sin-
gle gene level were identified and genes altered 
in cancer were classified in two main categories: 
oncogenes and tumour suppressor genes [3, 4].
Distinct types of genetic alterations have 
been identified in cancers. Normally, these 
alterations would activate specific error detec-
tion systems that would either repair them or, 
if unsuccessful, arrest further cell cycle pro-
gression. Classically, they can be divided into 
4 categories: subtle sequence changes, altera-
tions in chromosome or chromosome fragment 
number, chromosome translocations, and gene 
amplification [5]. In colon cancer, the former two 
have been most frequently studied. Put simply, 
genetic instability in colon cancer may manifest 
itself as either subtle single gene changes or 
as large chromosomal aberrations. Grossly, the 
former case has been associated with micro-
satellite instability (MIN), the latter case is also 
denoted as chromosomal instability (CIN). MIN 
tumour cell DNA content usually is conserved in 
the peri-diploid state, whereas in CIN tumours, 
tumour cells’ DNA content is altered leading to 
a state of aneuploidy [2]. Interestingly, in colon 
cancer, these two manifestations seem to (at 
least partly) exclude each other.
The level of gene transcription is influenced 
by quantity of transcription factors and micro 
RNAs, or by altered DNA accessibility for these. 
Accessibility is determined by the state of DNA 
A
normal
epithelium
dysplastic 
ACF
early 
adenoma
intermed
adenoma
late
adenoma
carcinoma metastasis
APC k-ras DCC p53
B
self-suciency in growth signals
insensitivity to anti-growth signals
limitless replicative potential
sustained angiogenesis
evading apoptosis
tissue invasion and metastasis
C
Figure 1. The roadmap to colon cancer.
The six features of cancer cell biology shown in C, need to be acquired. However, the order of acquisition 
may differ between different tumours, as illustrated in A. The seven-step model of colorectal cancer nicely 
fits to this model, as shown in B. Adapted from [1] and [2].
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hyper- and hypomethylation, and histone modi-
fications [6]. The epigenetic state can be passed 
on to daughter cells. The epigenetic state can be 
passed on to daughter cells and the accumula-
tion of both genetic and epigenetic changes is 
a typical characteristic of tumour development.
As cancer is not the plan of an evil genius 
but rather the unfortunate outcome of chance 
events cells do not have a will of their own, nor 
do tumours wish to become destroyers of their 
host; they are simply the survivors of a Dar-
winian micro-evolution [7]. The acquisition of 
necessary features therefore are the result of a 
multistep progression process, in which – like 
in macro-evolution –mutations may provide a 
selective growth advantage leading to clonal 
expansion of daughter cells and to clonal diver-
gence. Furthermore, a tumour comprises in 
fact a collection of heterogeneous cell popula-
tions, but may in the long run be overgrown by 
a population that is best adapted to its micro-
environment [8].
Is has been a debate for decades whether 
genetic instability is the cause or effect of neo-
plastic transformation, and the same discussion 
may be repeated for epigenetic mechanisms 
[9]. Do tumours need increased mutability as 
a driving force, or is it merely an accumulation 
of normally occurring errors derived by clonal 
expansion? Is genetic instability a state or rate? 
Mathematical models showed that the number 
of mutations found in tumours is too great to 
be explained by basal mutation rate [10]. How-
ever these models did not take into account the 
effect of clonal selection and expansion, nor the 
fact that cell turnover exceeds tumour growth. 
Such models show that an increased mutation 
rate may merely be a side effect, not a neces-
sity [11]. It has also been argued that the level 
of aneuploidy itself contributes to malignant 
transformation. By increasing the expression of 
thousands of genes at once, this might lead to 
the necessary qualitative changes of cell physi-
ology and metabolism [12]. However, as men-
tioned above, not all neoplastic cells are aneu-
ploid. Finally, it is stated that increasing genetic 
instability would be detrimental for a tumour, 
as the chances of deleterious mutations would 
exceed the chance of growth advantage. Yet, 
evolutionary models have shown exactly the 
opposite. Enlarging its diversity a cell population 
increases its chance of surviving micro-environ-
mental changes and genetic instability achieves 
just that [13]. Besides, clones giving birth to non 
viable progenitors will be overgrown by more 
successful clones. Darwinian selection results 
automatically in a ‘just right’ rate of instability 
[14]. So as the state or rate question remains, we 
conclude that tumours have two ‘vehicles’ avail-
able during their roadtrip, genetic instability and 
clonal expansion, and they probably use both.
1.3.  Tumour development and 
metastasis: which order of 
appearance?
Clinically, metastases are considered the end 
stage of cancer. Dissemination increases the 
tumour chances to survive medical therapy anni-
hilation and therefore commonly causes cancer 
patients’ death. However as discussed in para-
graph 1.2, tumours can not anticipate to a chang-
ing environment. Therefore metastasis should be 
considered as a side effect of the micro-evolu-
tionary process by which tumour cells acquire 
adaptations to the local micro-environment 
and vice versa. So what determines metastatic 
progression and when is it acquired? Different 
theories exist, which we will discuss hereinafter.
• The progression model. Ever since Nowell’s 
theory of step-wise evolution, this classi-
cal model foresees a step by step progres-
sion driven by clonal expansion of random 
mutants, which was elegantly implemented 
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in the multi-step model of colon cancer (see 
paragraph 1.1), where metastasis confines the 
last step [2, 7]. Considering tumour hetero-
geneity, the subpopulation with metastatic 
capacity would actually not need to contain 
the majority of tumour cells; in fact, one may 
expect it not to be so, since the cells tends to 
disseminate and the acquisition of metastatic 
prone mutations would not likely lead to 
growth advantages at the primary site.
• Cancer stem cells. Tumours comprise hetero-
geneous cell populations and may contain a 
subpopulation of stem cells that - in contrast 
to other populations - has unlimited repli-
cative potential. Only these cells would be 
capable of forming new tumours, even at dis-
tant locations, as they can self-renew infinitely 
[15].
• Alternative pathways. As addressed in para-
graph 1.1, the roads toward the acquisition 
of proliferative benefits are many. Thus, there 
are multiple alternative genetic paths that 
lead to tumour formation [16]. According 
to this model, some combinations of muta-
tions yield a high tendency to metastasize, 
whereas other combinations would not. This 
implies that metastatic potential may already 
be defined early during tumorigenesis and 
does not result from mutations or epigenetic 
changes involving specific genes.
• Genetic predisposition model. This model 
pleads for the contribution of the allelic com-
position of the host genome [17, 18]. Subtle 
changes in gene functions, already present 
before tumour formation, may determine the 
metastatic potential. Interestingly, this may 
also predict that the micro-environment, both 
at primary and distant sites, fills a principal 
part in tumour development.
We may conclude that we still have insufficient 
insight in the factors driving the metastatic 
process. This is illustrated by the fact that despite 
huge efforts so far only few ‘metastasis’ genes 
have been identified. Furthermore, it remains 
puzzling that disseminating tumour cells can be 
detected even at early stages of tumour develop-
ment which does not necessarily predict distant 
metastasis [15, 19, 20]. Finally, it is remarkable 
that metastatic potential may be predicted by 
the gene expression profile of bulk tumour tis-
sue including multiple heterogeneous tumour 
subsets and a significant share of tumour stroma 
[21, 22].
2.  MultiPle Colon CanCer 
syndroMes and roadMaPs
The identification of hereditary cancer syn-
dromes has contributed largely to the identi-
fication of tumour suppressor genes. Based on 
Knudson’s two hit model, carriers of heterozy-
gous germline mutations have such a raised 
risk of developing cancer that it is inherited 
in an autosomal dominant way [23]. Another 
hereditary colon cancer syndrome that has been 
identified, the MUTYH-associated polyposis, is 
inherited in an autosomal recessive way. Inter-
estingly, genetic and genealogical studies have 
revealed that the increased risk only applies for 
specific tissues, or even specific tumour types. 
This issue remains a puzzle. The syndromes asso-
ciated with increased risk of colon tumours are 
displayed in table 1.
Sporadically developing colon tumours, i.e. 
non-syndrome associated (constituting almost 
95% of all colon tumours), also bear mutations 
of the colon cancer syndromes associated genes, 
and their development may parallel the heredi-
tary counterpart in some way. Classically, they 
have been assigned to the tumorigenic pathway 
of either of the two most commonly studied 
colon cancer syndromes: familial adenomatous 
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polyposis (FAP) and Lynch syndrome (previously 
depicted hereditary non-polyposis colorectal 
cancer). The former, FAP, is characterized by muta-
tions of APC [2]. Normally, APC protein captures 
free cytoplasmic β-catenin in order to have it 
destroyed. β-catenin is involved in at least two 
distinct cellular processes: cellular adhesion 
(through E-cadherin, and important in the normal 
crypt organization of the colon epithelium), and 
the Wnt signalling pathway leading to transcrip-
tion of, amongst others, cell cycle promoters 
c-myc and cyclin D1 [25, 26]. Both processes may 
be involved in the APC gatekeeper function in 
colon tumours. Patients develop hundreds of ade-
nomatous polyps, of which some may develop 
into the carcinoma stage. The Lynch syndrome 
is caused by germline mutations of members of 
the DNA mismatch repair family hMLH1, hMSH2, 
hMSH6, and PMS2. Mutation carriers also have an 
increased risk of developing endometrial carci-
noma and other lesions, but do not develop many 
polyps. Due to mismatch repair defects these 
tumours are characterized by a large accumula-
tion of subtle DNA sequence changes, preferably 
of microsatellite repeats, referred to as micro-
satellite instability (MSI). Approximately 60% of 
Neoplastic lesions Inheritance Syndrome OMIM Genes 
responsible
colorectal cancer without 
polyps
AD Lynch syndrome or Hereditaru 
non-polyposis colorectal 
cancer (HNPCC)
#120435 hMLH1, hMLH2, 
hMSH6, hPMS2
 
colorectal cancer with 
adenomatous polyps AD
Familial adenomatous 
polyposis (FAP) #175100 APC
colorectal cancer with 
hamartomatous/mixed/
hyperplastic polyps
AD Birt-Hogg-Dube syndrome* #135150 FLCN
AD Cowden disease (CD)* #158350 PTEN
AD
Hereditary mixed polyposis 
syndrome 1* %601228 #15q15.2-q22.1
AD
Hyperplastic polyposis 
syndrome* unassigned
AD Juvenile polyposis (JPS) #174900 SMAD4, BMPR1A
AD Juvenile polyposis/hereditary 
hemorrhagic telangiectasia 
syndrome (JPHT)*
#175050 SMAD4
AD Peutz Jegher’s syndrome (PJS) #175200 STK11
colorectal cancer with 
adenomatous, serrated 
adenoma and hyperplastic 
polyps
AR
MUTYH-associated polyposis 
(MAP) #608456 MUTYH
       
table 1. Clinical syndromes with an increased risk of colorectal cancer. Adapted from [24]. OMIM annota-
tion as used and explained on http://www.ncbi.nlm.nih.gov/omim. * colorectal cancer risk not clear
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sporadically developed tumours develop from a 
polyp and bear somatic mutations of APC. How-
ever, in 15% of consecutive series of colorectal 
cancer MSI is observed, mainly due to epigenetic 
knock-out of the mismatch repair gene hMLH1 
[27].
During embryogenesis, the mid-gut develops 
into the proximal colon (cecum, ascending colon 
and two third of the transverse colon), whereas 
the hindgut develops to the distal colon (one 
third of transverse colon, descending colon, and 
rectum). These separate embryological origins 
have distinct blood- and lymph supply and drain-
age, e.g. the micro-vascular volume is greater 
in the proximal colon. The regions are exposed 
to different dietary and digestive constitutes, 
pH conditions and microbial colonization [28]. 
Therefore, one may suggest that tumours arising 
from the proximal (also called right-sided) colon 
differ from those of the distal colon. This is partly 
reflected in molecular tumour development. MSI 
tumours primarily develop in the proximal colon. 
Furthermore, especially within the proximal 
colon distinct subsets of carcinomas have been 
identified based on differences in morphology, 
microsatellite instability, (underlying germline) 
mismatch repair gene mutations, high or low fre-
quent CpG island hypermethylation, and KRAS 
and BRAF mutations [29].
The identification of multiple pathways of 
development pleas for distinct tumour entities 
even though they arise from the same organ and 
cell type. Indeed, subsets have been associated 
with distinct clinical features such as dissemina-
tion and chemotherapy response [30]. Unravel-
ling these differences is necessary to direct future 
therapeutic strategies of colon cancer effectively.
3.  tuMour iMMunology
3.1.  Immunosurveillance
Neoplasms develop from autologous cells and 
therefore intuitively one may think these would 
not evoke an immune response. Yet, the accu-
mulation of genetic aberrations during tumour 
development leads to numerous tumour spe-
cific antigens, which are potential targets of the 
adaptive immune system [31]. In fact, tumour 
immune control has already been proposed over 
a century ago [32] and has later been introduced 
as the immunosurveillance hypothesis [33]. Ini-
tially, the hypothesis could only be supported 
by studies on virally induced or allograft tumour 
development in immune compromised organ-
isms. It was not until the 1990s that increased 
risk ratios of developing sporadic tumours in 
immune compromised patients were shown to 
exist, although colorectal cancer is not typically 
frequent in such patients [34, 35]. Meanwhile, 
evidence for immunosurveillance has been 
backed up by the numerous tumour escape 
mechanisms that have been identified [36] as 
more knowledge is gained about the mecha-
nisms leading to proper adaptive (anti-tumour) 
immune responses, which will be discussed in 
the following paragraphs.
3.2.  Colon cancer immunity
A current model of colon cancer immunity is 
depicted in figure 2. It shows the key steps in 
the generation of a functional or non-functional 
immune responses to tumours. We will briefly 
discuss it here, and then explore several steps in 
more detail in the following paragraphs.
Tumour antigens are picked up from dying 
or dead tumour cells by dendritic cells. These 
sentinels (as one might consider them) will 
sequentially bring the antigens to nearby lymph 
nodes were they can activate cytotoxic T cells 
assisted by helper T cells through a process 
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called cross-presentation [37]. However, in order 
to do so, the sentinels must be awakened to an 
active state first, while searching the debris. Such 
awakening is caused by the local inflammatory 
environment, which is effectuated by the innate 
immune system; this is called the danger signal 
[38-40]. Without it, dendritic cells will only edu-
cate T cells to tolerate tumour antigens, leading 
to immune tolerance [41]. When tumour spe-
cific killer T cells are activated, they will migrate 
to, infiltrate and eventually kill tumour cells. 
They thereby represent clear selective forces of 
tumour development, a process referred to as 
immune editing [34]. The outcome of such is 
either tumour rejection or immune escape.
It is noteworthy to mention that consecu-
tively disseminating tumour cells may encoun-
ter quite different immune responses as they 
enter a completely different arena: the lymph 
and blood. However, this is beyond the scope of 
this introduction.
3.3.  Innate immune system and danger 
signal: an inflammation battlefield
Inflammation is the early physiological response 
to tissue damage. It is the first action of war. 
Furthermore, it may determine following attack 
modes, viz. the nature of adaptive immune 
responses. Therefore it is also referred to as the 
danger signal. If performed effectively inflam-
mation leads to tissue repair, growth and 
remodelling. Therefore a complex interplay of 
multiple units of the innate immune system 
army is needed. The units are directed towards 
the battlefield by signal molecules, including 
immune editing
activated dendritic cells
danger signal
!
tumour
lymph node
A
B
cytotoxic t cells
immature dendritic cells
immune tolerancetumour
lymph node
Figure 2. Model of cancer immunity. A. Tumour antigen pick up in the absence of danger signal leads to 
immune tolerance. B. In the presence of danger signal, activated dendritic cells will home to draining lymph 
nodes and there lead to activation of cytotoxic T cells, which will invade and attack the tumour. Adapted 
from [42].
Jan-Willem Dierssen BW druk 3.indd   14 08-09-10   10:17
General Introduction 15
cytokines, chemokines, growth factors and pro-
teases [43, 44].
At the front line are the neutrophils (who get 
there by regulating the expression of consecu-
tively selectins, integrins, cell-adhesion mol-
ecules, and, finally, proteases). Once arrived they 
will start ‘firing’ a considerable set of cytokines 
and chemokines. Eventually, this will recruit 
downstream effector cells and dictate the nature 
of an immune reaction.
The second movement involves the mono-
nuclear phagocytes. Entering battle as mono-
cytes they differentiate into either mature 
macrophages or immature dendritic cells (DCs). 
Mature macrophages produce the main body of 
growth factors and cytokines (the acute phase) 
and remodel the extracellular matrix by cleaning 
up (phagocytosis of dead cells and production 
of proteolytic enzymes) and by rebuilding (pro-
duction of matrix components and promoting 
angiogenesis and lymphangiogensis). Dendritic 
cells pick up antigens from the debris through 
various mechanisms and are essential in direct-
ing adaptive immune responses as discussed in 
paragraph 3.4.
Then the mast cells arrive which have stored 
various inflammatory mediators including his-
tamine, cytokines and lipid mediators such as 
prostaglandins and leukotrien. Once the mast 
cells are activated through the complement sys-
tem or by binding to immunoglobin E-antigen 
complexes these factors are secreted leading to 
clinical inflammation features, e.g. the increase 
of plasma into the tissue and consequent drain-
age of tissue fluids into lymph nodes.
Finally, fibroblasts take care of collagen 
deposition, epithelial cells reepithelialise while 
anti-inflammatory cytokines slowly evaporate 
the fog of war.
Normally, the intricately linked processes even-
tually fade out once the damage is repaired. 
Tumours however can be considered as chronic 
tissue damage like wounds that do not heal 
[45]. Paradoxically, as already known for over a 
century, chronic inflammation, f.e. inflammatory 
bowel disease, can also lead to neoplastic con-
version [46, 47]. Growth factors resulting from 
inflammation actually stimulate tumour growth 
(and even sometimes suppress immunity). Fur-
thermore, tumours also produce chemokines 
and cytokines, thereby directing inflammation 
themselves [43, 47]. Thus, inflammation actually 
serves a dual role in cancer: signalling danger 
and activating the immune system on the one 
hand, on the other hand growth stimulation and 
tissue remodeling [43, 48].
3.4.  Cross-presentation: intelligence at 
the battlefield
The regional lymph nodes are ‘command cen-
tres’ of the adaptive immune response. It is here 
that molecular information about the ‘enemy’, 
antigen, is delivered by antigen presenting 
cells. This is called cross-presentation. Occasion-
ally a ‘deserter’ of the enemy troops may enter 
the ‘camp’ by itself which could also supply the 
lymph node with information. However, it has 
been shown that this process in highly inef-
ficient and does not lead to proper immune 
response [38, 49]. There are actually three cell 
types that are able to pick up and show foreign 
antigens to effector cells, macrophages, B cells 
and DCs, but only the latter are able to pick up 
intracellular antigens and are able to activate 
naïve T cells.
As they are summoned at the site of inflam-
mation, immature DCs start collecting antigens 
through various mechanisms: through opsoni-
sation of apoptotic bodies, through receptors 
of (tumour) heat shock proteins that bound to 
(tumour) intracellular antigens, through recep-
tors of immunoglobins bound to antigens, or 
by pinocytosis [50]. During the collection of 
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antigens, dendritic cells develop into mature 
dendritic cells. This educational process, directed 
by earlier mentioned danger signals and possi-
bly other factors, is important for the outcome 
of cross-presentation later on.
Once mature and forced by the increasing 
lymph flow, DCs migrate to local lymph nodes 
where they spread throughout the cortex. There 
they will encounter naïve T cells who continu-
ously pass by through high endothelial venules 
(HEVs). The first encounter is managed by tran-
sient binding of cell adhesion molecules. Now, 
T cells have time to sample a large number of 
antigens as they are presented on the DC sur-
face by human leukocyte antigen family mol-
ecules (HLA, which are responsible for antigen 
presentation at every immune cell encounter, 
and will be discussed extensively in the next 
paragraphs). If a T cell recognizes an antigen pre-
sented (by binding of its unique T cell receptor 
to the HLA:antigen complex), it leads to stabilisa-
tion of the cell adhesion up to days, which gives 
the DC an opportunity to educate the naive 
T cell about the nature of the antigen, as itself 
was taught during maturisation. This is called co-
stimulation and numerous factors are involved 
in this co-stimulatory dialogue, including CD4/
CD8, B7:CD28, CD40:CD40L, 4-1BBL:CD137 and 
ICOS:ICOSL [44]. If successful it leads to clonal 
expansion (proliferation and differentiation) of 
the T cell, called cross-priming. If co-stimulation 
is poor or absent, it leads to T cell anergy (inac-
tivation), hence to immune tolerance of the spe-
cific antigen which is known as cross-tolerance.
3.5.  Adaptive cell-mediated immunity: 
the T cell army
The T cell arm of adaptive immunity is spe-
cialised in antigen specificity, which is a key 
feature in distinguishing tumour cells from nor-
mal cells. It basically encompasses two distinct 
‘soldiers’: CD8 and CD4. Both are activated by 
DC cross-priming. They differ in communicat-
ing antigen specificity through a different class 
of HLA molecules, being HLA class I for CD8, 
and HLA class II for CD4. HLA class I molecules 
present intracellular antigens, HLA class II mol-
ecules present extracellular antigens; CD8 and 
CD4 are the T cell receptor co-receptors for HLA 
class I and class II respectively. Since virtually all 
somatic cells express HLA class I molecules, the 
CD8 T cells are able to target these, and hence 
become - once activated – armed cytotoxic 
effector cells (CTL). To support the ‘search and 
destroy’ missions CD4 T cells are required. These 
provide regulatory signals to prime and orches-
trate the immune response, and become, once 
activated, so-called helper cells (Th). Basically, 
T helper cells do so by either of two strategies, 
Th1 or Th2. During co-stimulation naive CD4 
T cells either develop into Th1 or Th2 cells. Th1 
cells enforce man-to-man battle, cell-mediated 
immunity by priming CTLs and macrophages. 
Th2 cells command the ‘artillery’, viz. humoral 
immunity by activating plasma cells and granu-
locytes. Th1 and Th2 cells enforce their strategy 
by producing a variety of cytokines. Simultane-
ously, they inhibit one another. Hence, once 
again, an adequate, full scale adaptive cell medi-
ated immune attack is dependent on proper DC 
‘intelligence’: cross-presentation, which on its 
turn is dependent on the danger signal.
3.6.  Immune editing: tumour attack and 
escape
Once a proper cell-mediated immune response 
is generated, armed effector T cells will engage 
the enemy back at the battlefield. First, they initi-
ate attack by antigen-nonspecific cell-adhesion 
of LFA-1: ICAM-1/ICAM-2 [44]. If specific tumour-
antigen is sensed, this adhesion is enforced and 
remained long enough for the T cell to reori-
ent its cytoskeleton around in order to release 
induced effector molecules by exocytosis of 
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lytic granules. The CD8 CTL effector molecules 
encompass perforin (perforating the target cell 
membrane), granzymes (proteases that trigger 
apoptosis), and Fas ligand (targeting the ‘death 
receptor’, Fas)[51, 52]. Furthermore, CTLs secrete 
cytokines IFN-γ, TNF-α, and TNF-β which among 
other things activate macrophages and can even 
be cytotoxic directly. This scenario described 
above appears to apply to colon tumours as 
colon tumour-antigen-specific CD8 CTLs have 
been identified [53, 54], as well as CTLs infiltrat-
ing colon tumours [55], which have been found 
to produce effector molecules [56].
So now that we know how tumour cells are 
besieged, we can also figure out the ways of 
tumours to try to escape this: 1) tumour cells may 
shield by down regulation of the receptors for 
effector molecules, including Fas and IFNγ recep-
tor [57, 58] or block, e.g. expression of PI-9 which 
subsequently inactivates granzyme B [59], 2) 
tumour cells may fight back: expressing Fas ligand 
themselves [60], produce immunosuppressive 
cytokines [61], or even manipulate the tumour 
stroma to make it impenetrable for CTLs [62, 63], 
3) tumour cells may hide: they may shed (tumour) 
antigen presentation, by altering expression of 
HLA:antigen complexes. This would seem an 
effective strategy, for it guarantees escape from 
any CTL damage. There are different ways to do 
this, which is explained in the next chapter.
3.7.  Manipulating HLA class I expression: 
the art of hiding
Human leukocyte antigens are the human coun-
terpart of the major histocompatibility complex, 
which was originally discovered by tumour 
allograft studies in mice. Antigen presentation, as 
executed by these molecules, is now considered 
to play a key role in the formation and execution 
of adaptive immunity as it makes up the immu-
nologic language to communicate self from non 
self. As mentioned in paragraph 3.5, two classes 
of HLA molecules are distinguished: HLA class I 
antigens are expressed on nearly all body cells, 
HLA class II antigens primarily on lymphocytes 
and mononuclear phagocytes. HLA class I mol-
ecules are made up of a highly polymorphic 
heavy or α chain and a conserved light or β chain 
called β2-microglobulin (β2m, encoded on chro-
mosome 15q21). The heavy chain contains two 
peptide binding domains enabling it to present 
a nonamer peptide which constitutes the actual 
antigen [64]. The repertoire of peptides poten-
tially presented by HLA complexes is limited 
and is determined by the organisms set of class 
I heavy chains, which is encoded by a cluster of 
6 genes all located within the gene-dense chro-
mosome region 6p21.3, denoted as HLA A to G. 
Of these, HLA A,B, and C are called the classical 
HLA class I antigens, as they are the most poly-
morphic with 124, 258, and 74 different alleles 
distinguished [65]. HLA E, F, and G, the non-classi-
cal HLA class I antigens, vary much less with 5,1, 
and 14 different alleles respectively, and are con-
sidered less important in antigen presentation as 
they mainly present antigens derived from HLA 
class I heavy chains themselves.
Before the HLA:antigen complex is trans-
ported to the cell surface, antigen – primarily 
derived from endogenous, intracellular proteins 
- needs to be processed, and loaded on HLA 
molecule, which is assembled in the endoplas-
mic reticulum (see figure 3). Antigen processing 
is part of cellular ‘housekeeping’, i.e. removal of 
redundant proteins, which is executed by the 
proteasome, a multi-enzyme complex, com-
posed of a 20S complex, which is sandwiched 
by two 19S regulatory complexes. As charac-
terized in yeast, the 20S comprises 28 subunits 
organized into 4 stacked rings. The outer rings 
are formed by seven homologous polypeptides 
termed α subunits, the inner rings are formed by 
7 β subunits, 3 of which perform the actual pro-
teolytic activities [66, 67]. A subset of catalytic β 
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subunits called the large multifunctional pep-
tidases LMP2, LMP7, and LMP10 (MECL1) are 
encoded in the same chromosome region as the 
genes encoding for HLA. They replace the con-
stitutive subunits X (MB1), Y (delta), and Z after 
exposure to IFNγ, which enhances production of 
peptides capable of associating with HLA class I 
molecules or, alternatively, increases the variety 
of peptides that can be produced within a cell 
[67]. The peptides are then transported into the 
endoplasmic reticulum by TAP1-TAP2 heterodi-
mers, loaded on class I molecules. Consecutively, 
the secondary and tertiary structure of this 
HLA:antigen complex is obtained with help from 
chaperones calnexin, calreticulin, tapasin, and 
ERp57. Through the Golgi complex, the newly 
assembled HLA:antigen complexes are then 
transported to the cell surface [64].
If we restrict ourselves to the classical HLA I 
antigens, every individual carries two copies of 
the HLA genes leading to a phenotype of maxi-
mally six different alleles. In order to escape the 
presentation of a certain set of antigens, many 
phenotypic alterations are possible, but they 
have been classified into 5 types of altered HLA 
class I expression [69, 70]. Alterations of HLA phe-
notype in colorectal cancer have been reported 
in up to 87% [71], but because detection of the 
type of alteration strongly depends on labora-
tory techniques used, reports on frequencies of 
alterations detected seem to be incomplete (see 
chapter 5). Here, we will solely discuss the molec-
ular mechanisms leading to these alterations.
• Loss of all HLA class I antigens. Multiple mech-
anisms may lead to a total loss of HLA I mole-
cules on the surface, although they appear to 
be rather complex. Theoretically, it may be the 
result of the accumulation of mutations in all 
single HLA alleles or the deletion of the entire 
chromosomal HLA region of both chromo-
somes. More efficient would it be to get rid of 
the β2-m light chain by mutation or deletion, 
but this would probably still require mutation 
of both copies. Transcriptional silencing of the 
β2-m promoter or the entire HLA region might 
be an alternative mechanism, although this 
has not been observed yet.
• Haplotype loss. Loss of a single copy of the 
HLA region on 6p21.3 leads to loss of a haplo-
type. Chromosomal aberrations causing loss 
of heterozygosity are frequent in tumours and 
lead to such an altered phenotype.
• Locus down regulation. Down regulation of 
for instance both HLA A copies would need 
disturbance of transcriptional regulation, 
by manipulation of either genetic promoter 
β2-microglobulin
antigen
proteasome
TAP
calnexin
HLA 
heavy chain
tapasin
calreticulin
peptide
Figure 3. Antigen processing and HLA class I as-
sembly. Adapted from [68].
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elements, or the transcription factors. There 
are some differences in regulatory elements 
and factors between the different HLA loci 
[72].
• Allelic loss. Mutation of a single HLA allele.
• Composite phenotypes. Although originally 
designated as the waste bin of unexplained 
phenotypic alterations not matching one of 
above, composite phenotypes can now be 
considered as the dominant type of alteration 
in colon cancer (see chapter 5 and 6). Immune 
editing may require loss of some alleles but 
retention of others, complex phenotypes may 
be evolved during tumour development and 
appear not to be as random as expected (see 
chapter 5 and 6). Furthermore, disturbances 
in antigen processing and HLA assembly may 
lead to down regulation of some, but not all 
HLA alleles (see chapter 6).
4.  outline oF this thesis
In this thesis, we present our studies on the 
nature and distribution of HLA class I aberrations 
in colon cancer in relation to underlying genetic 
background.
First, we studied the feasibility of the use of 
both immunohistochemistry of mismatch repair 
genes and microsatellite instability analysis in 
Lynch syndrome-associated endometrial and 
colon tumours. As described in chapter 2, this is 
an effective approach in order to predict germ-
line mutations in Lynch syndrome patients. We 
applied the same strategy this time for large 
series of hereditary colon tumours in chapter 3. 
Furthermore, we extended the approach on a 
large series of hereditary colon tumours by con-
structing tissue micro-arrays and analysed its reli-
ance. Now, we acquired a powerful tool to study 
large series of colon tumour with preservation of 
essential information of molecular subtype.
Focussing on mismatch repair deficient colon 
tumours, we identified frequent mutations within 
the untranslated part of the IFNGR1 gene, coding 
for the IFNγ receptor. This cytokine is important 
for CTLs in order to effectively kill target cells, in 
part by boosting tumour cell HLA expression. In 
the current literature, conclusions regarding the 
importance of such mutations is often based 
on the frequency of its observation. However, 
in chapter 4 we show that this is not always the 
case. Studying functional consequences remains 
necessary. Mismatch repair deficient colon 
tumours retain their sensitivity to IFNγ.
In chapter 5, we focus on HLA expression in 
colon tumours. Using an elaborate flow cytom-
etry technique enabled us to study allele specific 
quantitative expression of freshly isolated single 
tumour cells. Doing so, we gained intriguing 
insights regarding the frequency and nature 
of HLA class I alterations: a) our study showed 
that complete eradication of HLA antigens is 
less common than previously assumed, but 
b) we identified two different patterns of HLA 
alterations, c) the patterns are related to dis-
tinct tumour subsets: mismatch repair deficient 
tumours and tumours from the proximal colon 
(i.e. proximal to the splenic flexure). Both enti-
ties showed frequent HLA alterations, which 
may cause them insensitive to immunotherapy 
approaches. Subsequently, we constructed 
tissue arrays to study large series of both spo-
radic and hereditary mismatch repair deficient 
tumours and tumours from the proximal colon, 
which, as explained in chapter 6, confirmed our 
findings above. Furthermore, we comprehen-
sively screened for genetic mutations contribut-
ing to the alterations of HLA phenotype which 
we identified in half of the cases. Interestingly, 
different mechanisms were identified and 
related to the three subtypes, underlining the 
difference in tumour development and behav-
iour of colon tumour subsets.
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In chapter 7, we conclude with a few general 
remarks concerning the topics covered in this 
thesis.
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2.  introduCtion
Hereditary non-polyposis colorectal cancer 
(HNPCC), or Lynch syndrome, is an autosomal 
dominant disease characterized by an excess 
of colorectal cancer, endometrial cancer, and/
or a variety of other cancers [1,2]. The disease 
is caused by a defect in the DNA mismatch 
repair system. Germline mutations in five genes 
involved in the human DNA mismatch repair 
(MMR) mechanism have been identified: MSH2, 
MLH1, PMS1, PMS2, and MSH6 [3]. Three of these 
genes, MSH2, MLH1, and MSH6, account for the 
MMR defect in the majority of HNPCC families. 
Defects in (one of ) these genes lead to genetic 
instability characterized by expansion or con-
traction of simple repeat sequences (micro-
satellite instability, MSI). Genetic instability is 
responsible for a rapid accumulation of somatic 
mutations in different oncogenes and tumour 
suppressor genes which play a crucial role in 
tumour initiation and progression [4].
Among the extracolonic malignancies that 
occur in HNPCC, endometrial cancer is the most 
common and was recently included in the clini-
cal criteria for HNPCC (Amsterdam II criteria)[5]. A 
high frequency of microsatellite instability (MSI-
high phenotype) in endometrial tumours has 
been reported in 25-30% of sporadic endome-
trial carcinomas, particularly of the endometri-
oid subtype [6,7]. Such tumours, usually referred 
to as MSI-high endometrial tumours, were 
shown to be diploid [6], indicating an absence 
of chromosomal instability; this is in contrast 
with MSI-stable non-endometrioid endometrial 
carcinomas, which are generally aneuploid [8,9]. 
1.  abstraCt
Instability of microsatellite repeat sequences has been observed in colorectal carcinomas and in 
extracolonic malignancies, predominantly endometrial tumours, occurring in the context of heredi-
tary non-polyposis colorectal cancer (HNPCC). Microsatellite instability (MSI) as a feature of human 
DNA mismatch repair (MMR)-driven tumourigenesis of the uterine mucosa has been studied pri-
marily in sporadic tumours showing predominantly somatic hypermethylation of MLH1. The pres-
ent study shows that all endometrial carcinomas (n=12) from carriers of MLH1 and MSH2 germline 
mutations demonstrate an MSI-high phenotype involving all types of repeat markers, while in endo-
metrial carcinomas from MSH6 mutation carriers, only 36% (4 out of 11) demonstrate an MSI-high 
phenotype. Interestingly, an MSI-high phenotype was found in endometrial hyperplasias from MSH2 
mutation carriers, in contrast to hyperplasias from MLH1 mutation carriers, which exhibited an MSI-
stable phenotype. Instability of only mononucleotide repeat markers was found in both endometrial 
carcinomas and hyperplasias from MSH6 mutation carriers. In 29 out of 31 (94%) endometrial tumour 
foci, combined MSI and immunohistochemical analysis of MLH1, MSH2, and MSH6 could predict the 
identified germline mutation. The observation of MSI in endometrial hyperplasia and of altered pro-
tein staining for the MMR genes supports the idea that inactivation of MMR genes is an early event in 
endometrial tumourigenesis. A correlation was found between the variation in the extent and level 
of MSI and the age of onset of carcinoma, suggesting differences in the rate of tumour progression. 
A high frequency of MSI in hyperplasias, found only in MSH2 mutation carriers, might indicate a more 
rapid tumour progression, correlating with an earlier age of onset of carcinoma. The present study 
indicates that assessment of altered protein staining combined with MSI analysis of endometrial 
tumours might direct the mutational analysis of MMR genes.
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No advanced MSI analysis of HNPCC-associated 
endometrial carcinomas has been described yet.
Classical HNPCC is characterized by an early 
age of onset of colorectal carcinoma (mean age 
of 44 years) [4]. Recently, MSH6 germline muta-
tions have been identified in patients from atypi-
cal HNPCC families with a later age of onset of 
carcinomas and a high frequency of extracolonic 
malignancies, in contrast to usual HNPCC fami-
lies with germline mutations in MLH1 or MSH2 
[10,11]. In a study by our group, we observed 
that endometrial carcinoma was the main clini-
cal manifestation of (atypical) HNPCC among 
females from families with MSH6 germline muta-
tions [12]. We found that the endometrial carci-
nomas from these families demonstrated only 
instability of mononucleotide repeat markers.
Previous authors have recommended MSI 
analysis in families with a low probability of 
detecting a mutation in MMR genes as a first 
screening test for MMR defects [13,14], but the 
detection of MSI in tumours does not define 
which one of the MMR genes is involved. A more 
direct assessment of the specific MMR gene 
involved might be possible by immunohisto-
chemical analysis of MMR genes, as was shown 
for MLH1 and MSH2 in colorectal carcinomas 
[15].
The aims of the present investigation were, 
firstly, to study microsatellite instability (MSI 
phenotype) in a series of HNPCC-associated 
endometrial tumours from patients with germ-
line mutations in different MMR genes and, 
secondly, to correlate MSI phenotype, mutation 
status, and immunohistochemical protein stain-
ing for MLH1, MSH2, and MSH6 in endometrial 
carcinoma and hyperplasia. It was of particular 
interest to study MSI and MMR protein staining 
in endometrial hyperplasia, to assess whether 
defective DNA mismatch repair by inactivation 
of MMR genes is an early event in the tumouri-
genesis of the uterine mucosa.
3.  Materials and Methods
3.1.  Patient selection
We analysed in total 31 endometrial and six 
colorectal tumour foci in HNPCC patients from 
15 families complying with the Amsterdam I 
criteria [16], in which a germline mutation in 
one of the MMR genes MLH1, MSH2 or MSH6 
had been identified. For endometrial tumour 
foci, we investigated 23 carcinomas and eight 
hyperplasias. From four HNPCC patients (patient 
ID: 102-1, 5-12, 5-15, and 88-2), both endome-
trial carcinoma and associated hyperplasia were 
analysed.
Histological review was based on the corre-
sponding haematoxylin and eosin (H&E)-stained 
tissue sections for determination of tumour cell 
type and grade, using the criteria of AFIP [17] and 
FIGO [18]. The group of 31 endometrial tumour 
foci consisted of 14 endometrioid adenocarcino-
mas (B1), two endometrioid adenocarcinomas 
with squamous differentiation (B2), one serous 
papillary adenocarcinoma (B3), one squamous 
cell carcinoma (B6), one mixed carcinoma (B7/
B9), four endometrioid adenocarcinomas with 
complex hyperplasia with atypia (A4/B1), six 
complex hyperplasias with atypia (A4), one com-
plex hyperplasia without atypia (A3), and one 
simple hyperplasia with atypia (A2) (Table 1).
According to the FIGO criteria [18], 12 carci-
nomas were classified as grade 1, eight carcino-
mas as grade 2 (patient IDs: 9796-1, 91-1, 7-96, 
5-11, 867-6, 686-3, 686-4, and 22-52), and three 
carcinomas as grade 3 tumours (patient IDs: 686-
5, 22-6, and 50176-3); low grade denotes a pre-
dominance of gland formation and high grade 
its relative absence. FIGO stage was assigned on 
the basis of histological reports and findings. 
Seventeen carcinomas were classified as stage 
IA, IB or IC; one carcinoma as stage IIA; and one 
carcinoma as stage IIIA.
Jan-Willem Dierssen BW druk 3.indd   27 08-09-10   10:17
Ch
ap
te
r 2
28
Tumour-type Patient ID Histology-AFIP MSI Immunohistochemistry
      Total NCI MLH1 MSH2 MSH6
MLH1 germline mutation
 E 102-1 A3 6/24 0/3 + + 0
 E 5-12 A4 2/40 0/4 + +++ +
 E 5-15 A4 3/25 0/3 + +++ +++
 E 9769-2 A4/B1 25/30 5/5 0 +++ ++
 E 9769-1 B1 22/28 5/5 ++ +++ ++
 E 91-1 B1 11/28 3/5 + +++ ++
 E 7-96 B1 22/29 3/3 + ++ +
 E 102-1 B1 12/27 3/5 + + 0
 E 5-11 B1 18/28 3/4 + ++ 0
 E 5-12 B1 22/40 4/5 + +++ +
 E 5-15 B2 25/28 4/5 + +++ +++
 C 5-11 - 22/32 2/3 + ++ +++
 C 9769-1 - 18/25 2/3 0 ++ +
MSH2 germline mutation
 E 139-1 A2 20/32 4/5 + 0 0
 E 88-2 A4 12/34 2/4 + 0 0
 E 99-1 A4 11/34 3/5 ++ 0 0
 E 139-1 A4 18/33 3/5 + 0 0
 E 57-33 A4/B1 11/38 3/5 +++ 0 0
 E 77-2 B1 6/9 2/3 ++ 0 0
 E 88-2 B1 14/26 2/3 + 0 0
 E 90-1 B1 16/30 2/4 ++ 0 0
 C 77-2 - 19/24 4/4 ++ 0 0
 C 99-1 - 22/33 5/5 + 0 0
MSH6 germline mutation
 E 50176-5 A4 3/35 2/5 + ++ 0
 E 867-1 A4/B1 3/36 2/5 +++ + 0
 E 867-6 B1 3/36 2/5 +++ + 0
 E 22-2 B1 1/25 0/5 na na 0
 E 50176-2 B1 2/36 1/5 ++ + 0
 E 50176-4 B1 2/36 0/5 +++ ++ 0
 E 686-3 B1 1/36 2/5 +++ + 0
 E 686-4 B1 2/36 1/5 +++ + 0
 E 686-5 B2 3/36 0/5 +++ + 0
 E 22-6 B3 4/27 2/4 ++ + 0
 E 22-52 B6 0/31 0/4 0 ++ 0
 E 50176-3 B7 3/36 1/5 + + 0
 R 50176-2 - 19/23 4/5 + 0 0
 R 867-1 - 10/36 4/5 + ++ 0
table 1. Clinicopathological, microsatellite instability (MSI), and immunohistochemical analysis of HNPCC-
associated tumours.
Tumour type: E, endometrial; C, colorectal; R, rectum; patient ID, family-patient number; clinicopathology: 
AFIP [17]: A2, simple hyperplasia with atypia; A3, complex hyperplasia without atypia; A4, complex hyper-
plasia with atypia; B1, endometrioid adenocarcinoma; B2, endometrioid adenocarcinoma with squamous 
differentiation; B3, serous papillary adenocarcinoma; B6, squamous cell carcinoma; B7, mixed carcinoma; 
microsatellite instability: total, set of 40 microsatellite markers; NCI, international set of five microsatellite 
markers [19]; +, instability; 0, no instability; immunohistochemistry: +++, strong; ++, moderate; +, weak; 0, 
no staining; na, not analysed.
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3.2.  DNA isolation
Genomic DNA of normal and tumour tissue was 
isolated from formalin-fixed, paraffin-embed-
ded material by microdissection. In all cases 
except one (patient ID: 867-6), normal epithelial 
and tumour cells were microdissected from tis-
sue embedded in the same paraffin block. From 
five cases (patient IDs: 91-1, 9769-1, 50176-2, 
686-3, and 686-5), tissue was obtained by curet-
tage, but from all other cases, including 686-5, 
resection material was available. Using a Chelex 
extraction method, DNA was isolated from five 
consecutive 10 µm sections, resuspended in 250 
µl of PK-1 lysis buffer [50 mM KCl, 10 mM Tris (pH 
8.3), 2.5 mM MgCl2, 0.45% NP40, 0.45% Tween 
20, 0.1 mg/ml gelatine] containing 5% Chelex 
beads (Biorad, Hercules, USA) and 10 µl of pro-
teinase K (10 mg/ml), and incubated for 12 h 
at 56°C. The suspension was incubated 10 min 
at 100°C, centrifuged, and the supernatant was 
carefully decanted.
3.3.  Microsatellite instability analysis
We analysed 40 microsatellite markers, includ-
ing five markers (two mononucleotide repeats: 
BAT25, BAT26; and three dinucleotide repeats: 
D2S123, D5S346, D17S250) recommended by 
the 1997 National Cancer Institute (NCI) work-
shop on Microsatellite Instability for Cancer 
Detection and Familial Predisposition held in 
Bethesda, December 1997 (referred to as the 
NCI set) [19]. Also analysed were one mono-
nucleotide repeat: BAT40; 16 dinucleotide (CA)
n repeats: TP53, D1S158, D3S1029, D3S1611, 
D7S255, D8S133, NEFL, D10S197, D11S901, 
D11S35, D11S968, D13S175, D13S153, D17S588, 
D18S58, D18S61; four trinucleotide repeats: 
FABP2, DRPLA, D4S243, D17S1288; and nine 
tetranucleotide repeats: D3S1768, D3S2456, 
D4S1629, D8S1130, D11S1998, D13S321, 
D15S1232, D16S752, D17S1537. In addition, 
five mononucleotide repeats in the coding 
regions of transforming growth factor receptor 
type II (TGFRII), insulin-like growth factor receptor 
type II (IGFRII), and BAX [20-22], as well as the 
mismatch repair genes MSH3 and MSH6, were 
analysed [23]. All primer sequences for micro-
satellite repeat markers can be attained from the 
Genome Database (http://www.gdb.org).
One microlitre of DNA was loaded on a 
polyvinyl-chloride microtitre plate (Dynatech 
Laboratories, Chantilly, USA). Polymerase chain 
reaction (PCR) was performed in a total reaction 
volume of 12 µl, containing 10 pmol of forward 
and reverse primer, 1% BSA, 10 mM Tris-HCl (pH 
9.0), 50 mM KCl, 2.0 mM MgCl2, 200 µM dATP, 
200 µM dGTP, 200 µM dCTP, 200 µM dTTP, 0.2 
µM fluorescent dCTP (R110 or R6G) or 0.8 µM 
(Tamra) (PE Applied Biosystems Inc., Foster City, 
USA), and 2.5 U of AmpliTaq gold polymerase (PE 
Applied Biosystems Inc., Foster City, USA) for 12 
min at 96°C and 33 cycles of 1 min at 96°C, 2 min 
at 55°C, 1 min at 72°C, and a delay extension step 
of 7 min at 72°C in a GeneAmp 9700 thermocy-
cler (PE Applied Biosystems Inc., Foster City, 
USA). 3.5 µl of loading mix (2.5 µl formamide, 0.5 
µl of xylene-cyanol loading dye, 0.5 µl of Rox-500 
size standard) (PE Applied Biosystems Inc., Foster 
City, USA) was added to 1.5 µl of sample (0.5 µl of 
R110, 0.5 µl of R6G, and 0.5 µl of Tamra labelled 
PCR product). After denaturation for 5 min at 
96°C, 3.0 µl was subjected to electrophoresis on 
a 0.1 mm thick, 6% polyacrylamide gel contain-
ing 7 M urea and 1xTBE [0.09 M Tris- borate, 20 
mM EDTA (pH 8.0)] on an ABI 377 sequencer (PE 
Applied Biosystems Inc., Foster City, USA) for 3 
h with run profile GS-2400A and analysed with 
GeneScan 2.0.
Instability of a microsatellite marker is char-
acterized by additional PCR products from the 
tumour DNA, compared with the electrophore-
sis profile of the matching normal DNA. This is 
facilitated by loading the differently fluorescent-
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labelled PCR products from tumour and normal 
DNA in the same lane.
According to the recently established inter-
national criteria for MSI at the NCI workshop 
[19], tumours were classified as (i) tumours with 
instability for two or more markers (MSI-high); 
(ii) tumours with instability for one marker (MSI-
low); and (iii) no instability (MSI-stable). Since 
these criteria for MSI analysis are based on stud-
ies of colorectal carcinomas and have not been 
tested for endometrial carcinomas, the MSI 
results in this report were presented based on 
the set of 40 markers and the NCI set (Table 1).
3.4.  Immunohistochemical analysis of 
MLH1, MSH2, and MSH6
Immunohistochemical staining was performed 
on 3 µm sections of formalin-fixed, paraffin-
embedded tissues using standard procedures. 
After antigen retrieval by boiling for 10 min in 
1 mM EDTA (pH 8.0) for MLH1 and MSH2, and 
in 10 mM citrate buffer (pH 6.0) for MSH6, tis-
sue sections were incubated overnight at room 
temperature with antibodies against human 
MLH1 (clone 14; Calbiogen, Cambridge, USA), 
dilution 1:75; human MSH2 (clone GB-12; Calbio-
gen, Cambridge, USA), dilution 1:75; or human 
MSH6 (clone 44; Transduction Laboratories/
Becton Dickinson, Hamburg, Germany), dilution 
1:800. Immunoreactivity was detected using an 
Envision two-step peroxidase detection system 
(DAKO, Denmark). Staining was evaluated semi-
quantitatively, using normal epithelial cells or 
the centres of lymphoid follicles as an internal 
control. Both the intensity of nuclear staining, 
presented in Table 1 as strong (+++), moderate 
(++), weak (+), or absent (0), and the percentage 
of tumour cells showing positive nuclear stain-
ing were scored in the area which was microdis-
sected for MSI analysis. The latter scoring did 
not, however, alter the overall interpretation of 
the individual cases and is therefore not shown.
4.  results
4.1.  Clinicopathological features of 
endometrial carcinoma
Seventy-eight per cent (18/23) of endometrial 
carcinomas were of the endometrioid subtype 
(histology AFIP) [17]. According to the FIGO 
criteria [18], 12 of 23 (52%) carcinomas were 
grade 1 tumours, eight of 23 (35%) were grade 2 
tumours and there were three grade 3 tumours. 
The majority of carcinomas (89%) were classi-
fied as FIGO stage I. The mean age of onset of 
all endometrial carcinomas was 48.7 years. A 
significantly earlier age of onset of endometrial 
carcinoma was found in patients with a germ-
line mutation in MSH2 than in MLH1 mutation 
carriers (41.0 vs. 49.5 years, p=0.032). The mean 
age of onset of endometrial carcinoma in MSH6 
mutation carriers (55.5 years) was significantly 
later than in MLH1 and MSH2 mutation carriers 
(p=0.005 and p=0.006, respectively).
4.2.  Microsatellite instability analysis
In the group of eight MLH1 mutation carriers, a 
MSI-high phenotype (according to the NCI crite-
ria [19]) was observed in all endometrial carci-
nomas. Instability of all types of repeat markers 
was found by analysing the set of 40 markers 
(Table 1). Remarkably, in two foci of endometrial 
complex hyperplasia with nuclear atypia, we 
found instability of predominantly tri- and tetra-
nucleotide repeat markers (i.e. FABP2, D3S2456, 
D8S1130, D15S1232, and D16S752). In one focus 
of endometrial complex hyperplasia without 
nuclear atypia (patient ID: 102-1), instability was 
found in 25% (6/24) of the markers investigated, 
involving all types of repeat markers (D15S1232, 
D8S1130, FABP2, D13S175, D18S58, and BAT40). 
No instability was found in the NCI set of markers 
in the foci of endometrial hyperplasia. Tumours 
were therefore classified as MSI-stable (Table 1).
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Endometrial hyperplasias and carcinomas 
from six MSH2 mutation carriers demonstrated 
an MSI-high phenotype involving all types of 
repeat markers. Instability was also found in two 
or more markers from the NCI set (Table 1).
In the group of 12 MSH6 mutation carriers, 
a low frequency of instability was observed in 
all endometrial tumours by using the set of 40 
markers. Instability was only found in the mono-
nucleotide repeat markers (Table 1). According 
to the NCI criteria, four endometrial carcinomas 
were classified as MSI-high since BAT25 and 
BAT26, included in the NCI set, exhibited instabil-
ity. In three endometrial carcinomas, instability 
was observed of only one of these two mononu-
cleotide repeat markers, and in four endometrial 
carcinomas no instability was found of BAT25 or 
BAT26. These tumours were classified as MSI-low 
and MSI-stable, respectively (Table 1). One endo-
metrial complex hyperplasia with nuclear atypia 
demonstrating instability of BAT25 and BAT26 
was classified as MSI-high.
We also investigated the instability for five 
intragenic mononucleotide repeat sequences in 
TGFRII, IGFRII, BAX, MSH6, and MSH3, respectively, 
which frequently show instability in colorectal 
tumours [20-23]. Contraction of the A(10) repeat 
sequence (deletions) in TGFRII was found in all 
six colorectal carcinomas tested, but in none 
of the endometrial tumours. Contraction of 
the (A)8 repeat in IGFRII and the (G)8 repeat in 
BAX was found in respectively four and five of 
23 endometrial carcinomas, but in none of the 
colorectal carcinomas. Interestingly, no instabil-
ity was found of the (G)8 in BAX in an endome-
trial complex hyperplasia without atypia from 
a patient (patient ID: 102-1) with a germline 
mutation in MLH1, whereas contraction of this 
repeat was present in the endometrial carci-
noma from the same patient. Contraction of the 
(C)8 in MSH6 and the (A)8 in MSH3 were found 
in respectively two and one of 12 endometrial 
carcinomas from MLH1 and MSH2 mutation car-
riers. As we have shown previously [12], in MSH6 
mutation carriers, alterations in the (C)8 in MSH6 
were found in all endometrial and colorectal car-
cinomas, whereas alterations in the (A)8 in MSH3 
were only found in the colorectal carcinomas.
4.3.  Immunohistochemical analysis of 
MLH1, MSH2, and MSH6
Loss of or markedly reduced nuclear staining for 
MLH1, MSH2 or MSH6, respectively, was found 
in all tumours from HNPCC patients (Table 1 and 
Figure 1). In all specimens, pre-existing glands 
or germinal centres staining for MLH1, MSH2, 
and MSH6 were retained, although we observed 
variations in the staining intensity, probably 
related to differences in the fixation standards 
and intervals of tissue storage.
In the majority of endometrial carcinomas 
and hyperplasias from MLH1 mutation carriers a 
reduced or complete loss of MLH1 nuclear stain-
ing was found. In 5/11 of these tumours, both 
MSH2 and MSH6 staining was retained. Further-
more, in both the endometrial hyperplasia and 
carcinoma from one patient (patient ID: 102-1), 
markedly reduced staining of MSH2 and loss of 
MSH6 staining were also found. In three endo-
metrial carcinomas, additional reduced (patient 
IDs: 5-12 and 7-96) or absent (patient ID: 5-11) 
MSH6 staining was found. All tumours from 
MSH2 mutation carriers showed loss of MSH2 
and complete loss of MSH6 staining. Conversely, 
in tumours from MSH6 mutation carriers, loss 
of MSH6 staining and primarily reduced MSH2 
staining were found. In two endometrial carci-
nomas and four foci of hyperplasia from MSH2 
and MSH6 mutation carriers, reduced MLH1 
staining was also observed.
It is remarkable that in an area of complex 
hyperplasia without atypia (patient ID: 102-1, 
Table 1 and Figure 1B) and in an area of simple 
hyperplasia without atypia (patient ID: 57-33, 
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Figure 1. (A) Immunoreactivity for MLH1, MSH2, and MSH6 in three endometrial tumours from Table 1. 
First row: endometrial carcinoma of patient 91-1 (MLH1 mutation carrier) stained with anti-human MLH1, 
MSH2, and MSH6 antibodies, respectively. MLH1 nuclear staining is reduced. MSH2 and MSH6 staining is 
retained. Second row: endometrial carcinoma of patient 57-33 (MSH2 mutation carrier) stained with anti-
human MLH1, MSH2, and MSH6 antibodies, respectively. Nuclear staining for both MSH2 and MSH6 is ab-
sent (abrogation MutS/). MLH1 staining is retained. Third row: endometrial carcinoma from patient 22-6 
(MSH6 mutation carrier) stained with anti-human MLH1, MSH2, and MSH6 antibodies, respectively. MLH1 
staining is retained. Nuclear staining for MSH6 is absent. MSH2 staining is reduced (abrogation MutS). (B) 
Areas of complex and simple endometrial hyperplasia. Left: H&E staining of the complex hyperplasia with-
out atypia from patient 102-1 (MLH1 mutation carrier, Table 1). Middle: same tumour area stained with 
anti-human MSH2 and MLH1 antibodies, respectively. With both antibodies, nuclear staining is markedly 
reduced (MSH6 staining was absent, not shown). Right: area of simple hyperplasia without atypia from pa-
tient 57-33 (MSH2 mutation carrier). In hyperplastic glands, MSH2 staining (large arrow) is absent, whereas 
in normal glands MSH2 nuclear staining (small arrow) is retained.
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Figure 1B) diminished or absent nuclear staining 
of MLH1 or MSH2, respectively, can already be 
observed.
5.  disCussion
In the present study we performed MSI and 
immunohistochemical analysis in endometrial 
carcinomas and hyperplasias from patients with 
identified gene mutations in MLH1, MSH2 or 
MSH6. All endometrial carcinomas from carriers 
of MLH1 and MSH2 germline mutations showed, 
according to the NCI citeria [19], an MSI-high 
phenotype involving all types of repeat mark-
ers, while endometrial carcinomas from MSH6 
mutation carriers exhibited an MSI-high pheno-
type in only 36% (4 out of 11) of the tumours. 
An overall low frequency of MSI was found by 
analysing the set of 40 markers, but in all MSH6-
associated tumours, instability was observed 
only of the mononucleotide repeat markers. 
Interestingly, an MSI-high phenotype involving 
all types of repeat markers was found in endo-
metrial hyperplasias from MSH2 mutation carri-
ers, but not in hyperplasias from MLH1 mutation 
carriers exhibiting an MSI-stable phenotype. In 
these hyperplasias, extensive analysis with the 
set of 40 markers detected instability predomi-
nantly of tri- and tetranucleotide repeat markers. 
In conclusion, in our study we found a mutated 
MMR gene-specific phenotype of MSI in endo-
metrial hyperplasia from HNPCC patients.
The immunohistochemical analysis using 
antibodies directed against the MMR gene pro-
teins MSH2 and MSH6 showed a complete loss 
of staining for these proteins in both endome-
trial carcinomas and hyperplasias from HNPCC 
patients, concordant with identified germline 
mutation in these genes. Reduced staining for 
MLH1 was found in endometrial carcinomas 
and hyperplasias from MLH1 mutation carriers. 
In tumours from MSH2 mutation carriers, absent 
staining for the MSH6 protein was also observed, 
while conversely, in tumours from MSH6 muta-
tion carriers, reduced staining for MSH2 was 
found. These reduced nuclear staining patterns 
are most likely the result of abrogation of the 
MutS complex [24,25]. Residual MSH2 staining 
in tumour cells might be due to MSH2 protein 
within the MutS complex. The observation of 
MSI in endometrial hyperplasia, and altered pro-
tein staining for MLH1, MSH2, and MSH6, respec-
tively, concordant with identified germline 
mutation in one of these MMR genes, supports 
the hypothesis that inactivation of MMR genes 
is an early event in endometrial tumourigenesis. 
The finding of MSI and altered MMR protein 
staining in one endometrial complex hyperpla-
sia without atypia is remarkable. Endometrial 
hyperplasia without atypia is a manifestation 
of unopposed oestrogenic stimulation, but by 
itself is not thought to be a precursor of endo-
metrial carcinoma.
The observation of an MSI-high phenotype in 
both endometrial hyperplasias and carcinomas 
from MSH2 mutation carriers, the MSI-high phe-
notype in carcinomas but not in hyperplasias 
from MLH1 mutation carriers, and the predomi-
nantly MSI-low or -stable phenotype in carcino-
mas from MSH6 mutation carriers, may suggest 
differences in tumour progression. The variation 
in the extent and level of MSI may account for 
the differences in the age of onset of endo-
metrial cancer between carriers of germline 
mutations in different MMR genes. The series 
of HNPCC-associated endometrial carcinomas 
in the present study has a relatively early age 
of onset (mean 48.7 years) compared with spo-
radic cases (mean 59 years) [26]. Interestingly, 
we observed a significant difference in the age 
of onset of endometrial carcinoma between 
patients with a germline mutation in the MMR 
genes MLH1, MSH2, and MSH6 (49.5, 41.0, and 
Jan-Willem Dierssen BW druk 3.indd   33 08-09-10   10:17
Ch
ap
te
r 2
34
55.5 years, respectively). The high frequency of 
MSI in endometrial hyperplasias found only in 
MSH2 mutation carriers, correlated with an early 
age of onset of carcinoma, might indicate rapid 
tumour progression. The predominantly MSI-
low or stable phenotypes in carcinomas from 
MSH6 mutation carriers correlate with a later 
age of onset of carcinoma, indicating a slower 
tumour progression rate.
Previous studies have evaluated genes con-
taining intragenic mononucleotide repeats. 
A high frequency of instability of BAX, TGFRII, 
IGFIIR, MSH3, and MSH6 has been reported in 
colorectal carcinomas [20-23]. We identified 
instability of BAX, IGFRII, and TGFRII in respec-
tively 22%, 17%, and 0% of endometrial carci-
nomas, similar to previous studies of MSI in spo-
radic endometrial carcinomas [6,7,27-30]. On the 
other hand, in all endometrial carcinomas from 
MSH6 mutation carriers, there was instability of 
the (C)8 repeat in MSH6 [12]. In contrast, only 
17% of carcinomas from MLH1 and MSH2 muta-
tion carriers demonstrate instability of MSH6. 
In sporadic endometrial carcinomas, instabil-
ity of MSH6 was reported in 7% of tumours [7]. 
The high frequency of instability in our series of 
HNPCC-associated endometrial tumours might 
indicate that MSH6 represents a preferential tar-
get for somatic mutations in MSH6 mutation car-
riers, which is in agreement with earlier obser-
vations [10-12]. Although inactivation of MSH6 
might be important for tumour progression in 
MSH6 mutation carriers, other molecular targets 
of MSI in endometrial tumourigenesis remain to 
be elucidated.
The search for MMR gene mutations is time-
consuming and thus expensive. Wijnen et al. 
described that if the probability of detecting 
a mutation in MMR genes based on clinical 
features in HNPCC families is low, MSI analysis 
should be considered as an initial screening 
test for MMR defects [13]. The present study has 
shown that it is possible to predict which MMR 
gene is mutated by using MSI and immunohis-
tochemical analysis of MLH1, MSH2 and MSH6 
in endometrial tumours. In 29 out of 31 (94%) 
endometrial tumour foci, both carcinoma and 
hyperplasia, combined MSI and immunohisto-
chemical analysis could predict the identified 
germline mutation. The distinction between 
MSH2 and MSH6 defects, however, is very subtle; 
instability of only mononucleotide markers indi-
cates a MSH6 defect.
In endometrial carcinomas, MSI analysis 
alone could not predict the identified germline 
mutations in the MMR genes MLH1 and MSH2, 
since a high frequency of instability is found in all 
types of microsatellite markers in both groups. 
However, a focus of hyperplasia with instabil-
ity in all types of microsatellite markers (MSI-
high) might indicate an MSH2 defect. Selective 
instability in predominantly mononucleotide 
repeat markers in both endometrial carcinomas 
and hyperplasias from MSH6 mutation carriers 
can predict MSH6 germline mutations in 8/12 
tumours, using the NCI set, and in 11/12, using 
the extended marker set.
Only in 3/11 endometrial tumour foci of 
MLH1 mutation carriers could immunohisto-
chemical analysis alone predict the germline 
mutation in MLH1. In the group of MSH2 and 
MSH6 in 8/8 and 9/12 tumours, respectively, 
immunohistochemistry could predict a poten-
tial MSH2 or MSH6 mutation. However, although 
the immunohistochemical data seem promis-
ing, we do not favour the use of immunohis-
tochemistry alone to direct mutation analysis. 
Distinction between MSH2 and MSH6 defects by 
immunohistochemistry is very subtle and the 
staining pattern predicting an MLH1 defect is 
unreliable in our hands. In families with two or 
more endometrial cancers, with an endometrial 
cancer patient diagnosed at an unusually young 
age, or with colorectal and endometrial cancer, 
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in which colorectal cancer tissue is not available, 
we recommend MSI analysis and immunohisto-
chemistry as a first investigative step.
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2.  introduCtion
Colorectal cancer (CRC) is the second most com-
mon cause of death because of malignancy in 
the Western world. The cause of CRC is multifac-
torial, involving hereditary and environmental 
factors and somatic genetic changes during 
tumor progression [1]. A family history of CRC 
is a clinically significant risk factor and may be 
found in up to 15% of all patients with CRC [2]. 
The most common hereditary CRC syndromes 
are familial adenomatous polyposis coli (FAP), 
accounting for <1% of CRC cases and HNPCC 
(hereditary nonpolyposis colorectal cancer), 
accounting for 1 to 6% of the cases [3]. HNPCC 
is an autosomal dominantly inherited disorder 
that is clinically defined by the Amsterdam Cri-
teria [4,5]. In HNPCC, germline mutations have 
been identified in four DNA mismatch repair 
(MMR) genes, MSH2 [6], MLH1 [7], PMS2 [8], and 
MSH6 [9-14]. In 50 to 70% of the families fulfill-
ing the Amsterdam criteria a germline mutation 
is detected in MLH1 or MSH2 [15,16]. Germline 
mutations have been found in MSH6 in families 
with atypical HNPCC, ie not entirely fulfilling the 
Amsterdam criteria [11-14].
Microsatellite instability (MSI) in colorectal 
tumors, first reported in 1993 [17-19], is caused 
by a failure of the DNA MMR machinery to repair 
errors occurring during DNA replication and 
leading to length alterations in simple, repetitive 
microsatellite sequences distributed through-
out the genome [20]. According to international 
guidelines, a panel of five specific microsatellite 
markers has been recommended for MSI evalua-
tion [20]. If at least two markers show instability, 
the tumor is referred to as MSI-high (MSI-H), if 
only one marker is unstable, the tumor is con-
sidered MSI-low (MSI-L). MSI is reported in 85 to 
92% of CRC associated with HNPCC and in 10 to 
15% of sporadic CRC [17,21-23].
In 1996, Leach and colleagues [24] and 
Thibodeau and colleagues [25] reported the 
use of monoclonal antibodies directed against 
1.  abstraCt
Immunohistochemistry (IHC) of mismatch repair (MMR) proteins in colorectal tumors together with 
microsatellite analysis (MSI) can be helpful in identifying families eligible for mutation analysis. The 
aims were to determine sensitivity of IHC for MLH1, MSH2, and MSH6 and MSI analysis in tumors from 
known MMR gene mutation carriers; and to evaluate the use of tissue microarrays for IHC (IHC-TMA) 
of colon tumors in its ability to identify potential carriers of MMR gene mutations, and compare it 
with IHC on whole slides. IHC on whole slides was performed in colorectal tumors from 45 carriers of 
a germline mutation in one of the MMR genes. The TMA cohort consisted of 129 colon tumors from 
(suspected) hereditary nonpolyposis colorectal cancer (HNPCC) patients. Whole slide IHC analysis 
had a sensitivity of 89% in detecting MMR deficiency in carriers of a pathogenic MMR mutation. Sen-
sitivity by MSI analysis was 93%. IHC can also be used to predict which gene is expected to harbor 
the mutation: for MLH1, MSH2, and MSH6, IHC on whole slides would have correctly predicted the 
mutation in 48%, 92%, and 75% of the cases, respectively. We propose a scheme for the diagnostic 
approach of families with (suspected) HNPCC. Comparison of the IHC results based on whole slides 
versus TMA, showed a concordance of 85%, 95%, and 75% for MLH, MSH2, and MSH6, respectively. 
This study therefore shows that IHC-TMA can be reliably used to simultaneously screen a large num-
ber of tumors from (suspected) HNPCC patients, at first in a research setting.
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MSH2 and MLH1 in the immunohistochemical 
analysis of CRCs. Subsequent reports described 
immunohistochemistry (IHC) of MLH1, MSH2, 
and MSH6 in sporadic and HNPCC tumors with 
varying results [26-35]. Some authors suggested 
that IHC can be used as a prescreening method 
for the actual mutation analysis of the MMR 
genes [32,36,37]. Others concluded, however, 
that IHC cannot replace MSI analysis as a pre-
screening method, because of a lower sensitivity 
[35,38,39]. The studies on the value of IHC pub-
lished so far are hampered by small numbers 
of tumors associated with a known MMR gene 
mutation. In addition, most studies focused on 
tumors associated with MLH1 and MSH2 muta-
tions and not MSH6 mutations.
IHC for diagnostic purposes is usually per-
formed on whole slides. A novel approach that 
allows high-throughput IHC is provided by the 
so-called tissue microarrays (TMAs) composed 
by large numbers of small punched-out tissue 
cores from different tumors [40]. With this tech-
nique up to 1000 different samples can be ana-
lyzed in a single immunohistochemical staining 
experiment [41]. Previous reports concluded 
that binary immunophenotypes can be reliably 
investigated on TMAs using two to three repre-
sentative cores per tumor sample [42]. However, 
validation of data generated by TMA is needed to 
determine the minimal amount of tissue cores/
tumor required in one TMA and to inventory 
possible problems of TMA that might influence 
staining results including technical artifacts such 
as differences in fixation of archived material or 
loss of tissue [43].
The aim of the present study was to evalu-
ate whether IHC analysis of colorectal tumors 
could predict the presence of a MMR mutation 
in tumors in a large series of HNPCC patients 
with a known mutation, and to compare these 
results with the outcome of MSI. In addition, 
we compared the results of IHC performed on 
whole slides with the TMA technique. Validation 
of TMA for IHC has not yet been performed for 
colorectal tumors.
3.  Patients and Methods
3.1 Patients
A total of 45 patients (25 males and 20 females) 
with a known germline mutation in MLH1, MSH2, 
or MSH6, were selected from 35 HNPCC families. 
Information on cancer site, age at diagnosis, and 
location of the colon tumors were collected for 
all patients (Table 1). The paraffin-embedded tis-
sue blocks from these patients dated back from 
1976 until 1999. One tumor from each patient 
was used for the analysis. In total, 44 CRCs and a 
single duodenal carcinoma were analyzed.
Among the 35 families with a known MMR 
defect, 27 different germline mutations have 
been identified by denaturing gradient-gel elec-
trophoresis or Southern blotting [44-47]: 14 in 
MLH1, 11 of which were pathogenic (nonsense, 
frameshift, or splice site mutants) and 3 unspeci-
fied variants; 8 in MSH2 (seven pathogenic, 
one unspecified variant); five in MSH6 (three 
pathogenic, two unspecified variants) (Table 1). 
Twenty-four of the 45 patients in our cohort, orig-
inating from 20 families, carry an MLH1 mutation. 
The same mutation was identified in six different 
families (1852_1854del, K618del). Thirteen of the 
45 patients, originating from 10 families, were 
carriers of a mutation in MSH2. Two common 
mutations have been identified in two different 
families. Seven patients from five families were 
carriers of five different MSH6 mutations.
The average age at cancer diagnosis of the 
carriers of MLH1 (n = 21), MSH2 (n = 12), and 
MSH6 (n = 4) pathogenic mutations was 44 years 
(range, 28 to 68 years), 41 years (range, 23 to 
61 years), and 54 years (range, 26 to 84 years), 
respectively.
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We defined four categories of clinical diag-
noses (Table 1). The first category includes 
families that fulfilled the revised Amsterdam 
criteria (AII+) [5]. The second category includes 
suspected HNPCC families, ie, familial cases 
fulfilling the Bethesda criteria (B+) [48]. The 
third category encompasses late onset families 
consisting of three CRC patients within two or 
three generations, with no diagnosis made at 
younger than the age of 50 years. The fourth 
category includes sporadic patients diagnosed 
at younger than the age of 40 years.
3.2.  MSI
MSI analysis was performed on paired tumor-
normal tissue DNA samples using the Bethesda 
panel of microsatellite markers (D2S123, 
D5S346, D17S250, BAT25, and BAT26) [20]. This 
panel was extended with the additional markers 
BAT 40, MSH3, and MSH6, as previously reported 
[49]. Tumors were scored as MSI-H (high) if at 
least two of the five Bethesda markers showed 
instability, MSI-L (low) if only one of these mark-
ers showed instability, or MSS (stable) if none of 
the Bethesda markers showed any shift in mobil-
ity.
The annotations +, ++, or +++ were used 
to indicate if, respectively, one, two, or three of 
the additional (BAT40, MSH3, and MSH6) mono-
nucleotide markers showed instability.
3.3.  Tissue Microarray (TMA)
TMAs were assembled from formalin-fixed, par-
affin-embedded tissues as previously described 
[40] using a 0.6-mm-diameter punch (Beecher 
Instruments, Silver Spring, MD). The arrays 
encompass 362 tissue cores from colorectal 
tumors derived from 129 (suspected) HNPCC 
patients, including the 45 tumors from MMR 
gene mutation carriers. These tumor samples 
dated back from 1974 until 2000. Also, we 
included three tissue cores from normal colonic 
mucosa and one core of lung tissue (for orienta-
tion purposes).
Using a tape-transfer system (Instrumed-
ics, Hackensack, NJ), 4 µm sections were trans-
ferred to glass slides. We were unable to analyze, 
because of tissue loss during processing, 52 
(14%), 41 (11%), and 56 (15%) of the punches for 
MLH1, MSH2, and MSH6, respectively. Because 
two to three punches were taken per tumor this 
meant that for six (5%), five (4%), and five (4%) 
of the tumors, respectively, we were unable to 
analyze the staining of these proteins.
3.4.  IHC
Conventional IHC on whole tumor sections was 
performed for all tumor samples. Immunohis-
tochemical staining was performed on 4 µm 
sections of formalin-fixed, paraffin-embedded 
tissues. Whole tissue slides and TMA slides were 
stained with antibodies against MLH1 (clone 
14; Calbiochem, Cambridge, MA), MSH2 (clone 
GB12) and MSH6 (clone 44; Transduction Labo-
ratories/Becton Dickinson, Lexington, KY) in 
a DAKO Techmate 500+ (Glostrup, Denmark) 
automated tissue stainer using standard pro-
tocols [49] and procedures as indicated by the 
manufacturer. We initially tested the influence of 
different fixation intervals on the results of IHC 
for MLH1, MSH2, and MSH6. Therefore tumor 
parts of two control cases (one colon carcinoma 
and one rectal carcinoma) were fixated in buff-
ered formalin for 1, 7, and 40 days, respectively. 
Overall the results were comparable. When 
fixation was performed with ethanol (for 1 and 
4 days, respectively) in comparison with fixation 
in buffered formalin (also for 1 and 4 days) stain-
ing results were extremely poor after fixation 
with ethanol. For two initially frozen tissues, sub-
sequent fixation in buffered formalin for 1 and 
4 days seems to give less strong staining than 
what we normally experience after immediate 
fixation in formalin. Furthermore, when testing 
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tissue blocks from laboratories that use a pre-
treatment step with acetone for tissues such as 
colon resections we seem to encounter a nega-
tive influence on the quality of the stainings of 
the MMR proteins.
Staining patterns of MMR proteins were 
evaluated using normal epithelial, stromal, or 
inflammatory cells, or the centers of lymphoid 
follicles as internal controls. The pathologist and 
technician who reviewed the immunostaining 
of the tissue samples were blinded to the germ-
line mutation status of the patients.
Stained slides and individual cores were 
scored as either positive (showing nuclear stain-
ing in at least some tumor cells) or negative. To 
validate TMA, patients were considered posi-
tive if at least one tissue core showed nuclear 
staining and negative if none of the tissue cores 
showed nuclear staining of the protein.
4.  results
4.1.  MSI Analysis
MSI analysis was performed in 33 of the 45 
tumors derived from HNPCC mutation carriers 
(Table 1). Although the majority of the cases 
showed a high frequency of instability (28 MSI-
H), 3 MSI-L and 2 MSS tumors (one of which was 
MSS+), were found. One of the MSI-L tumors 
was found in a carrier of a pathogenic MLH1 
mutation (1852_1854del, K618del, exon 16). In 
this tumor, too, the BAT40 and MSH6 markers 
showed instability. IHC showed positive stain-
ing for MSH2 and MSH6 and absent staining 
for MLH1. Moreover, a CRC from an additional 
family member was MSI-H. The other two MSI-L 
tumors occurred in carriers of an unclassified 
variant. The MSS tumor occurred in a carrier of 
a pathogenic MLH1 mutation (677G>A, R266Q, 
splice donor, exon 8) and could not be tested for 
the three additional markers BAT40, MSH3, and 
MSH6. IHC indicated a mutation in MLH1. Fur-
thermore, two tumors from additional carriers of 
the same mutation were scored as MSI-H. In the 
MSS+ tumor, found in a carrier of a pathogenic 
MSH6 mutation (1784delT, L595fsX609, exon 4), 
the BAT40 marker additionally showed instabil-
ity. IHC showed absent staining for MSH6 while 
staining was positive for MLH1 and MSH2. Again, 
another tumor from an affected family member 
was MSI-H.
The BAT40 marker showed instability in 26 of 
the 29 tumors in which it was tested. MSI analy-
sis, if both patients with MSI-H and with MSI-L 
tumors are considered candidates for mutation 
analysis, gives a sensitivity of 93% (25 of 27) in 
predicting an MMR pathogenic mutation if the 
five standard Bethesda markers are used and 
a sensitivity of 96% (26 of 27) using the BAT40, 
MSH3, and MSH6 markers in addition to the 
standard markers. The increase of sensitivity is 
mainly because of the use of the BAT40 marker.
In addition, 71 of 84 colorectal lesions from 
(suspected) HNPCC patients without known 
mutations were tested for MSI. The vast majority 
(53 of 71, 74%) of these tumors were classified as 
MSI-H, whereas 6% (4 of 71) were MSI-L and 20% 
(14 of 71) MSS.
4.2.  Whole Slide Immunohistochemical 
Analysis of Tumors from Mutation 
Carriers
4.2.1 Individual Staining of the MMR Proteins
Twenty of the 25 (80%) tumors derived from 
MLH1 mutation carriers did not stain for the 
MLH1 protein. When unspecified variants are 
excluded, this figure rises to 18 of 21 (86%) (Table 
2). The remaining three (14%) MLH1-positive 
tumors were found in carriers of small in-frame 
deletions or splice mutations. Notably, two of 
the MLH1-positive tumors were part of a series of 
seven tumors from carriers of the 1852_1854del 
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mutation in exon 16. The remaining five stained 
negative. Contrasting MLH1-staining patterns 
were also obtained with tumor samples from 
different carriers of the 277A>G, S93G missense 
mutation. The third MLH1-positive case was 
found in a carrier of a splice donor (677 + 1delG) 
mutation (according to the splice site prediction 
program, BDGP splice site prediction by Neural 
Network, the value decreased from 0.98 to 0.14).
Eleven of 13 tumors (85%) from MSH2 muta-
tion carriers show no MSH2 staining. Again, this 
percentage increases when unspecified variants 
are excluded (11 of 12, 92%) (Table 2). MSH2-
positive staining was observed in only one of 
three tumors from carriers of an in-frame exon 
3 deletion.
Seventy-five percent (three of four) of the 
tumors from carriers of a pathogenic MSH6 
mutation show no staining for the correspond-
ing protein. Of the three tumors from patients 
with an MSH6 unspecified variant, only one 
(G670R) tumor could be analyzed: no MSH6 
staining was found, thus indicating, but not 
proving, pathogenicity of this mutation. When 
unspecified variants are included 80% (four of 
five) of the tumors from MSH6 mutation carri-
ers show absent staining of the corresponding 
protein.
To determine sensitivity of IHC in detecting 
MSI in general we considered all tumor samples 
that showed abrogation of at least one of the 
three proteins tested to be positive for MMR 
deficiency. In 86% (18 of 21), 100% (12 of 12), 
and 75% (3 of 4) of tumors from carriers of a 
MLH1, MSH2, or MSH6 pathogenic mutation, 
respectively, absent staining for at least one of 
the three proteins was shown. MMR deficiency 
would thus have been detected in 89% (33 of 37) 
of the cases.
4.2.2 Staining Patterns
MMR-IHC analysis in carriers of pathogenic MLH1 
mutations revealed that in only 48% of the cases 
was an MLH1-negative staining accompanied 
by normal MSH2 and MSH6 staining patterns 
(Table 3). In these cases, the IHC results clearly 
direct the mutation analysis to a single gene, 
namely MLH1. However, in another subset (24%) 
of the MLH1-mutant tumors, an MSH6-negative 
staining pattern accompanied the loss of MLH1 
IHC MMR MLH1 MSH2 MSH6 Total
No nuclear staining 18 (86%) 11 (92%) 3 (75%)
Nuclear staining 3 (14%) 1 (8%) 1 (25%)
Total   21 12 4 37
table 2. IHC in Carriers of a Pathogenic Mutation
IHC MMR MLH1 MSH2 MSH6
1+/2+/6+ 3 (14%) 1 (25%)
1-/2+/6+ 10 (48%)
1+/2-/6+
1+/2+/6- 1 (8%) 3 (75%)
1-/2+/6- 5 (24%)
1+/2-/6- 11 (92%)
1-/2-/6+
1-/2-/6- 3 (14%)
Total   21 12 4
table 3. IHC Staining Pattern in Carriers of a Pathogenic Mutation
1, MLH1; 2, MSH2; 6, MSH6; +, nuclear staining; -, no nuclear staining.
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signal, thus providing a more ambiguous indi-
cation for the subsequent mutation analysis. In 
three tumors (14%) positive staining for all three 
proteins was found. All three were scored as MSI-
H. Therefore, these patients would not have been 
considered candidates for mutation analysis if 
IHC alone had been performed. Another three 
tumors (14%) showed no staining for all three 
proteins. Notably, negative staining patterns for 
all three MMR proteins were found exclusively 
in combination with a germline MLH1 mutation 
(Table 1 and 3).
In the vast majority of tumors from patho-
genic MSH2 mutation carriers (11 of 12, 92%), 
loss of the MSH2 signal is accompanied by 
MSH6-negative and MLH1-positive staining pat-
terns. Only in one case (exon 3 deletion) were the 
corresponding MSH2 and MLH1 signals positive 
while MSH6 staining was lost. The latter would 
have unjustly indicated mutation analysis of the 
MSH6 gene. However, IHC analysis of a tumor 
from an additional patient from the same family 
clearly showed both MSH2- and MSH6-negative 
staining patterns.
In the three of four cases with a pathogenic 
MSH6 mutation, the expected MSH6-negative 
staining is accompanied by normal MLH1 and 
MSH2 patterns. In the fourth case, in which it 
was predicted that a missense mutation would 
affect RNA splicing (4001G>A, splice donor), 
positive staining for all three MMR proteins was 
found. The tumor was MSI-H (Table 1c).
4.3.  Tissue Microarray 
Immunohistochemical Analysis 
(TMA-IHC)
A TMA encompassing the total cohort of 129 
colorectal tumors was generated. We evaluated 
TMA-IHC staining for the presence or absence of 
the three main MMR proteins in the (suspected) 
HNPCC tumors and compared these with the 
results obtained by whole tumor section IHC 
when available (Table 4). An example of the 
staining pattern in a tumor from an MLH1 muta-
tion carrier (1744 C>T, L582F; Table 1a) is shown 
in Figure 1 for the MLH1 (Figure 1A), MSH2 (Fig-
ure 1B), and MSH6 (Figure 1C) protein, respec-
tively; MLH1 is abrogated, whereas MSH2 and 
MSH6 are present in the nuclei of the tumor cells.
Staining was concordant in 71 of 84 (85%) 
cases tested for MLH1, and in 77 of the 81 (95%) 
for MSH2. A somewhat lower level of concor-
dance was found for MSH6: only 49 of 65 (75%) 
tumors showed similar results, mainly because 
of a high number [13] of positive staining results 
in TMA, scored as negative on whole slides. Of 
the latter samples six belonged to MLH1 muta-
tion carriers (all AII+), two to MSH2 mutation 
carriers (all AII+), one to an MSH6 mutation car-
rier and four samples belonged to individuals in 
whom no mutation was identified (2 times AII+, 
2 times AII-, B+).
  ws +, tma + ws +, tma - ws -, tma - ws -, tma + Total Concordance Sensitivity Specificity
MLH1 52 10 19 3 84 85% 84% 86%
MSH2 55 2 22 2 81 95% 96% 92%
MSH6 23 3 26 13 65 75% 88% 67%
table 4. Validation of TMA for Mismatch Repair Proteins
Staining results of the array compared to results of staining of whole slides from the same patients for 
MLH1, MSH2, and MSH6. Staining was scored as either positive or negative, as described above. Tma, tissue 
microarray; ws, whole slide; +, positive nuclear staining; -, negative nuclear staining; conc, percentage con-
cordance; sensitivity (percentage of true positives), specificity (percentage of true negatives).
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5.  disCussion
The identification of MMR gene mutations in 
suspected HNPCC families is of great relevance 
for allowing the identification of mutation 
carriers for whom surveillance of the colon is 
required and has been proven to lower the risk 
to develop and to die of colorectal carcinoma 
[50]. A potential problem in the everyday clinical 
practice is that MMR genetic testing is expen-
sive and time-consuming. In this study, we first 
evaluated the sensitivity of conventional whole 
section IHC analysis of MLH1, MSH2, and MSH6 
in colon tumors from 45 established carriers of a 
MMR gene mutation and compared it with MSI 
analysis.
The sensitivity of IHC in predicting a patho-
genic mutation was 89% (33 of 37), only 
slightly lower than that of MSI analysis using 
the Bethesda panel of five markers (93%, 25 of 
27), or using the additional three markers (96%, 
26 of 27). For IHC these results are remarkable 
because the paraffin blocks dated back from 
1976 until 1999, with 35% of the samples older 
than 10 years, and fixation until now not fully 
standardized. We argue that intratumor het-
erogeneity will not be a problem in hereditary 
cases because of the fact that loss of MMR, and 
consequently often abrogation of MMR protein 
expression, is such an early event that it is pres-
ent in all tumor cells. Should IHC become a stan-
dard of care in unselected cases heterogeneity 
is an issue that still needs further investigation, 
although in colorectal tumors with a MMR defect 
because of somatic abrogation of MLH1, this fea-
ture seems to be a dominant characteristic, as 
Figure 1. Immunoreactivity in a TMA of mainly (suspected) HNPCC patients. A tissue core with a colon car-
cinoma from a patient with a germline hMLH1 missense mutation (1744C>T, L582F) is shown, stained for 
MLH1 (A), MSH2 (B), and MSH6 (C). MLH1 is abrogated, whereas MSH2 and MSH6 are present in the nuclei 
of the tumor cells. Slides were stained with antibodies against MLH1 (clone 14, Calbiochem, Cambridge, 
MA), MSH2 (clone GB12, Calbiochem), and MSH6 (clone 44, Transduction Laboratories/Becton Dickinson, 
Lexington, KY). Original magnifications, x100.
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can be interpreted from a study on such hetero-
geneity [51].
An important advantage of IHC compared to 
MSI analysis is represented by the prediction of 
the specific MMR gene mutated in the germline 
of the corresponding patient. In tumors from 
most MLH1 mutation carriers (80%), staining 
of the MLH1 protein was absent, as expected. 
However, in only half (48%) of the tumors 
associated with a MLH1 mutation, the staining 
pattern (MLH1-, MSH2+, MSH6+) would have 
predicted unequivocally a pathogenic mutation 
in the MLH1 gene. In the future, the inclusion of 
PMS2 staining, which is often negative in tumors 
associated with MLH1 germline mutations [52], 
will most likely lead to a further increase of IHC 
sensitivity.
Negative staining for both MSH2 and MSH6 
was found in tumors from MSH2 mutation car-
riers. Tumors from MSH6 mutation carriers, 
showed a lack of MSH6 staining only. These 
findings are most likely because of the fail-
ure of MSH6 to form a stable heterodimer in 
the absence of MSH2 [53]. On the other hand, 
if MSH6 is absent, a heterodimer can still be 
formed between MSH2 and MSH3, thus result-
ing in stabilization and positive staining of the 
MSH2 protein [49,54]. In our study, the specific 
staining pattern (MLH1+, MSH2-, MSH6-)of 
MSH2 mutated tumors would have correctly 
predicted the mutated MMR gene in all but one 
(92%) of the cases, while the specific staining 
pattern of tumors from MSH6 mutation carriers 
(MLH1+, MSH2+, MSH6-) would have predicted 
the presence of a MSH6 mutation in 75% of the 
cases.
In previous smaller studies, the sensitivity 
of IHC and MSI analysis has been evaluated in 
colorectal tumors of carriers of specified MLH1, 
MSH2 [25,30,32,35,55], and MSH6 [27,54,56] 
mutations. A problem we cannot solve is the pos-
sibility that variable outcomes of IHC analyses 
might be because of differences in staining 
protocols and antibodies used. Furthermore, a 
considerable number of mutations included in 
these studies are unclassified variants in which 
pathogenicity is by definition uncertain. In the 
present study, only pathogenic mutations were 
included in the determination of the sensitivity 
of IHC on whole slides.
The results of our study show that both IHC 
and MSI are sensitive prescreening methods 
to identify patients for mutation analysis. At 
present, IHC cannot completely replace MSI 
analysis until the sensitivity of MLH1 staining is 
improved, as recently discussed by de la Cha-
pelle [57], and as long as the role of other puta-
tive MMR genes in hereditary CRC has not been 
elucidated. Because of its gene predictive value, 
and because of its speed and low cost, we would 
recommend IHC as a first diagnostic step in fami-
lies fulfilling the revised Amsterdam criteria in 
which the probability of detecting a MMR gene 
mutation is relatively high [58] and MSI analysis 
is likely to give superfluous information. If a neg-
ative staining pattern is found, mutation analysis 
of the respective gene(s) is the next step. In case 
of doubtful interpretation or positive staining 
of all MMR proteins, MSI analysis should be per-
formed In the case of the absence of microsat-
ellite instability (MSS), the analysis of a second 
tumor from the same family is recommended, 
to exclude intrafamilial variability in MSI analysis 
and IHC results, as shown in this study, and/or 
the presence of phenocopies.
In families not fulfilling the Amsterdam cri-
teria, we would recommend MSI analysis as 
the first step. In these cases, the probability of 
detecting a MLH1 or MSH2 mutation is low [58] 
and IHC is less likely to be informative. MSH6 
families, predominantly found not to comply 
with the Amsterdam criteria, represent excep-
tions. In the total group of Amsterdam-negative 
families MSI analysis is expected to provide 
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global information on loss of MMR function, 
including pathogenic missense mutations and 
alterations in MMR genes other than the known 
ones. In MSI-H or MSI-L (if the unstable marker is 
a mononucleotide marker) cases, IHC of all four 
MMR proteins should be performed as second 
step. In the case of MSS, IHC for MSH6 is recom-
mended as it was shown that tumors from MSH6 
mutation carriers are characterized by a variable 
MSI phenotype [54,59]. If no IHC abnormality is 
found, examination of a second tumor could be 
considered depending on the family history and 
age of the patient already tested. A scheme for 
clinical use, summarizing our current approach 
to patients from families with suspected HNPCC, 
is given in Figure 2.
The generation of a tissue array encompass-
ing microsatellite unstable tumors has provided 
us with a powerful tool to quickly characterize 
the immunohistochemical staining patterns of 
MMR proteins in hereditary colorectal tumors 
for research purposes. We found a high level 
of concordance for MLH1 and MSH2 (85% and 
95%, respectively). A somewhat lower concor-
dance level was found for MSH6 (75%), primar-
ily because of positive staining within the TMA 
and negative staining with the whole slide IHC. 
Six of the 13 tumors with discordant results for 
MSH6 originated from patients in whom an 
MLH1 mutation has been identified, where posi-
tive staining for MSH6 is expected. Two and one 
samples originated from carriers of a MSH2 and 
MSH6 mutation, respectively, where negative 
staining for MSH6 is expected. The other four 
samples originate from individuals in whom to 
date no mutation is identified and therefore no 
golden standard is available. Our first goal is to 
rapidly characterize the staining of other candi-
date MMR proteins particularly in tumors from 
(suspected) HNPCC patients in whom to date 
Figure 2. Approach of patients with familial clustering of CRC. 1: IHC for MLH1, MSH2, MSH6, PMS2. 2: If the 
tumor is MSI-H, mutation analysis is the next step. 3: If the tumor is MSI-H and mutation has already been 
performed, research is the next step.
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no mutation was detected, to direct mutation 
analysis. Problems relative to differences in fixa-
tion standardization, age of tissues, punching 
outside the tumor area, and loss of tissue still 
represent serious obstacles. For fixation stan-
dardization we tend to suggest fixation for 1 
day in buffered formalin. Use of ethanol fixation 
and acetone pretreatment should be avoided 
(see Patients and Methods). However, our study 
shows the general validity of this approach in 
the molecular diagnosis of familial CRC. Accord-
ingly, recent IHC-TMA analysis has enabled us to 
identify a number of patients with abrogated 
staining of PMS2 with or without MLH1 staining, 
thus providing direction to mutation analysis of 
PMS2.
In conclusion, we have demonstrated the 
value of IHC using both whole slides and TMA as 
prescreening tools in selecting patients eligible 
for mutation analysis of MMR genes, in diagnos-
tic and research settings respectively.
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2.  introduCtion
DNA mismatch repair deficiency in tumours is 
characterized by a high frequency of microsatel-
lite instability (MSI-H)[1]. Microsatellite instabil-
ity is associated with the hereditary non-polypo-
sis colorectal cancer syndrome and also appears 
in approximately 15% of sporadic colorectal 
tumours [2]. A subset of genes that encompass 
coding microsatellites may be specifically tar-
geted in MSI-H tumours. Systemic sequence 
database searches have identified in the human 
genome up to 17.000 intra-exon coding repeat 
sequences with a length of six or more nucleo-
tides [3,4].
Frameshift mutations in MSI-H colorectal 
tumours have been demonstrated for genes 
involved in signal transduction (TGFBRII, IGFIIR, 
PTEN), apoptosis (BAX, CASPASE 5), DNA repair 
(hMSH3, hMSH6, MBD4), transcriptional regula-
tion (TCF-4) and immune surveillance (B2M), 
with mutation frequencies ranging from 4 to 
80% [5]. Non-coding microsatellite repeats, 
however, may just as well be mutated. Of those 
with potential functional significance are those 
that lie within the untranslated regions (UTR) of 
genes. Elements in such regions can regulate 
mRNA degradation, translation and localization 
[6–8]. However, such elements have not been 
extensively studied for and their identification is 
complicated by the fact that their activity often 
depends on specific secondary RNA structures 
[9]. Suraweera et al [10] characterized frequent 
mutations in a number of conserved mono-
nucleotide repeats within UTRs and high levels 
of mutations were found in a novel T25 mono-
nucleotide marker in the 3’ UTR of the CASP2 
gene [11].
Interferon γ (IFNγ) is important in regulat-
ing cell mediated immune responses. It directly 
increases the sensitivity of a target cell to CD8+ 
cytotoxic lymphocyte attack by upregulating 
the expression of a variety of genes, including 
the human leukocyte antigen (HLA) class I genes 
and Fas/CD95 [12]. Mismatch repair-deficient 
tumours potentially exhibit a large number of 
tumour-specific ‘frameshift’ antigens due to 
instability of coding microsatellite sequences. 
This has been suggested to render them more 
susceptible to both native and therapeutically 
induced antitumour immune responses [13]. 
Indeed, these tumours are associated with an 
elevated CD8+ intra-epithelial infiltrate [14,15]. 
Tumour IFNγ responsiveness is important in 
regulating anti-tumour immune response in 
vivo, partly depending on antigen presentation 
[16,17]. Downregulation of the IFNγ receptor has 
been shown in hepatocellular carcinoma [18], 
basal cell carcinoma [19] and virus-associated 
tumours [20,21], and was correlated with larger 
1.  abstraCt
Microsatellite repeats are frequently found to be mutated in microsatellite-instable colorectal 
tumours. This suggests that these mutations are important events during tumour development. We 
have observed frequent mutations in microsatellite-instable (MSI-H) tumours and cell lines of a con-
served A14 repeat within the 30-untranslated region of the interferon γ receptor 1 gene (IFNGR1). The 
repeat was mutated in 59% (41 of 70) of colon carcinomas and in all four MSI-H colon cancer cell lines 
tested. In-vitro analysis of these cell lines did not show a decreased responsiveness to standard IFNγ 
concentrations when compared to microsatellite-stable colon cancer cell lines. A functional conse-
quence of the frequently found microsatellite instability in IFNGR1 is therefore not evident.
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tumour size and a higher frequency of metas-
tases [18]. IFNγ also increases the sensitivity to 
chemotherapy-induced Fas-mediated apoptosis 
[22]. Although the use of IFNγ solely has yielded 
somewhat disappointing results in clinical anti-
cancer treatment trials [23], its use in combina-
tion with different chemotherapeutics, such as 
5-fluorouracil, indomethacin, phenyl butyrate, 
mitomycin C, cyclosporine A or clarithromycin 
has shown synergetic anti-tumour effects [24 
– 30]. Thus, loss of IFNγ responsiveness would 
denote a loss of potential for future immuno- 
and chemo-based adjuvant therapies.
In this study, we describe frequent mutation 
of the A14 repeat within the 3’ UTR of IFNGR1. 
As will be discussed, it is difficult to draw con-
clusions regarding its importance on basis of 
frequencies alone. Therefore, we also analysed 
IFNγ responsiveness of colon cancer cells bear-
ing these mutations.
3.  Materials and Methods
3.1.  Colon tumour samples and cell 
culture
Tumour samples were derived from formalin-
fixed, paraffin embedded material sent to our 
department for MSI analysis between 1999 and 
2002. Cases were analysed following the medical 
ethnical guidelines described in the Code Proper 
Secondary Use of Human Tissue established by 
the Dutch Federation of Medical Sciences. The 
present study falls under approval by the Medi-
cal Ethical Committee of the LUMC (protocol 
P01–019).
Cell lines HCT 15, LoVo, LS180, LS411N, 
SW480 and SW837 were obtained from the 
American Type Culture Collection (Atlanta, GA, 
USA) and cultured and harvested according to 
standard methods.
3.2.  Microsatellite instability and 
sequence analysis
MSI and sequence analyses were performed 
as described previously [31]. MSI analysis was 
performed using the NCI markers BAT25, BAT26, 
D2S123, D5S346, D17S250 [32], supplemented 
with BAT40, MSH3 and MSH6. Tumours were 
classified as MSI-H (instability of at least 30% of 
the markers) or MSS (no instability). IFNGR1 was 
analysed using forward primer 50-GAGGATGT-
GTGGCATTTTCA-30 and reverse primer 50-TGC-
TATACCAAGGCAGAGAAAAG-30.
3.3.  IFNGR1 mRNA expression
Total RNA was isolated using TriZol (Ambion, 
Austin, TX, USA) following the manufacturer’s 
recommendations. RNA (2 mg) was used for 
cDNA synthesis using Oligo dT primers and AMV 
Reverse Transcriptase (Roche Applied Science, 
Penzberg, Germany). We performed quantita-
tive real-time PCR using SYBR Green (Eurogen-
tec, Seraing, Belgium) on an iCycler real-time 
PCR detection system (Bio-Rad, Hercules, CA, 
USA). Ct values were calibrated to an amount 
of Human Total Colon RNA (Clontech, BD Bio-
sciences, Palo Alto, CA, USA) and normalized to 
the level of expression of three stably expressed 
housekeeping genes HNRPM, CPSF6 and TBP 
[33]. Calibrated Ct values were divided by Ct 
values of 2 mg Human Total Colon RNA. Prim-
ers for amplification of IFNGR1 mRNA used were 
50-TCCTCAGTGCCTACACCAACTAA-30 (nucleo-
tides 79–101, exon 1–2), and 50-CTCGTCACAAT-
CATCTTCCTTCTG-30 (nucleotides 568–591, exon 
5).
3.4.  Flow cytometry of IFNγ-stimulated 
cells
HLA I and Fas expression was analysed by flow 
cytometry of viable cells as described previ-
ously [34,35] using the primary antibodies 
W6/32 (supernatant), 2R2 (Alexis Biochemicals, 
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Carlsbad, CA, USA), and mouse isotype controls 
(Dako Cytomation, Glostrup, Denmark). Samples 
containing 1 mM propidium iodide (Calbio-
chem, San Diego, CA, USA) were collected on an 
FACSCalibur (Becton Dickinson Immunocytome-
try Systems, San Jose, CA, USA). Linearized mean 
fluorescence intensity values were determined 
by WinList (Verity Software House Inc., Topsham, 
ME, USA) and subtracted by control values. 
Means derived from duplicate experiments were 
used; single experiments encompassed one-
session analyses of all cell lines using the same 
instrument settings. We constructed a dose–
response curve using 8, 40, 200 and 1000 U/ml 
IFNγ (PeproTech Inc., Rocky Hill, NJ, USA) for 48 
h. All cell lines were already maximally respon-
sive to a concentration of 8 U/ml. The extent of 
upregulation was further analysed using 200 U/
ml IFNγ.
3.5.  Fas-induced apoptosis
To quantify Fas-induced apoptosis using 1 mg/
ml 2R2 (Alexis Biochemicals) and 1 mg/ml pro-
tein A for 6 h, percentages of apoptotic cells 
were determined using the Nicoletti assay as 
described previously [22,36]. For analysis we 
used a modified ModFit algorithm previously 
described [37] and kindly provided by Verity 
Software House Inc. Means derived from dupli-
cate experiments were used.
4.  results and disCussion
Frequently found MSI suggests a clonally selec-
tive advantage, although passenger mutations 
due to a possible lack of selection pressure of 
innocent bystander genes, ie genes whose func-
tion is irrelevant during tumourigenesis, cannot 
be excluded [38]. For TCF-4, it has been shown 
that frameshift mutations due to instability of a 
coding A9 repeat lack functional consequences 
[39]. Therefore, comprehensive criteria have 
been proposed at the Bethesda meeting to 
define valid target genes in MSI-H tumours, 
including (1) a high frequency of mutation, (2) bi-
allelic inactivation, (3) involvement in a tumour 
suppressor pathway, which is (4) also involved in 
MSS tumours and (5) functional consequences 
of the mutation [2]. However, few reports have 
taken these criteria into account [40,41] and sta-
tistical methods have been proposed to identify 
valid target genes by statistical analysis of muta-
tion frequencies only [42,43].
To examine the (in)stability of the IFNGR1 
repeat we first analysed 17 MSS colon can-
cer samples and 2 MSS colon cancer cell lines 
(SW480 and SW837). In all cases the repeat 
was conserved, ie monomorphic [10]. Subse-
quently, 70 MSI-H colon tumour specimens 
were tested from patients complying with 
the clinical Bethesda criteria [1], 38 of whom 
a germ line mutation was identified in one of 
the MMR genes. MSI in the repeat was found in 
tumours from 12 of 20 (60%) hMLH1 patients, 6 
of 12 (50%) hMSH2 patients, 2 of 6 (33%) hMSH6 
patients, in 21 of 32 (66%) of the residual MSI-H 
tumours and in 4 of 4 (100%) MSI-H colon cancer 
cell lines.
The frequency of mutations in microsatellite 
tracts is associated with the number and type 
of repeats [32,44]. Previous studies reported 
a mutation frequency up to 54% in 29 mono-
nucleotide repeats (8–10 bp) within intronic 
sequences;38 in conserved repeats instability 
was found in up to 28% of tumours only [42]. 
Furthermore, G-repeats are considerably more 
prone to mutations than A-repeats [38]. In 19 
conserved UTR repeats studied [10] a mutation 
frequency was found up to 95%, but the repeat 
lengths ranged from 15 up to 32 nucleotides. 
Led by the Bethesda criteria [2] we decided to 
study whether 59% MSI in the A14 repeat is truly 
indicative of a valid target.
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First, we studied bi-allelicity of the mutations. 
The microsatellite analysis used cannot discrimi-
nate between mono- or bi-allelic mutations of 
tumour tissue due to contaminating normal cells. 
Therefore, we analysed the cell lines described 
above and performed sequence analysis for con-
firmation of the observed deletions. A bi-allelic 
A3 deletion was detected in LoVo and LS411N, 
in LS180 both an A4 and an A5 deletions were 
seen and in HCT 15 only a mono-allelic deletion 
of a single A was observed. No mutations in the 
MSS cell lines SW480 and SW837 were observed 
in line with the MSI results.
To detect a possible decline in IFNGR1 mRNA 
expression upon 3’ UTR mutations we applied 
quantitative RT-PCR. The receptor is normally 
expressed on colon epithelium [45] and no 
decreased IFNGR1 mRNA expression of the 
MSI-H colon cancer cell lines was observed when 
compared to the MSS cell lines (Table 1).
To rule out other regulatory effects of the 
3’ UTR mutation we investigated the extent of 
IFNγ-mediated HLA class I and Fas/CD95 upreg-
ulation in MSI-H compared to MSS colon cancer 
cell lines. HLA class I molecules are not present 
on the cell surface of LoVo and HCT 15 cells, due 
to mutations of the light chain β2-microglobulin 
[46]. We analysed dose–response curves to 
make sure the experiments were performed 
under conditions leading to maximum respon-
siveness. No decreased responsiveness to IFNγ 
was observed for MSI-H cell lines compared to 
the MSS cell lines (Table 1). To study the effect of 
IFNγ on Fas-induced apoptosis, we measured the 
fraction of apoptotic cells as quantified by flow 
cytometry. Again, no impaired IFNγ response 
was noted in the MSI-H cell lines (Table 1).
Although, the concentrations used are simi-
lar to other studies on in-vitro IFNγ responses 
in colon cancer cell lines [47], we cannot com-
pletely rule out a differential response to far 
lower concentration of IFNγ not yielding maxi-
mum response.
In conclusion, we identified a conserved 
A14 microsatellite repeat within the 3’ UTR of 
the potential tumour suppressor IFNGR1 that 
is mutated in 59% of MSI-H colorectal tumours. 
Compared to MSI of other conserved, non-
coding but transcribed short mononucleotide 
tracts, the high frequency of instability suggests 
it to be a valid target during colorectal tumou-
rigenesis. However, in vitro analysis did not 
show an impaired response to IFNγ in any cell 
line harbouring the mutated gene questioning 
      HLA I Fas Fas-ind. apoptosis
    mRNA - + f.i. - + f.i. - + f.i.
MSS 
SW480 0,1 442,3 1801,8 4,1 28,6 30,3 1,1 17,1 34,1 2,0
SW837 1,1 657,0 1517,4 2,3 16,6 25,6 1,5 11,8 40,5 3,4
MSI-H
HCT-15 1,0 ne ne ne 22,6 32,5 1,4 8,9 85,8 9,6
LoVo 0,9 ne ne ne 36,0 22,3 0,9 67,7 81,7 1,2
LS411N 1,3 60,7 375,5 6,2 5,1 22,3 4,4 11,7 61,6 5,3
LS180 1,0 210,6 369,5 1,8 25,0 51,7 2,1 29,2 80,9 2,8
table 1 IFNγ receptor expression and IFNγ responsiveness of colon cancer cell lines HLA I Fas Fas-induced 
apoptosis. Abbreviations: f.i., fold increase; NE, not expressed. Displayed are normalized Ct values as de-
rived from IFNGR1 qRT-PCR, fluorescence intensity values of HLA class I and Fas surface expression acquired 
by flow cytometry and percentages of apopotopic cells after incubation with Fas as determined by prop-
idium iodide staining. + and-: with or without IFNγ stimulation.
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the functional consequences of MSI in this 
repeat. High mutation rates as a consequence 
of unidentified sequence-dependent factors, 
chromatin structure or mechanisms associated 
with transcription may contribute to the high 
frequency of mutations found in tumours in 
the absence of selective advantage [38,40,48]. 
Studying functional consequences seems indis-
pensable to describe the role of these mutations 
in tumourigenesis rather than the frequency of 
genomic instability per se [49,50]. Despite a high 
frequency of MSI of the 3’ UTR of IFNGR1, it prob-
ably does not contribute to colorectal tumour 
progression.
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2.  baCkground
The high morbidity and mortality of colorectal 
cancer underscores the need for new, more 
effective adjuvant treatment strategies. One 
promising approach centers on boosting 
cell-mediated anti-tumor immune responses. 
Numerous tumor-associated peptides have been 
identified that can be specifically targeted with 
vaccine-based immune therapy strategies [1]. 
Specifically, such strategies may be employed 
for colorectal tumors with a so-called microsat-
ellite instability-high (MSI-H) phenotype [2,3]. 
These tumors are characterized by a deficient 
DNA mismatch repair mechanism which results 
in an abundance of frame shift mutations of 
(coding) microsatellite repeat sequences. The 
peptides produced by such frame shift muta-
tions can evoke specific anti-tumor immune 
responses [4-6]. Nevertheless, however promis-
ing the approach, its success is dependent on 
the extent of operational immune surveillance 
mechanisms in the tumor.
Human Leukocyte Antigen (HLA) class I mol-
ecules are of major importance for cell-mediated 
anti-tumor immune responses. Expression of 
HLA class I/β2-microglobulin (β2-m) complexes 
carrying tumor-specific peptides is a prereq-
uisite for adaptively matured cytotoxic T cells 
(CTLs) to be able to recognize tumor cells [7]. 
HLA class I antigens are encoded by a family 
of highly polymorphic genes, with each allele 
responsible for a different repertoire of antigen 
presentation. Thus, even the loss of a single 
1.  abstraCt
1.1.  Background
Previous studies indicate that alterations in Human Leukocyte Antigen (HLA) class I expression are 
frequent in colorectal tumors. This would suggest serious limitations for immunotherapy-based 
strategies involving T-cell recognition. Distinct patterns of HLA surface expression might conceal dif-
ferent immune escape mechanisms employed by the tumors and are worth further study.
1.2.  Method
We applied four-color multiparameter flow cytometry (FCM), using a large panel of alloantigen-spe-
cific anti-HLA-A and -B monoclonal antibodies, to study membranous expression of individual HLA 
alleles in freshly isolated colorectal cancer cell suspensions from 21 patients.
1.3.  Results
Alterations in HLA class I phenotype were observed in 8 (38%) of the 21 tumors and comprised loss of 
a single A or B alleles in 4 cases, and loss of all four A and B alleles in the other 4 cases. Seven of these 
8 tumors were located on the right side of the colon, and those showing loss of both HLA-A and -B 
membranous expression were all of the MSI-H phenotype.
1.4.  Conclusion
FCM allows the discrimination of complex phenotypes related to the expression of HLA class I. The 
different patterns of HLA class I expression might underlie different tumor behavior and influence 
the success rate of immunotherapy.
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allele could potentially allow the escape from 
an antigen-specific anti-tumor response. Loss 
of expression of HLA class I molecules has been 
frequently reported for colorectal tumors [8-10]. 
This would therefore represent a serious limita-
tion for vaccine-based anti-tumor therapies.
However, these studies have primarily been 
based on immunohistochemical analyses (IHC) 
and therefore have a number of intrinsic limita-
tions [11]. HLA staining by IHC is often strongly 
cytoplasmic, which could potentially obscure 
functionally relevant membranous co-expres-
sion and result in a false negative interpretation. 
Additionally, adequate study by IHC is hampered 
by the limited choice of antibodies (Abs) avail-
able for the analysis of formalin-fixed, paraffin-
embedded tissue and importantly, despite the 
fact that the use of fresh frozen tissue allows the 
employment of a higher number of Abs, com-
plete panels of the latter are not yet readily avail-
able. Another important consideration is that 
certain HLA class I complexes also mediate inhibi-
tory signals through receptors expressed by CTLs 
and natural killer (NK) cells, averting the so-called 
‘missing self’ recognition [12,13]. Hence, an effec-
tive tumor immune escape mechanism could 
occur through a subtle alteration of the tumor 
cell HLA phenotype, circumventing both CTL and 
NK cell attack. Thus far, it has not been technically 
feasible to study these intricacies comprehen-
sively, and the molecular mechanisms proposed 
to generate HLA alterations have been contra-
dictory, as they could not always account for the 
observed phenotypic alterations.
In an attempt to overcome these limitations, 
we have employed four-color multiparameter 
flow cytometry (FCM) on freshly isolated tumor 
cells using a large panel of human alloantigen 
specific monoclonal antibodies (mAbs). This 
approach has numerous advantages: i) it allows 
for the study of complex phenotypes, ii) FCM 
is much more sensitive than IHC, and iii) it is 
possible to study membranous HLA expression 
alone. Using the FCM technique we were able 
to distinguish two distinct patterns of altered 
HLA expression restricted to specific colorectal 
tumor subsets.
3.  Methods
3.1.  Patient material
Fresh tumor samples, macroscopically identi-
fied by a pathologist (HM), were collected from 
21 patients with surgical resections between 
2001 and 2003 at the department of Surgery of 
the Leiden University Medical Center. Peripheral 
blood samples were collected from 15 patients 
pre-operatively. There was no pre-selection of 
the patients included in this series. All patients 
agreed to participate and provided written 
informed consent, and the study was approved 
by the local ethical review committee.
3.2.  HLA genotyping
DNA was extracted from peripheral blood leu-
cocytes using a standard salting-out procedure. 
Patients were HLA-A and -B genotyped using 
PCR-sequence-specific oligonucleotide probes 
(Dynal Biotech Ltd., Wirral, U.K.), as described 
previously [14]. Patient HLA genotype is shown 
on Table 2.
3.3.  Tissue dissociation
Minced fresh tumor samples were weighed, 
cut in fragments of approximately 1 mm3, and 
incubated over night at 4°C with 5 ml/g serum-
free RPMI 1640 medium (Invitrogen, Paisley, UK) 
supplemented with 50 IU/ml penicillin-strepto-
mycin (ICN Biomedicals Inc., Aurora), 128 U/ml 
collagenase type I (Sigma-Aldrich, St. Louis, MO), 
100 U/ml hyaluronidase type V Sigma-Aldrich), 
and 250 U/ml DNAse I (Sigma-Aldrich). The next 
day, the same suspension was incubated for 
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mAb species isotype HLA specificity reference
116.5.28 M IgG2a Bw4 *
126/39 M IgG3 Bw6 *
A11.1M M IgG3 A11, A24 18
BB7.2 M IgG2b A2, Aw68 18
Bbm1 M IgG2b β 2-m 18
GAP.A3 M IgG2a A3 18
MA2.1 M IgG1 A2, B17 18
SFR8.B6 R IgG2b Bw6 18
W6/32 M IgG2a HLA -A,-B,-C 18
BV 8E9 H IgM,κ A28, A33, A34 16
BVK 5B10 H IgM,κ B8 †
BVK 5C4 H IgM,κ A80, A9 21
DMS 4G2 H IgG1,λ B62, B35 17
FVS 4G4 H IgM,κ B15, B17, B5, B37, B16, B18, B35 16
GK 31F12 H IgM,κ B13 16
GV 5D1 H IgG1,λ A1, A9 16
GVK 10H7 H IgM,λ B5, B35, B18, B37, B38, B14, B77, B72, B53 †
GVK 4H11 H IgM,κ B35, B62, B5, B16, B18, B37, B53, B70, B14 †
HDG 2G7 H IgG1,κ A19, B17, B63, B47 16
HDG 8D9 H IgG1,λ B51, B35 16
IN 2D12 H IgM,λ B15, B35, B21, B70 16
JOK 3H5 H IgM,λ B40, B21, B13, B12, B41, B70 †
KAL 3D5 H IgG1,λ B51, B52, B77 17
KG 30A7 H IgM,λ B27, B12, B14, B49 18
KLL 5E10 H IgG1,κ B51, B52 †
MUS 4H4 H IgG1,λ Bw4 †
Nie 44B8 H IgM,κ A10 16
OK 1C9 H IgM,λ A3, A11, A33, A31, A26 18
OK 2F3 H IgM,κ A3 16
OK 2H12 H IgM,κ A11, A3, A36, A32, A1 16
OK 3C8 H IgM,κ A3, A11, A32, A36, A31 16
OK 4F10 H IgM,κ A1, A3, A11, A31, A33, A26, A29, A30 †
OK 4F9 H IgM,κ A1, A36, A3, A11, A34, A66, A26, A29, A30, A31, A33 16
OK 5A3 H IgM,λ A1, A3, A11, A24, A36 18
OK 6H10 H IgM,κ B15, B21, B56, B35, B72 16
OK 6H12 H IgM,κ B21, B56, B70, B35, B62 18
ROU 9A6 H IgG3,λ B12, B13, B40, B21, B41 †
SN 607D8 H IgG1,κ A2, A28 16
SN 66E3 H IgM,κ A2, A28 16
vD1F11 H IgM,λ B62, B35, B57, B21, B56, B70, B55 16
VTM 1F11 H IgG1,κ B27, B7, B60 †
VTM 4D9 H IgG1,κ B7, B27 †
VTM 9A10 H IgG1,κ B7, B27 †
WAR 5D5 H IgG1,κ B7, B27, B42, B55 †
WIM 8E5 H IgG1,κ A1, A10, A11, A9, A29, A30, A31, A33 †
WK 3D10 H IgM,κ A2, A3, A23, A31, B7, B13, B17, B21, B40, B62 †
WK 4E3 H IgM,λ A locus (not A1, A24) †
table 1. Monoclonal anti-human antibodies used for flow cytometry analysis of HLA Class I expression.
M, Mouse; H, Human; R, Rat; *, kindly donated by Dr. K. Gelsthorpe, Sheffield, U.K.; †, this paper.
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90 min at 37°C followed by two washing steps 
with RPMI including 10% FCS (Invitrogen) to 
block proteolysis, and Hank’s Balanced Salt 
Solution (Sigma-Aldrich). Cells were incubated 
for another 15 min at 37°C with 0.25% Trypsin 
(Invitrogen), 1 mM EDTA in Hank’s Balanced Salt 
Solution, chilled to 4°C, and washed with RPMI 
with 10% FCS. Finally, the suspension was fil-
tered through a 100 μm sieve (Verseidag-Indus-
trietextilien GmbH, Kempen, Germany) and used 
immediately for flow cytometry.
3.4.  Anti-HLA antibodies
A large panel of human and mouse anti-HLA 
mAbs was used for FCM (Table 1), some of which 
were previously described [15-17]. To estab-
lish the activity of the human mAbs (hu-mAb), 
peripheral blood lymphocytes were isolated 
from multiparous women who had developed 
HLA alloantigen specific antibodies during preg-
nancy, and the lymphocytes transformed with 
Epstein Barr virus (EBV). HLA antibody produc-
ing EBV cell lines were stabilized by electrofu-
sion and rigorous cloning [18]. The specificity of 
hu-mAbs was determined by testing these anti-
bodies with a large (n > 240) panel of HLA-typed 
peripheral blood mononuclear cell suspensions 
in a conventional complement dependent 
microcytotoxicity (CDC) assay [19]. On the basis 
of the mAb reactivity patterns, suitable HLA 
alloantigen-specific sub-panels were chosen for 
each colorectal cancer patient’s HLA phenotype, 
as well as proper negative isotype controls. Sev-
eral mAbs were used to address the same HLA 
allelic products to rule out artifacts caused by 
differences in mAb in specificity/affinity.
case A.1 A.2 B.1 B.2
40 A2 A3 B15 B38
43 A2 A3 B18 B49
44 A2 A24 B7 B55
45 A1 A2 B8 B62
48 A3 A3 B7 B62
55 A1 A3 B8 B62
56 A1 A30 B8 B51
58 A2 A32 B44 B60
59 A1 A2 B7 B62
61* A2 Bw4 Bw6
63* A2 Bw4 Bw6
69 A2 A24 B7 B39
106* A3 Bw4 Bw6
108 A2 A68 B51 B53
109* A3 Bw4 Bw6
110 A1 A23 B8 B50
120 A2 A3 B7 B44
122 A1 A24 B44 B56
124* A2 Bw4
179 A3 A3 B7 B35
191 A2 A24 B15 B40
table 2. HLA genotype and phenotype of the 21 patients whose tumor tissue was used for flow cytometry.
A.1, A.2, B.1 and B.2 indicate the different HLA A and B alleles. * HLA genotype was not known prior to tumor 
resection, phenotype based on flow cytometry of vim+ cells with mouse monoclonal antibodies (Table 1).
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3.5.  Flow cytometry
A seven-step, four-color staining procedure was 
performed as described previously [20]. Simulta-
neous labeling of HLA, β2m, DNA, and the inter-
mediate filaments keratin and vimentin enabled 
us to discriminate HLA expression in keratin 
positive (tumor) epithelial cells from those in 
vimentin positive ‘normal’ cells (leucocytes and 
fibroblasts). Importantly, we specifically ana-
lyzed membranous expression since cells were 
only permeabilized after HLA immunostaining 
making the cytoplasm inaccessible to the anti-
HLA Abs. In 15 cases, we used a complete panel 
of human and mouse anti-HLA mAbs, and in 
another 5 cases we used mouse mAbs (mu-mAb) 
because the HLA genotype was not known prior 
to tumor resection. Reagents used were bioti-
nylated goat anti-mouse and anti-human mAbs 
(Southern Biotechnology Associates, Birming-
ham, AL), Streptavidin-allophycocyanin (APC) 
(Molecular Probes, Eugene, OR), goat F(ab’)2 
anti-mouse IgG1 and IgG2a-RPE, and goat F(ab’)2 
anti-mouse IgG2b or IgG1-FITC polyclonal anti-
bodies (SBA), paraformaldehyde (Merck, White-
house Station, NJ), L-α-lysophosphatidylcholine 
(lysolecithin, Sigma-Aldrich), RNase (Sigma-
Aldrich), and propidium iodide (Calbiochem) 
were used. We used three different combina-
tions of anti-keratin and anti-vimentin mAbs 
to prevent cross-reactivity of the secondary 
reagents with the anti-HLA antibody. The first 
combined anti-keratin IgG1 mAbs M9, M20, and 
AE1/AE3 (Chemicon International Inc., Temecula, 
CA) and anti-vimentin Ig2b mAb V9; the second 
combined anti-keratin IgG2a mAbs CAM5.2 (BD 
Biosciences, San Jose, CA) and anti-vimentin 
IgG1 mAb V9; and the third combined anti-ker-
atin IgG2a mAb CAM5.2 and anti-vimentin Ig2b 
mAb V9. Clones M9, M20, and V9 were estab-
lished at the Department of Pathology, Leiden 
University Medical Center, The Netherlands, and 
are commercially available from ARA, Alphen 
a/d Rijn, the Netherlands. For each sample, mea-
surements from 10,000–20,000 single cells were 
collected using a standard FACSCalibur™ flow 
cytometer (BD Biosciences). Data were analyzed 
using WinList 5.0 and ModFit 3.0 software (Verity 
Software House Inc., Topsham, ME). After elec-
tronic gating on keratin and vimentin content, 
single parameter histograms were obtained for 
DNA content and HLA expression. Geomean 
APC fluorescence intensity values (MFI) were 
subtracted by MFI values from proper negative 
controls. These ratios were used to calculate the 
relative expression value (REV) of keratin posi-
tive (ker+) cells compared to vimentin positive 
(vim+) cells.
REV = MFI[ker+;HLA]-MFI[ker+;negative con-
trol]/MFI[vim+;HLA]-MFI[vim+;negative control]
3.6.  Immunohistochemistry
A standard three-step, indirect immunohisto-
chemistry was performed on consecutive 4 μm 
formalin-fixed, paraffin-embedded tissue sec-
tions mounted on aminopropylethoxysilane 
coated glass slides. Antigen retrieval was per-
formed in boiling citrate 10 mM (pH 6.0) for 20 
min followed by a peroxidase block with 0.03% 
hydrogen-peroxide methanol and an endog-
enous avidin-binding activity-block by incuba-
tion with avidin solution for 15 min (one chicken 
egg white resuspended in 100 ml PBS) and 15 
min in biotin solution (pasteurized cow milk), 
and di-aminobenzidine development. Antibod-
ies used included biotinylated rabbit anti-mouse 
(DAKOCytomation, Glostrup, Denmark), goat 
anti-rabbit (DAKOCytomation), biotinylated-
peroxidase streptavidin complex (SABC; DAKO-
Cytomation), anti-HLA-A heavy chain mAb 
HCA2, anti-HLA-B/C heavy chain mAb HC10 
(supernatant kindly provided by Dr. J. Neefjes, 
NKI, Amsterdam, The Netherlands and Dr. H. L. 
Ploegh, MIT, MA, at 1:400 and 1:100 dilutions, 
respectively) [21,22], rabbit anti-β2-m polyclonal 
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Ab (A 072; DAKOCytomation; 167 μg/l), anti-
MLH1 (clone G168-728; BD Biosciences Pharmin-
gen; 20 mg/l), and anti-PMS2 (clone A16-4; BD 
Biosciences PharMingen, San Diego, CA, USA; 10 
mg/l). Loss of expression was defined as com-
plete loss of staining in both the membrane and 
cytoplasm (HCA2, HC10, and anti-β2-m) or in the 
nucleus (anti-MLH1 and anti-PMS2) with concur-
rent expression in normal epithelium, stroma, or 
infiltrating leukocytes.
3.7.  Microsatellite instability analysis
Microsatellite instability (MSI) analysis was per-
formed and scored as described previously [23] 
using the markers BAT25, BAT26, BAT40, D2S123, 
D5S346, D17S250, MSH3 and MSH6. β2m frame-
shift analysis was performed with primers (avail-
able upon request) build around coding repeats 
of the β2m gene; the (CT)4 repeat in exon 1 and 
two (A)5 repeats in exon 2[24]. Genomic DNA of 
both normal and tumor tissue was isolated from 
3 tissue cores of 0.6 mm diameter of formalin-
fixed, paraffin-embedded material using the 
Chelex extraction method [25].
3.8.  Statistics
Values of significance were calculated using 
the software package SPSS 10.0.7 (SPSS Inc., 
Chicago, IL, USA). We performed Pearson Chi-
square tests or, when expected count was below 
5, Fisher’s exact 2-sided tests. The independent 
sample t-test was performed to test equality of 
means of the age at operation.
4.  results
4.1.  Two patterns of alteration in HLA 
class I phenotype as observed by 
flow cytometry
Loss of expression of HLA class I alleles was 
observed in 8 of 21 (38%) colorectal cancer 
cases studied (see additional file 1). Two distinct 
patterns of HLA loss were identified; the loss of 
a single HLA-A or -B allele which was observed 
in 4 of 8 cases (cases 61, 63, 109, and 191), and 
the loss of both HLA-A and -B alleles which was 
observed in the remaining 4 cases (cases 55, 56, 
120, and 179). Importantly, in the latter group, 
membranous expression of β2-microglobulin 
(β2-M) and remaining HLA class I antigens was 
retained in the 4 tumors, but was diminished as 
determined with the mAbs BBM.1 and W6/32. In 
these samples, the average Relative Expression 
Values (REV, see Methods section) was 0.43 and 
0.38, respectively, compared to the average REVS 
of 2.9 and 2.2, respectively, in the other 17 cases 
(Figure 1; see also additional file 1). This would 
suggest the retention of at least one of the other 
HLA class I alleles, i.e. HLA-C, -E, -F or -G.
4.2.  Alterations of HLA phenotype are 
found in specific subsets of colorectal 
cancer
The 7 of 8 cases with HLA alterations were all right 
sided (p = 0.024). Interestingly, all 5 MSI-H cases 
in the series (5/21) demonstrated HLA altera-
tions [see 1]. Four of the 5 cases demonstrated 
loss of HLA-A and -B (p = 0.028); in 1 of the 5 
cases, we observed the loss of a single HLA allele 
(case 191). Loss of expression of the heterodi-
mer of MLH1 and PMS2 was observed in the 4 
MSI-H cases through IHC, and was not observed 
in any other cases [see 1]. These patients do not 
fulfill any criteria indicative of HNPCC are thus 
most likely sporadic. Other clinicopathological 
features typical of sporadic MSI-H tumors [26] 
were also present; they occurred in elderly 
patients (mean age 75 years, p = 0.043), 3 of 4 
were located in the caecum (p = 0.019), and 3 of 
4 were peri-diploid (p = 0.053). The other MSI-H 
tumor (case 120) was located in the sigmoid, 
occurring in the setting of the Hereditary Non-
Polyposis Colorectal Cancer (HNPCC) syndrome. 
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A mutation in the Mut-S-Homologue 2 (MSH2) 
gene (G674R, exon 13 2020G>C) segregated in 
this particular family, a variant that is probably 
pathogenic. The abrogation of MSH2 expression 
in this tumor was confirmed by IHC. Since all the 
4 MSI-H tumors that lost HLA A and B expression 
showed diminished membranous expression 
of β2m we have screened the microsatellite 
Figure 1. Membranous HLA class I expression analysis by four-color multiparameter flow cytometry of 
colorectal tumor cell suspensions. Fluorescence intensities of HLA class I with antibodies W6/32 (HC), BBM.1 
(B2M), and alloantigen-specific antibodies against single A and B alleles (A.1 – B.2; see Table 2) are displayed 
in filled curves; corresponding negative controls are in non-filled curves. A, keratin positive (ker+) epithelial 
cells are distinguished from vimentin positive (vim+) stroma cells and infiltrating leukocytes. DNA ploidy 
analysis of case 122 reveals an aneuploid ker+ tumor cell fraction (black) compared to the normal diploid 
vim+ cells (light gray). B, Expression of all HLA molecules tested in case 122 of both ker+, tumor (black), and 
vim+ ‘normal’ (gray) cells. C, loss of the single A.1 (HLA-A2) allele was observed for tumor cells in case 191. 
D, loss of expression of all 4 HLA-A and -B alleles in tumor cells, but retention of HC and B2M, in case 179. 
The patient is homozygous for HLA-A3 (--;see Table 2).
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sequences of the corresponding gene but failed 
to find any frameshift mutation.
One case (case 55, MSI-H, multi-ploid) was 
particularly intriguing. Ploidy studies indicated a 
peri-diploid tumor cell population as well as an 
aneuploid population (Figure 2). Interestingly, 
while the aneuploid population retained HLA 
expression for all HLA alleles examined, the dip-
loid population was characterized by two popu-
lations of cells; one population that retained 
HLA expression, and one population (the largest 
tumor cell population) that demonstrated a loss 
of expression of both HLA-A and -B alleles.
The 4 cases showing loss of both HLA-A and 
-B expression have not presented with lymph 
node or distant metastases to date, while 3 of 
the 4 cases with loss of a single allele (including 
1 MSI-H case) and 10 of the remaining 13 cases 
without alterations of the HLA phenotype, did 
metastasize (p = 0.035) to either lymph nodes or 
to distant extranodal sites.
4.3.  Comparison of FCM with 
conventional immunohistochemistry
Using FCM, we detected a significantly lower 
frequency of HLA class I aberrations than pre-
viously reported [8-10,27]. Consequently, we 
decided to compare our FCM results with those 
obtained using conventional IHC. The human 
anti-HLA mAbs used for flow cytometry could 
clearly not be used for the IHC analyses due to 
high background staining caused by non-infor-
mative cross-reactivity of the secondary anti-
human antibody. Consequently, we chose to use 
a panel of mouse anti-HLA antibodies (HCA2, 
HC10, anti-β2-m) for the IHC analyses, although 
these are not alloantigen specific. Loss of expres-
sion of a single HLA allele could not be detected 
using these antibodies.
IHC of cases 55, 56, 120, and 179 (the 4 
HLA-A and -B negative cases) showed com-
plete absence of HCA2 and HC10 staining in 
tumor cells, and decreased anti-β2-m staining 
which was primarily cytoplasmic (see Figure 3) 
and, consequently, probably irrelevant since 
cytoplasmic localization of HLA molecules is 
not functional. However, membranous stain-
ing of HCA2, HC10, and anti-β2-m was clearly 
observed in the adjacent stroma cells (posi-
tive internal control). The FCM data would thus 
appear to corroborate the IHC findings. Loss 
of staining was not observed in the remaining 
cases studied by IHC (see additional file 1). A het-
erogeneous staining pattern, i.e. both positively 
and negatively staining tumor fields within the 
same section, was frequently observed; such 
heterogeneity in membranous expression was 
Figure 2. HLA phenotype alteration is associated 
with DNA ploidy of the cells within one tumor. Flow 
cytometry analysis of case 55 reveals a synchro-
nous divergence of tumor cell populations with 
DNA ploidy and HLA expression. Keratin positive 
(ker+, black) epithelial cells are distinguished from 
vimentin positive (vim+, light gray) stroma cells and 
infiltrating leukocytes (a). Compared to the diploid 
vim+ cells (b), peri-diploid and aneuploid cell popu-
lations of ker+ cells are revealed (c). By plotting HLA 
expression to DNA content, 3 ker+ cell populations 
can be discriminated, including a HLA negative 
DNA diploid tumor cell population and a HLA posi-
tive aneuploid population (d).
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Figure 3. Conventional HLA immunohistochemistry of formalin-fixed paraffin-embedded tissue. Using 
HCA2 (HLA-A heavy chain), HC10 (HLA-B/C heavy chain) and anti-B2M antibodies, loss of HLA A and B 
expression as detected by flow cytometry (see Figures 1 and 2) could be confirmed. In the top panel, mem-
branous staining (arrows) of B2M, HCA2, and HC10 is observed in the moderately differentiated sigmoid ad-
enocarcinoma of case 122. In the bottom panel, loss of HLA-A and -B is illustrated for the mucinous caecum 
adenocarcinoma of case 179. Tumor B2M staining was mainly restricted to the cytoplasm (arrow), but some 
membranous expression of B2M was observed by FCM (see Figure 1). The HCA2 and HC10 staining was 
completely lost in tumor epithelium (t). Typically, the retained HLA expression of stroma cells (s) resulted in 
an inverted staining pattern in comparison to case 122. HE, haematoxylin and eosin staining. Pictures were 
made at 400 × magnification, HEs at 100×.
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not observed as discrete populations (peaks) in 
our FCM data.
5.  disCussion
We used four-color multiparameter FCM to 
study complete HLA-A and -B phenotypes in 
colorectal tumors using a large panel of alloan-
tigen-specific mAbs. FCM allows the detection 
of variation in expression over a dynamic range 
of 4 logarithmic decades and therefore FCM 
appears to be very sensitive. Loss of membra-
nous expression was detected in 38% (8 of 21 
cases) of tumors in our study. Previous studies 
based on IHC demonstrated variable alterations 
in up to 73% of cases [8-10,27]. This discrepancy 
may be explained by the different technical 
approaches used and/or by the different compo-
sition of the groups under study (e.g. microsatel-
lite stable/MSI-H distribution, tumor staging).
Except for one case (case 55) our FCM data 
did not provide evidence for discrete intratu-
moral epithelial subpopulations of differing HLA 
expression as was observed using IHC, although 
the lognormal distribution of the measured fluo-
rescence may obscure these variations in expres-
sion. Nevertheless, the heterogeneous IHC stain-
ing patterns are difficult to interpret, and may be 
falsely regarded as loss of expression.
Using FCM, we characterized two distinc-
tive alterations in colorectal tumors. We found 
4 cases demonstrating loss of a single HLA-A 
or B allele (alterations not identified through 
immunohistochemistry), and 4 cases demon-
strating loss of expression of both the A and B 
alleles, but not loss of all HLA class I molecules. 
The expression of HLA I antigen complexes is a 
prerequisite for the optimal targeting of tumor 
cells by CD8+ CTLs. However, NK cells and CTLs 
also carry inhibitory receptors for specific HLA 
class I alleles. Immunoselection thus relies on 
a delicate balance between HLA allele loss and 
retention. Examples of tumor immune escape 
due to such intricate alterations of HLA phe-
notype have been described recently [16,28]. 
In tumors showing loss of a single allele in our 
study, this loss was restricted to HLA-A2 in 3 of 
the 4 cases. HLA-A2 is not a ligand for inhibitory 
receptors. Those tumors may have effectively 
shed (HLA-A2) restricted epitopes and remained 
inhibitory to NK cell attack. Additionally, the 4 
cases demonstrating loss of both HLA-A and -B 
alleles (also applicable to the cases showing loss 
of a single allele) retained expression of some 
total HLA class I molecules, which was detected 
through the W6/32 antibody and might indicate 
retention of HLA-C or other non classical HLA 
molecules like HLA-G or -E. Of these, HLA-E is nor-
mally expressed in colon epithelial cells [29] and 
predominantly function as inhibitors of NK-cell 
function [30]. These tumor cells may escape CTL 
attack and attack by a subset of NK cells. HIV-1 
infected cells, for example, avoid both CTL and 
NK cell-mediated lysis through specific HLA-A 
and -B downregulation caused by the HIV-1 
gene product nef [31]. These different pheno-
typic alterations may reflect differences in local 
immune selective forces between the tumor 
subsets. Such differences remain to be identified.
All but one of the tumors with an altered 
HLA phenotype were located on the right side 
of the colon. The exception was a left sided 
tumor arising in the setting of HNPCC. Further-
more, the loss of both HLA-A and -B alleles was 
found exclusively in tumors with the MSI-H phe-
notype. Mismatch repair deficiency has previ-
ously been associated with frequent mutations 
in the β2-m gene (B2M) [24,32-35]. This gene 
harbors multiple short tandem repeats that are 
preferentially mutated, leading to total loss of 
membranous HLA class I expression. However, 
we did not observe frame shift mutations in 
these repeats in the MSI-H tumors with HLA-A 
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and -B loss, which is in line with the retention 
of membranous staining (although diminished) 
with the W6/32 and anti-β2-m mAbs. Yet, the 
common loss of expression of HLA-A and -B in 
3 of 4 sporadic MSI-H tumors, which is not due 
to B2M frame shift mutations, would suggest 
that another general mechanism may cause this 
altered phenotype.
Sporadic MSI-H tumors are usually relatively 
large, but rarely disseminate [3,36,37]. This favor-
able tumor behavior has been associated with an 
increased intra-epithelial CD8+ CTLs and CD57+ 
NK cells infiltrate when compared with the 
microsatellite stable tumors. CD4+ cells are not 
frequently found in the intraepithelial infiltrate 
of MSI-H tumors. [24,38-42]. The MSI of numer-
ous coding microsatellites results in a large 
repertoire of immunogenic frame shift pep-
tides which can give rise to specific anti-tumor 
immune responses [4-6]. However, these infil-
trating lymphocytes may lead to the selection of 
HLA alterations in tumor cells. High levels of infil-
trate were present in the HLA-A and -B negative 
cases in this study as observed by microscopy. 
Alternatively, the observed T cell infiltrate could 
represent an innocent bystander effect. Previ-
ously, we identified loss of HLA-A and -B expres-
sion in 6 of 88 cases of sporadic colorectal cancer 
using IHC that, surprisingly, did not present with 
recurrences or metastases during follow-up [27]. 
Although we could not determine the exact HLA 
phenotypic alteration at that time, the previous 
cases resemble the 3 sporadic MSI-H cases found 
in this study that lacked HLA-A and -B expression 
and that have not presented with lymph node 
or distant metastases to date. The NK cells that 
reside in the lymph and blood and that specifi-
cally kill metastasizing tumor cells (that lack total 
HLA class I expression) may explain the more 
favorable prognosis. However, the postulated 
expression of the remaining non HLA-A and -B 
alleles by tumor cells may specifically inhibit 
these NK cells.
6.  ConClusion
FCM allows the discrimination of complex phe-
notypes related to the expression of HLA class I. 
The different patterns of HLA class I expression 
might underlie different tumor behavior and 
influence the success rate of immunotherapy.
7.  aCknowledgeMents
We would like to thank Dr. K. Gelthorpe and Dr. J. 
Neefjes for the generous gifts of antibodies, Dr. J. 
Frans Graadt van Roggen for his critical reading 
of the manuscript, Annemarie M.E.G. Voet-van 
den Brink and Graziella Kallenberg-Lantrua for 
providing the peripheral blood samples, Ronald 
L.P. Vlierberghe and Christa S. van Urk-van den 
Berg for technical assistance, Chantal Eijsink, 
Marrie J. Kardol and Marry E.I. Franke-van Dijk 
for human monoclonal HLA-antibody devel-
opment, and the Rijnland Hospital Pathology 
Department for tissue specimens.
8.  reFerenCes
 1. Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, 
Panichelli C, Schultz ES, Chapiro J, Van Den Eynde 
BJ, Brasseur F, Boon T: Tumor-specific shared 
antigenic peptides recognized by human T 
cells. Immunol Rev 2002, 188: 51-64.
 2. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, 
Perucho M: Ubiquitous somatic mutations in 
simple repeated sequences reveal a new mech-
anism for colonic carcinogenesis. Nature 1993, 
363: 558-561.
 3. Thibodeau SN, Bren G, Schaid D: Microsatellite 
Jan-Willem Dierssen BW druk 3.indd   74 08-09-10   10:18
HLA class I alterations in colorectal cancer 75
instability in cancer of the proximal colon. Sci-
ence 1993, 260: 816-819.
 4. Linnebacher M, Gebert J, Rudy W, Woerner S, 
Yuan YP, Bork P, von Knebel DM: Frameshift pep-
tide-derived T-cell epitopes: a source of novel 
tumor- specific antigens. Int J Cancer 2001, 93: 
6-11.
 5. Ishikawa T, Fujita T, Suzuki Y, Okabe S, Yuasa Y, Iwai 
T, Kawakami Y: Tumor-specific immunological 
recognition of frameshift-mutated peptides in 
colon cancer with microsatellite instability. Can-
cer Res 2003, 63: 5564-5572.
 6. Saeterdal I, Bjorheim J, Lislerud K, Gjertsen MK, 
Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, 
Moller M, Lindblom A, Gaudernack G: Frame-
shift-mutation-derived peptides as tumor-
specific antigens in inherited and spontaneous 
colorectal cancer. Proc Natl Acad Sci U S A 2001, 
98: 13255-13260.
 7. Townsend A, Bodmer H: Antigen recognition by 
class I-restricted T lymphocytes. Annu Rev Immu-
nol 1989, 7: 601-624.
 8. Kaklamanis L, Gatter KC, Hill AB, Mortensen N, 
Harris AL, Krausa P, McMichael A, Bodmer JG, Bod-
mer WF: Loss of HLA class-I alleles, heavy chains 
and beta 2-microglobulin in colorectal cancer. 
Int J Cancer 1992, 51: 379-385.
 9. Cabrera T, Collado A, Fernandez MA, Ferron A, 
Sancho J, Ruiz-Cabello F, Garrido F: High fre-
quency of altered HLA class I phenotypes in 
invasive colorectal carcinomas. Tissue Antigens 
1998, 52: 114-123.
 10. Momburg F, Ziegler A, Harpprecht J, Moller P, 
Moldenhauer G, Hammerling GJ: Selective loss 
of HLA-A or HLA-B antigen expression in colon 
carcinoma. J Immunol 1989, 142: 352-358.
 11. Leong AS: Pitfalls in diagnostic immunohistol-
ogy. Adv Anat Pathol 2004, 11: 86-93.
 12. Ljunggren HG, Karre K: Host resistance directed 
selectively against H-2-deficient lymphoma 
variants. Analysis of the mechanism. J Exp Med 
1985, 162: 1745-1759.
 13. Long EO: Tumor cell recognition by natural killer 
cells. Semin Cancer Biol 2002, 12: 57-61.
 14. Oudshoorn M, Doxiadis II, PM BL, Voorter CE, Ver-
duyn W, Claas FH: Functional versus structural 
matching: can the CTLp test be replaced by HLA 
allele typing? Hum Immunol 2002, 63: 176-184.
 15. Mulder A, Kardol M, Regan J, Buelow R, Claas 
F: Reactivity of twenty-two cytotoxic human 
monoclonal HLA antibodies towards soluble 
HLA class I in an enzyme-linked immunosor-
bent assay (PRA-STAT). Hum Immunol 1997, 56: 
106-113.
 16. Demanet C, Mulder A, Deneys V, Worsham MJ, 
Maes P, Claas FH, Ferrone S: Down-regulation 
of HLA-A and HLA-Bw6, but not HLA-Bw4, allo-
specificities in leukemic cells: an escape mecha-
nism from CTL and NK attack? Blood 2004, 103: 
3122-3130.
 17. Koopman LA, Mulder A, Corver WE, Anholts JD, 
Giphart MJ, Claas FH, Fleuren GJ: HLA class I phe-
notype and genotype alterations in cervical car-
cinomas and derivative cell lines. Tissue Antigens 
1998, 51: 623-636.
 18. Mulder A, Kardol M, Blom J, Jolley WB, Melief CJ, 
Bruning H: A human monoclonal antibody, pro-
duced following in vitro immunization, recog-
nizing an epitope shared by HLA-A2 subtypes 
and HLA-A28. Tissue Antigens 1993, 42: 27-34.
 19. Mulder A, Kardol M, Blom J, Jolley WB, Melief CJ, 
Bruning JW: Characterization of two human 
monoclonal antibodies reactive with HLA-B12 
and HLA-B60, respectively, raised by in vitro 
secondary immunization of peripheral blood 
lymphocytes. Hum Immunol 1993, 36: 186-192.
 20. Corver WE, Koopman LA, Mulder A, Cornelisse CJ, 
Fleuren GJ: Distinction between HLA class I-pos-
itive and -negative cervical tumor subpopula-
tions by multiparameter DNA flow cytometry. 
Cytometry 2000, 41: 73-80.
 21. Stam NJ, Vroom TM, Peters PJ, Pastoors EB, Ploegh 
HL: HLA-A- and HLA-B-specific monoclonal anti-
bodies reactive with free heavy chains in western 
Jan-Willem Dierssen BW druk 3.indd   75 08-09-10   10:18
Ch
ap
te
r 5
76
blots, in formalin-fixed, paraffin-embedded 
tissue sections and in cryo-immuno-electron 
microscopy. Int Immunol 1990, 2: 113-125.
 22. Stam NJ, Spits H, Ploegh HL: Monoclonal anti-
bodies raised against denatured HLA-B locus 
heavy chains permit biochemical characteriza-
tion of certain HLA-C locus products. J Immunol 
1986, 137: 2299-2306.
 23. de Leeuw WJ, van Puijenbroek M, Merx R, Wijnen 
JT, Brocker-Vriends AH, Tops C, Vasen H, Corne-
lisse CJ, Morreau H: Bias in detection of instabil-
ity of the (C)8 mononucleotide repeat of MSH6 
in tumours from HNPCC patients. Oncogene 
2001, 20: 6241-6244.
 24. Kloor M, Becker C, Benner A, Woerner SM, Gebert 
J, Ferrone S, Doeberitz MV: Immunoselective 
pressure and human leukocyte antigen class 
I antigen machinery defects in microsatellite 
unstable colorectal cancers. Cancer Res 2005, 65: 
6418-6424.
 25. de Leeuw WJ, Dierssen J, Vasen HF, Wijnen JT, 
Kenter GG, Meijers-Heijboer H, Brocker-Vriends 
A, Stormorken A, Moller P, Menko F, Cornelisse 
CJ, Morreau H: Prediction of a mismatch repair 
gene defect by microsatellite instability and 
immunohistochemical analysis in endometrial 
tumours from HNPCC patients. J Pathol 2000, 
192: 328-335.
 26. Jass JR, Whitehall VL, Young J, Leggett BA: Emerg-
ing concepts in colorectal neoplasia. Gastroen-
terology 2002, 123: 862-876.
 27. Menon AG, Morreau H, Tollenaar RA, Alphen-
aar E, van Puijenbroek M, Putter H, Janssen-Van 
Rhijn CM, Van De Velde CJ, Fleuren GJ, Kuppen 
PJ: Down-regulation of HLA-A expression corre-
lates with a better prognosis in colorectal can-
cer patients. Lab Invest 2002, 82: 1725-1733.
 28. Giorda E, Sibilio L, Martayan A, Moretti S, Venturo 
I, Mottolese M, Ferrara GB, Cappellacci S, Eiben-
schutz L, Catricala C, Grammatico P, Giacomini 
P: The antigen processing machinery of class I 
human leukocyte antigens: linked patterns of 
gene expression in neoplastic cells. Cancer Res 
2003, 63: 4119-4127.
 29. van den Elsen PJ, Holling TM, Kuipers HF, van der 
Stoep N: Transcriptional regulation of antigen 
presentation. Curr Opin Immunol 2004, 16: 67-75.
 30. Braud VM, Allan DS, McMichael AJ: Functions of 
nonclassical MHC and non-MHC-encoded class 
I molecules. Curr Opin Immunol 1999, 11: 100-108.
 31. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, 
Chen BK, Strominger JL, Baltimore D: The selec-
tive downregulation of class I major histocom-
patibility complex proteins by HIV-1 protects 
HIV-infected cells from NK cells. Immunity 1999, 
10: 661-671.
 32. Bicknell DC, Rowan A, Bodmer WF: Beta 2-micro-
globulin gene mutations: a study of established 
colorectal cell lines and fresh tumors. Proc Natl 
Acad Sci U S A 1994, 91: 4751-4756.
 33. Browning M, Petronzelli F, Bicknell D, Krausa P, 
Rowan A, Tonks S, Murray N, Bodmer J, Bodmer 
W: Mechanisms of loss of HLA class I expression 
on colorectal tumor cells. Tissue Antigens 1996, 
47: 364-371.
 34. Bicknell DC, Kaklamanis L, Hampson R, Bodmer 
WF, Karran P: Selection for beta 2-microglobulin 
mutation in mismatch repair-defective colorec-
tal carcinomas. Curr Biol 1996, 6: 1695-1697.
 35. Cabrera CM, Jimenez P, Cabrera T, Esparza C, 
Ruiz-Cabello F, Garrido F: Total loss of MHC class 
I in colorectal tumors can be explained by two 
molecular pathways: beta2-microglobulin inac-
tivation in MSI-positive tumors and LMP7/TAP2 
downregulation in MSI-negative tumors. Tissue 
Antigens 2003, 61: 211-219.
 36. Lothe RA, Peltomaki P, Meling GI, Aaltonen LA, 
Nystrom-Lahti M, Pylkkanen L, Heimdal K, Ander-
sen TI, Moller P, Rognum TO: Genomic instability 
in colorectal cancer: relationship to clinicopath-
ological variables and family history. Cancer Res 
1993, 53: 5849-5852.
 37. Wright CM, Dent OF, Barker M, Newland RC, 
Chapuis PH, Bokey EL, Young JP, Leggett BA, Jass 
Jan-Willem Dierssen BW druk 3.indd   76 08-09-10   10:18
HLA class I alterations in colorectal cancer 77
JR, Macdonald GA: Prognostic significance of 
extensive microsatellite instability in sporadic 
clinicopathological stage C colorectal cancer. Br 
J Surg 2000, 87: 1197-1202.
 38. Dolcetti R, Viel A, Doglioni C, Russo A, Guidoboni 
M, Capozzi E, Vecchiato N, Macri E, Fornasarig 
M, Boiocchi M: High prevalence of activated 
intraepithelial cytotoxic T lymphocytes and 
increased neoplastic cell apoptosis in colorectal 
carcinomas with microsatellite instability. Am J 
Pathol 1999, 154: 1805-1813.
 39. Jass JR, Do KA, Simms LA, Iino H, Wynter C, Pillay 
SP, Searle J, Radford-Smith G, Young J, Leggett B: 
Morphology of sporadic colorectal cancer with 
DNA replication errors. Gut 1998, 42: 673-679.
 40. Michael-Robinson JM, Biemer-Huttmann A, 
Purdie DM, Walsh MD, Simms LA, Biden KG, 
Young JP, Leggett BA, Jass JR, Radford-Smith GL: 
Tumour infiltrating lymphocytes and apoptosis 
are independent features in colorectal cancer 
stratified according to microsatellite instability 
status. Gut 2001, 48: 360-366.
 41. Young J, Simms LA, Biden KG, Wynter C, Whitehall 
V, Karamatic R, George J, Goldblatt J, Walpole I, 
Robin SA, Borten MM, Stitz R, Searle J, McKeone 
D, Fraser L, Purdie DR, Podger K, Price R, Butten-
shaw R, Walsh MD, Barker M, Leggett BA, Jass JR: 
Features of colorectal cancers with high-level 
microsatellite instability occurring in familial 
and sporadic settings: parallel pathways of 
tumorigenesis. Am J Pathol 2001, 159: 2107-2116.
 42. Menon AG, Janssen-Van Rhijn CM, Morreau H, 
Putter H, Tollenaar RA, Van De Velde CJ, Fleuren 
GJ, Kuppen PJ: Immune system and prognosis 
in colorectal cancer: a detailed immunohisto-
chemical analysis. Lab Invest 2004, 84: 493-501.
 43. Gunderson LL, Sosin H: Areas of failure found at 
reoperation (second or symptomatic look) fol-
lowing “curative surgery” for adenocarcinoma 
of the rectum. Clinicopathologic correlation 
and implications for adjuvant therapy. Cancer 
1974, 34: 1278-1292.
Jan-Willem Dierssen BW druk 3.indd   77 08-09-10   10:18
Ch
ap
te
r 5
78
additional File 1. HLA phenotype alterations and clinicopathological features of colorectal tumors and 
their mismatch repair status. These data provides the HLA phenotypes assessed by flow cytometry of the 
different tumors and their clinicopathological features and mismatch repair status. Clinicopathology: loc., 
tumor localization: A, colon ascendens; Ce, caecum; D, colon descendens; R, rectum; RS, rectosigmoid; S, 
sigmoid; modified Dukes stages [43]; F-U, follow-up (max. 2 years): DOD, dead of disease; DND, dead but 
not due to disease; M, distant metastasis; nr, no recurrences. MMR, mismatch repair status: MSI, microsatel-
lite instability: H, MSI-High; S, microsatellite stable; *, HNPCC, hereditary non-polyposis colorectal cancer; +, 
tumor epithelium staining positive as described in text; -, no staining of tumor cells, but staining of ‘normal’ 
cells, - +, heterogeneous staining of tumor cells; FCM, flow cytometry: A, aneuploid; D, diploid; M, multip-
loid; HLA FCM: Relative HLA Expression Values were calculated from flow cytometry analyses as described 
in the methods section. Depicted in black are cases in which fluorescence intensity of ker+ cells was equal 
to the negative control (see Figure 1). A.1 – B.2, HLA-A and -B alleles as depicted in Table 2; HC, HLA heavy 
chain expression detected with the W6/32 antibody. †, HLA-A and -B negative and positive populations are 
present, therefore REV is not informative (see Figure 2); ‡, homozygous HLA-A genotype. HLA IHC, immuno-
histochemistry of HLA molecules: +, tumor epithelium staining positive as described in text; -, no staining 
of tumor cells, but staining of ‘normal’ cells; c, tumor epithelium staining restricted to the cytoplasm; -+, 
heterogeneous staining of tumor epithelium.
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2.  baCkground
During cancer development, tumor cells may 
elicit cytotoxic T-lymphocyte (CTL)-mediated 
immune responses–partly a consequence of 
accumulated gene mutations that are translated 
into altered peptides [1]. Tumor cell expression 
of HLA class I-antigen complexes is essential for 
CTL recognition of aberrant peptides and sub-
sequent activation [2]. Consequently, alteration 
of HLA class I cell surface expression provides 
an effective mechanism by which tumors can 
escape immune detection [3,4]. Multiple mecha-
nisms have been shown to underlie defects 
in HLA class I expression by tumor cells. They 
include mutations in the individual HLA class I 
1.  abstraCt
1.1.  Background
Abnormalities in Human Leukocyte Antigen (HLA) class I expression are common in colorectal cancer. 
Since HLA expression is required to activate tumor antigen-specific cytotoxic T-lymphocytes (CTL), 
HLA class I abnormalities represent a mechanism by which tumors circumvent immune surveillance. 
Tumors with high microsatellite instability (MSI-H) are believed to face strong selective pressure to 
evade CTL activity since they produce large amounts of immunogenic peptides. Previous studies 
identified the prevalence of HLA class I alterations in MSI-H tumors. However, those reports did not 
compare the frequency of alterations between hereditary and sporadic MSI-H tumors neither the 
mechanisms that led to HLA class I alterations in each subgroup.
1.2.  Methods
To characterize the HLA class I expression among sporadic MSI-H and microsatellite-stable (MSS) 
tumors, and HNPCC tumors we compared immunohistochemically the expression of HLA class I, 
β2-microglobulin (β2m), and Antigen Processing Machinery (APM) components in 81 right-sided 
sporadic and 75 HNPCC tumors. Moreover, we investigated the genetic basis for these changes.
1.3.  Results
HLA class I loss was seen more frequently in MSI-H tumors than in MSS tumors (p < 0.0001). Distinct 
mechanisms were responsible for HLA class I loss in HNPCC and sporadic MSI-H tumors. Loss of HLA 
class I expression was associated with β2m loss in HNPCC tumors, but was correlated with APM com-
ponent defects in sporadic MSI-H tumors (p < 0.0001). In about half of the cases, loss of expression 
of HLA class I was concordant with the detection of one or more mutations in the β2m and APM 
components genes.
1.4.  Conclusion
HLA class I aberrations are found at varying frequencies in different colorectal tumor types and are 
caused by distinct genetic mechanisms. Chiefly, sporadic and hereditary MSI-H tumors follow differ-
ent routes toward HLA class I loss of expression supporting the idea that these tumors follow differ-
ent evolutionary pathways in tumorigenesis. The resulting variation in immune escape mechanisms 
may have repercussions in tumor progression and behavior.
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genes HLA-A, -B and -C, located on chromosome 
6p21.3) [5]; mutations in β2-microglobulin (β2m) 
[6-9], molecule required for cell surface expres-
sion of HLA class I antigens; and defects in com-
ponents of the HLA class I-associated antigen-
processing machinery (APM) [9-11]. The APM 
consists of proteasome components delta, MB1 
and Z; the immunoproteasome components 
LMP2, LMP7 and LMP10; peptide transporters 
TAP1 and TAP2; and chaperones Calnexin, Cal-
reticulin, ERp57, and Tapasin. The immunopro-
teasome generates peptides mostly, although 
not exclusively from endogenous proteins, TAP1 
and TAP2 facilitate peptide translocation from 
the cytosol into the lumen of the endoplasmic 
reticulum, where the peptides are loaded onto 
the HLA class I molecules with the aid from the 
several chaperones [12].
Chromosomal instability (CIN) and microsat-
ellite instability (MIN) are the two major forms 
of genetic instability in colorectal cancer. Com-
bined with distinct somatic mutation patterns 
and epigenetic modifications, CIN and MIN lead 
to the development of sporadic colorectal can-
cer [13]. MIN sporadic tumors, which constitute 
approximately 15% of all colorectal cancer cases 
and up to 40% of the tumors localized on the 
right side (preceding the splenic flexure) of the 
colon [14], have a phenotype resulting from the 
epigenetic inactivation of the mismatch repair 
gene hMLH1. Its inactivation destroys a cell’s 
ability to repair base-base mismatches and small 
insertions or deletions in repetitive stretches, 
leading to an accumulation of frameshift muta-
tions that get translated into abnormal peptide 
sequences. When these mutations are accu-
mulated to large extent in the cell genome the 
tumors are said to possess high-microsatellite 
instability (MSI-H) [15]. Hence, it is expected 
that genes containing microsatellite sequences 
within their coding regions are more susceptible 
to somatic mutations, as seen in the TGFβ-RII 
gene. TGFβ-RII’s third exon contains a microsat-
ellite repeat of 10 adenines that is frequently tar-
geted by frameshift mutations in MSI-H tumors 
[16]. MSI-H is also the hallmark of hereditary 
non-polyposis colorectal cancer (HNPCC), in 
which germline mutations of hMLH1, hMSH2, 
hMSH6 and PMS2 can be found. HNPCC consti-
tutes approximately 2–4% of all CRC cases [17]. 
Tumors with MSI-H are thought to be more able 
to stimulate a CTL-mediated immune response 
due to their frequent generation of the aber-
rant frameshift peptides [18]. Therefore, these 
tumors are subjected to a greater selective pres-
sure which favors the outgrowth of tumor cells 
with the ability to escape from recognition and 
destruction by host immune system.
Various studies have identified HLA altera-
tions in colorectal cancer [19-21], including the 
prevalence of HLA class I alterations in MSI-H 
tumors [8,22]. However, the latter studies did 
not compare the frequency of alterations 
between hereditary and sporadic MSI-H tumors 
neither the mechanisms that led to HLA class I 
alterations in each subgroup. It was suggested 
that MSI-H sporadic and hereditary tumors 
follow parallel evolutionary pathways during 
tumorigenesis in terms of both genotype and 
phenotype [23]. As far as HLA class I defects are 
concerned it was never investigated whether 
these different tumors present distinct escape 
mechanisms from the immune system. In the 
present study, we compared the frequency of 
defects in HLA class I expression in right-sided 
sporadic (MSI-H and microsatellite-stable (MSS) 
sub-groups) colon tumors and in HNPCC tumors 
and studied the mechanisms underlying any 
abnormalities in these subgroups.
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3.  Methods
3.1.  Patient material and tissue 
microarrays
Two tissue microarrays were constructed from 
formalin-fixed, paraffin-embedded tissues as 
described previously [24]. One array, previ-
ously described [25], included colorectal tumor 
specimens from 129 suspected HNPCC patients 
with MSI-H colon tumors of which 75 cases were 
analyzed in the present study after confirmation 
of their HNPCC status: 73.3% (n = 55) of the lat-
ter possessed a germline pathogenic mutation 
in hMLH1 (n = 24), hMSH2 (n = 18), hMSH6 (n = 
12) or PMS2 (n = 1), the remaining were MSI-H, 
without methylation of the hMLH1 promoter 
and/or with immunohistochemical loss of the 
MSH2/MSH6 heterodimer and/or possessed 
a very young age at diagnosis of colon cancer 
(<50 yrs old). All cases possessed a positive 
family history for MSI-H tumors. The second tis-
sue array included 3 tumor tissue cores from 81 
sporadic right-sided colon cancer cases resected 
between 1990 and 2005 at the Leiden University 
Medical Center (Leiden, The Netherlands) and 
at the Rijnland Hospital (Leiderdorp, The Neth-
erlands). The 81 patients in the latter array con-
sisted of 47 females and 34 males with a mean 
age of 71.15 years (SD= 9.958). Approximately 
60% (n = 48) of these cases were classified as 
MSS while the remaining (n = 33) possessed a 
MSI-H phenotype. The microsatellite instability 
status of the tumors was determined accord-
ing to recommendations of the National Cancer 
Institute/ICG-HNPCC [15]. Moreover all MSI-H 
sporadic cases have lost the expression of the 
MLH1/PMS2 heterodimer as assessed by immu-
nohistochemistry. The sporadic status of the 
MSI-H right-sided tumors (RST) was confirmed 
by methylation analysis of the hMLH1 promoter 
using a methylation-specific MLPA assay as pre-
viously described [26]. All MSI-H sporadic cases 
presented with hypermethylation at the hMLH1 
promoter.
The present study falls under approval by the 
Medical Ethical Committee of the LUMC (pro-
tocol P01–019). Cases were analyzed following 
the medical ethnical guidelines described in the 
Code Proper Secondary Use of Human Tissue 
established by the Dutch Federation of Medical 
Sciences [27].
3.2.  Immunohistochemistry
Standard three-step, indirect immunohisto-
chemistry was performed on 4-μm tissue sec-
tions transferred to glass slides using a tape-
transfer system (Instrumedics, Hackensack, NJ), 
including citrate antigen retrieval, blockage 
of endogenous peroxidase and endogenous 
avidin-binding activity, and di-aminobenzidine 
development.
The following primary antibodies were 
used: the mAb HCA2 which recognizes β2m-
free HLA-A (except -A24), -B7301 and -G heavy 
chains [28,29]; the mAb HC10, which recognizes 
a determinant expressed on all β2m-free HLA-B 
and C heavy chains and on β2m-free HLA-A10, 
-A28, -A29, -A30, -A31, -A32 and -A33 heavy 
chains (supernatant kindly provided by Dr. J. 
Neefjes, NKI, Amsterdam, The Netherlands and 
Dr. H. L. Ploegh, MIT, Boston, MA) [28,30]; TAP1 
specific mAb NOB1; LMP2-specific mAb SY-1; 
LMP7-specific mAb HB2; LPM10-specific mAb 
TO-7; Calnexin-specific mAb TO-5; Calreticulin-
specific mAb TO-11; Tapasin-specific mAb TO-3; 
ERp57-specific mAb TO-2 [31-33]; TAP2-specific 
mAb (BD Biosciences Pharmingen, San Diego, 
CA); rabbit anti-β2m polyclonal Ab (A 072; DAKO 
Cytomation, Glostrup, Denmark); anti-MLH1 
(clone G168–728; BD Biosciences) and anti-
PMS2 (clone A16-4; BD Biosciences). Secondary 
reagents used were biotinylated rabbit anti-
mouse IgG antibodies (DAKO Cytomation), goat 
anti-rabbit IgG antibodies (DAKO Cytomation), 
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and biotinylated-peroxidase streptavidin com-
plex (SABC; DAKO Cytomation).
Loss of expression was defined by complete 
lack of staining in membrane and cytoplasm 
(HCA2, HC10, and anti-β2m), in the nucleus 
(anti-MLH1 and anti-PMS2), in the peri-nucleus/
endoplasmic reticulum (NOB1, anti-TAP2, TO-2, 
TO-3, TO-5, TO-7, and TO-11), or in the cytoplasm 
(SY-1, HB2, and TO-7), but with concurrent stain-
ing in normal epithelium, stroma or infiltrating 
leukocytes. HLA class I expression was con-
sidered to be lost when one of the HLA class I 
antigen-specific antibodies gave a negative 
result alongside a positive internal control (lym-
phocytic infiltrate).
3.3.  Flow cytometric sorting
The flow cytometric sorting procedure, includ-
ing tissue preparation, staining and flow cytom-
etry analysis was performed as described previ-
ously [34]. Briefly, 2 mm diameter punches from 
selected areas of formalin-fixed paraffin embed-
ded colorectal carcinomas were digested enzy-
matically in a mixture of 0.1% collagenase I-A 
(Sigma-Aldrich, St Louis, MO, USA) and 0.1% dis-
pase (Gibco BRL, Paisley, UK). After determina-
tion of cell concentration, one million cells were 
incubated with 100 μl of mAb mixture directed 
against keratin and vimentin containing clones 
MNF116 (anti-keratin; IgG1; DAKOCytomation, 
Golstrup, Denmark), AE1/AE3 (anti-keratin; IgG1; 
Chemicon International Inc, Temecula, CA, USA), 
and V9-2b (anti-vimentin; IgG2b; Department 
of Pathology, LUMC [35]). Next day, cells were 
incubated with 100 μl of premixed FITC and 
RPE-labelled goat F(ab’)2 anti-mouse subclass-
specific secondary reagents (Southern Bio-
technology Associates, Birmingham, AL, USA). 
After washing, cells were incubated with 10 
μM propidium iodide (PI) and 0.1% DNase-free 
RNase (Sigma). The next day cells were analyzed 
by flow cytometry. A standard FACSCalibur (BD 
Biosciences) was used for the simultaneous 
measurement of FITC, RPE, and PI. Tumor and 
normal cell populations were flow-sorted using 
a FACSVantage flow-sorter (BD Biosciences) 
using the FACSCalibur filter settings. Sorting 
was only performed on samples included in 
the RST array due to shortage of material from 
the HNPCC cases. DNA from flow-sorted tumor 
material was isolated as described by Jordanova 
et al. [36]. DNA from non-sorted material was 
isolated using Chelex extraction as described 
previously [37].
3.4.  LOH and fragment analysis
Markers for loss of heterozygosity (LOH) analysis 
were chosen from the dbMHC database [38] to 
map the chromosome 6p21.3 region between 
HLA-A and TAP2. They were MOGc, D6S510, 
C125, C141, D6S2444, TAP1 and M2426. A “linker” 
sequence of 5’-GTTTCTT was added to the 5’ 
terminus of all reverse primers [39]. LOH was 
defined as allelic imbalance >2 in the HNPCC 
cases (non-sorted) and allelic imbalance >5 in 
the sorted RST [40].
To detect frame-shift mutations in the HLA-
A, HLA-B, β2m, LMP2, LMP7, LMP10, TAP1, TAP2, 
Calnexin, Calreticulin, ERp57 and Tapasin genes, 
28 pairs of primers (Table 1) were constructed 
surrounding non-polymorphic microsatellite 
regions within the coding regions.
3.5.  Statistics
Significance values were calculated using the 
software package SPSS 10.0.7 (SPSS Inc., Chi-
cago, IL, USA).
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4.  results
4.1.  HLA class I, β2m and APM 
component expression
In order to compare the expression of HLA class 
I in sporadic MSI-H and MSS right sided tumors 
(RST) and HNPCC MSI-H cases, we used an anti-
body panel recognizing monomorphic deter-
minants expressed on HLA class I heavy chains, 
β2m and APM components (Figure 1).
In total, we identified loss of HLA class I 
expression in about 34.6% of the RST and 42.7% 
of the HNPCC cases. The frequency of alterations 
differed significantly between the sporadic MSS 
and MSI-H RST. The lack of HLA class I expression 
was more frequent in MSI-H sporadic cases than 
in MSS cases (p < 0.0001), as it was 16.7% in the 
latter group, but 60.6% in the former (Table 2).
Subsequently, we have investigated the 
frequency of a concomitant loss of HLA class 
I expression with that of either the β2m mol-
ecule or of any APM component. In the sporadic 
subset, loss of HLA class I expression was more 
often associated with that of one of the APM 
Gene Forward primer Reverse primer Microsatellite 
Repeat
HLA A 4th ex CCTGAATTTTCTGACTCTTCCCGT GTTTCTTTCCCGCTGCCAGGTCAGTGT 7(C)
HLA A 5th ex CCATCGTGGGCATCATTG GTTTCTTTCAGTGAGACAAGAAATCTC 3(GGA)
HLA B 2nd ex GCTTCATCTCAGTGGGCTAC GTTTCTTCTCGCTCTGGTTGTA 3(GA) + 3(CA)
β2m 1st ex GGCTGGGCACGCGTTTAAT GTTTCTTAGGGAGAGAAGGACCAGAG 4(CT)
β2m 2nd ex (1) TACCCTGGCAATATTAATGTG GTTTCTTGATAGAAAGACCAGTCCTTGC 4(GA) + 5(A)
β2m 2nd ex (2) CTTACTGAAGAATGGAGAGAG GTTTCTTGACTACTCATACACAACTTTCA 5(A)
TAP1 1st ex TAAATGGCTGAGCTTCTCGC GTTTCTTAGAGCTAGCCATTGGCA 5(C)
TAP1 3rd ex ACAGCCACTTGCAGGGAG GTTTCTTTATGAACAGTACATGGCGTAT 5(T)
TAP1 8th ex CTGCCCTGCTGCAGAATCTG GTTTCTTCAAGCCACCTGCTTCCAT 5(G)
TAP1 10th ex CTCTGCAGAGGTAGACGAGG GTTTCTTATTAAGAAGATGACTGCCTCAC 5(G)
TAP1 11th ex AGCACCTCAGCCTGGTGGA GTTTCTTGCAGGTCTGAGAAGGCTTTC 6(G) + 5(A)
TAP2 2nd ex TTCCTCAAGGGCTGCCAGGAC GTTTCTTGCTCCAAGGGGCTGAAG 6(C)
TAP2 9th ex CCTACGTCCTGGTGAGGTGA GTTTCTTCTGGCTGTGCAGGTAGC 5(G)
Tapasin 2nd ex TTGGTTCGTGGAGGATGC GTTTCTTCCTAGAGACTCACCGTGTAC 5(G)
Tapasin 3rd ex CTTCCTTCTCTACACTCAGACC GTTTCTTAGGACTGGGCTGGATATGC 5(C)
Tapasin 4th ex CCTGTCTTCCTCAGTGGTAC GTTTCTTGAGCAGATGTCCCTTACCC 6(C)
Tapasin 5th ex TGCTCATTTCGTCCTCTTTCC GTTTCTTGTTCCCACTCCACCTCCAG 5(G)
Calnexin 7th ex GAAGGATCAGTTCCATGACAAG GTTTCTTCTGCATCTGGCCTCTTAGC 5(A)
Calnexin 8th ex TCTGCTCAATGACATGACTCC GTTTCTTTGAAGACAGTTCCCCAAGAC 5(A)
Calnexin 11th 
ex
AACCTTTCAGAATGACTCCTTTTAG GTTTCTTCAAGCAGCAAACACGAACC 8(T)
Calreticulin 
3rd ex
CTACCGTCCCGTCTCAGG GTTTCTTTCTGTCTGGTCCAAACTATTAGG 5(G)
Calreticulin 
6th ex
GACAAGCCCGAGCATATCC GTTTCTTCACCTTGTACTCAGGGTTCTG 5(C)
ERp57 5th ex CACTTATTGCTTCTTCCTTGTG GTTTCTTAATACTTGGTCAGGAGATTCAAC 6(T)
ERp57 6th ex CTTCTGCTATCTGCCTACTGAG GTTTCTTTCAAGCAAATAAATCCCAGACAAG 6(A)
ERp57 13th ex ACTTTTAAGCTGATCTTTCTGTTTT GTTTCTTTTAGAGATCCTCCTGTGCCTT 6(C)
LMP2 2nd ex GAGGGCATCAAGGCTGTTC GTTTCTTGCAGACACTCGGGAATCAG 5(G)
LMP2 6th ex CCCTCTCTCCAACTTGAAACC GTTTCTTTGTAATAGTGACCAGGTAGATGAC 5(G)
LMP7 1st ex GGCTTTCGCTTTCACTTCC GTTTCTTGAGATCGCATAGAGAAACTGTAG 6(C)
table 1. Primers used in fragment analysis
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Figure 1. Example of immunohistochemical analysis performed on the RST and HNPCC tumors 
(Amplification 10×). A, Positive expression of HLA class I antigens detected with the HCA2 antibody. The 
epithelial (large arrow) membranous expression of HLA class I antigens is identical to the lymphocytic infil-
trate (small arrow). B, Loss of expression of HLA class I identified with the HCA 2 antibody. The lymphocytic 
infiltrate (small arrow) was used as a positive control to determine the loss of expression on the epithelial 
cells. C, Loss of expression of β2m in a HNPCC case. D, Loss of expression of one of the APM members 
(Tapasin) in a RST case.
      HLA† APM loss ‡ β2m loss ‡
RST N=81 MSS N=48 + 40 0 0
(59,3%)
- 8 (16,7%) 3 (37,5%)* 0
MSI-H N=33 + 13 0 0
(41,7%)
    - 20 (60,6%) 7 (35,0%)* 1 (5,0%)*
HNPCC N=75 MSI-H + 43 0 0
    - 32 (42,7%) 2 (6,3%)* 15 (46,9%)*
table 2. HLA, APM and β2m expression in RST and HNPCC colon cancer
* – The percentage of cases that lost APM or β2m expression is relative to the number of HLA negative cases 
of each subset
† – HLA expression differs significantly between sporadic MSI-H and MSS tumors (p < 0.0001) and between 
HNPCC and sporadic MSS tumors (p < 0.005)
‡ – The association of HLA class I loss with that of β2m and of APM components differs significantly (p < 
0.0001) between sporadic RST and HNPCC tumors.
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components, occurring in about 37% of HLA-
negative tumors regardless of their mismatch 
repair status (Table 2). β2m loss was only found 
in one HLA class I negative MSI-H sporadic tumor 
(case 65) that interestingly also presented loss 
of the APM molecules TAP2, Calreticulin and 
Tapasin (Figure 2). In contrast, loss of HLA class I 
expression in HNPCC cases was more frequently 
associated with that of β2m (Table 2), as it was 
found in 46.9% of the HLA class I-negative 
tumors. In contrast loss of any APM component 
was observed in only 6% of these cases (h38, 
h49) which also showed loss of β2m expression.
In sporadic RST, the simultaneous loss of 
more than one APM molecule per case was 
frequent (Figure 2). Only 3 out of 10 cases lost 
a single APM component. The TAP2 molecule 
was most frequently lost (6 cases), followed by 
TAP1, Tapasin and LMP2 (5 cases), Calreticulin (4 
cases), LMP7 (2 cases), and Calnexin and ERp57 
(1 case). Loss of the LPM10 protein was detected 
in neither sporadic RST nor HNPCC tumors. The 
HNPCC cases h38 and h49 lost the expression of 
TAP2 and LMP7 respectively.
4.2.  LOH and frameshift analysis
Polymorphic markers around the classical HLA 
genes (A, B and C), TAP 1 and TAP2 genes were 
used to study LOH and reveal possible chromo-
somal aberrations that could relate to loss of HLA 
class I expression (Figure 5A). In HNPCC cases, 
LOH analysis was only performed around the 
HLA genes since loss of the TAP1 and TAP2 pro-
teins was rarely associated with HLA class I loss. 
LOH was more frequent in the MSS tumors (50%) 
than in the MSI-H sporadic (20%) and HNPCC 
(6%) tumors with loss of HLA class I expression 
(P < 0.05) (Figure 3, 4). Furthermore, the patterns 
of LOH in the MSS cases might indicate loss of 
the entire 6p21.3 region, in contrast to the MSI-H 
cases (hereditary and sporadic forms) where 
LOH seems to be limited.
Frameshift mutation screening of the micro-
satellite sequences present in the coding regions 
of the HLA class I, APM components and β2m 
genes was performed on all cases with aberrant 
HLA class I expression (Figure 5B,C). However 
specific genes were only analyzed when lack of 
expression of the encoded proteins was detected 
by immunohistochemistry. Of the classical HLA 
class I genes only HLA-A and -B were analyzed 
since HLA-C does not carry any microsatellite 
repeat in its coding region. Ten RST cases and 20 
HNPCC control cases with normal expression of 
β2m and APM components were screened for 
frameshift mutations and none was detected.
Frameshift mutations were mainly found in 
the MSI-H cases (both sporadic and hereditary 
forms). At least one mutation in an APM com-
ponent gene was found in 6 of 7 sporadic MSI-H 
tumors that lost expression of one or more APM 
components. The single sporadic MSI-H case that 
lost β2m expression also presented with a single 
frameshift mutation in the β2m gene. Of the 13 
sporadic MSI-H cases in which loss of HLA class 
I expression was associated neither with APM 
component nor with β2m loss as detected by 
Figure 2. Loss of expression of β2m and differ-
ent APM members was detected by immunohis-
tochemistry in the RST that presented with HLA 
loss. The shadowing (in black) is indicative for loss 
of expression of the respective molecules (tpsn – 
Tapasin, calnx – Calnexin, crtcln – Calreticulin).
Jan-Willem Dierssen BW druk 3.indd   86 08-09-10   10:18
Distinct routes of HLA class I alterations in colon cancer 87
Figure 3. LOH and frameshift analysis was performed on sporadic RST that lost HLA class I expression. 
Only the tumors that presented with loss of one of the APM molecules or β2m were subjected to fragment 
analysis in their respective genes. The following repeats were analyzed for frameshift mutations: HLA A: 
1 – 4th exon 7(C), 2 – 5th exon 3 (GGA); HLA – B: 3(GA) & 3(CA);β2m: 1 – 1st exon 4(CT), 2 – 2nd exon 4(GA) 
& 5(A), 3 – 2nd exon 5(A); TAP1: 1 – 1st exon 5(C), 2 – 3rd exon 5(T), 3 – 8th exon 5(G), 4 – 10th exon 5(G), 
5 – 11th exon 6(G) & 5(A); TAP2: 1 – 2nd exon 6(C), 2 – 9th exon 5(G); Tapasin: 1 – 2nd exon 5(G), 2 – 3rd exon 
5(C), 3 – 4th exon 6(C), 4 – 5th exon 5(G); Calnexin: 1 – 7th exon 5(A), 2 – 8th exon 5(A), 3 – 11th exon 8(T); 
Calreticulin: 1 – 3rd exon 5(G), 6th exon 5(C); ERp57: 1 – 5th exon 6(T), 2 – 6th exon 6(A), 3 – 13th exon 6(C); 
LMP2: 1 – 2nd exon 5(G), 2 – 6th exon 5(G); LMP7: 1st exon 6(C) (key: ins – insertion; del – deletion; 0 – no 
mutation). LOH analysis of the 6p chromosome was also performed with the following markers: 1 – MOGc, 2 
– D6S510, 3 – C125, 4 – C141, 5 – D6S2444, 6 – TAP1, 7 – M2426 (Key: Black – Loss of heterozygosity; Striped 
– non informative marker; White – Retention of heterozygosity).
Figure 4. LOH and frameshift analysis was performed on HNPCC tumors that simultaneously lost HLA class 
I and β2m expression. LOH markers: (see legend from Figure 3 for key). Frameshift markers:HLA A: 1 – 4th 
exon 7(C) 2 – 5th exon 3 (GGA); HLA – B: 3(GA) & 3(CA); β2m: 1 – 1st exon 4(CT), 2 – 2nd exon 4(GA). & 5(A), 
3 – 2nd exon 5(A) (key: ins – insertion; del – deletion; 0 – no mutation; IHC -immunohistochemistry).
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immunohistochemical staining, one presented 
with a frameshift in an HLA gene (case 39, Figure 
3, Table 3) while 3 other cases showed LOH of the 
markers adjacent the HLA genes (cases 7, 44 and 
67). One frameshift mutation was found in the 
Tapasin gene in a MSS case (case 62). From 15 
HNPCC tumors that lost β2m expression at least 
one mutation was found in 8 cases (Figure 4). 
Three of the latter showed 2 mutations localized 
in different stretches. In the remaining 17 HNPCC 
cases that solely lost HLA class I expression, only 
4 showed genetic abnormalities. LOH was found 
in the HLA region in cases h16, h56 and h120 
(data not shown). A frameshift mutation in one 
of the HLA genes (HLA B) was found in one case 
(h99, Figure 4). In neither of the 2 HNPCC cases 
that immunohistochemically lost the expression 
of one of the APM components an APM frame-
shift mutation was found.
5.  disCussion
Abnormalities in HLA class I cell surface expres-
sion are commonly observed in tumors and are 
interpreted as a mechanism by which tumor 
cells evade the host immune system [1]. In 
colorectal cancer, especially in MSI-H tumors, the 
high degree of lymphocytic infiltrate in some 
cases may suggest an active immune response 
during tumor development [41,42]. Moreover, 
MSI-H tumors might cause increased immune 
reactivity as a consequence of the high amounts 
of aberrant frameshift peptides they generate 
[8,18]. A selective pressure by CTLs upon these 
tumors would favor the outgrowth of tumor 
cells that lost HLA class I expression at the cell 
surface allowing them to surpass the action of 
the immune system.
Figure 5. Genetic analysis performed on tumors that have lost HLA class I expression. The different peaks 
correspond to different sizes from the PCR-amplified products. Peaks corresponding to the normal samples 
are represented in green whereas tumor samples are represented in blue. A, LOH analysis performed on 
the RST 41 sample with the polymorphic marker C141. The total loss of a normal allele (on top) illustrates 
the technical advantage of using flow cytometric sorting to identify LOH events. B, Frameshift mutations 
identified in different members of the APM machinery. On top a homozygous deletion in the sample RST 65 
on the 4th exon of the Tapasin gene is shown. On the bottom, a heterozygous deletion in the sample RST 
18 on the second exon of the TAP2 gene is shown. C, Frameshift mutation identified in one HNPCC case (h4) 
in the 2nd exon of the β2m gene. Because flow sorting was not performed in the HNPCC cases, we cannot 
determine whether the frameshifts are homo- or heterozygous due to contamination with normal DNA.
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Applying immunohistochemistry on tissue 
arrays, we compared HLA class I expression in 
both sporadic RST (MSI-H and MSS sub-groups) 
and HNPCC tumors. RST were chosen because of 
the high percentage of MSI-H cases in this specific 
tumor type [43]. Indeed, immunohistochemical 
staining with mAb showed that HLA class I loss 
was frequent in the MSI-H cases analyzed when 
compared to their MSS counterpart. This find-
ing supports the hypothesis that MSI-H tumors 
face greater selective pressure to lose HLA class 
I expression, as described by Kloor et al[8]. How-
ever, we have shown for the first time that dis-
tinct molecular mechanisms underlie HLA class I 
loss in sporadic MSI-H and HNPCC colon cancers. 
In the latter, HLA class I loss was preferentially 
associated with that of β2m, while in the former 
HLA class I loss was associated with that of one or 
more APM components (p < 0.0001).
We investigated the genetic abnormalities 
underlying the HLA class I loss of expression. 
They included LOH on chromosome region 
6p21.3 (encompassing HLA class I and TAP 
genes), mutations in APM components and 
mutations in β2m.
Loss of heterozygosity at 6p21.3 was most 
prevalent in MSS tumors. This is consistent with 
the observation that these tumors frequently 
possess gross chromosomal aberrations and 
are often aneuploid [13]. Moreover, since LOH 
events in MSS tumors normally comprise large 
areas of a chromosome, LOH on 6p21 might 
not be a direct consequence of selective pres-
sure directed to the loss of HLA expression but 
instead to other genes within the same chro-
mosomal region. The general absence of LOH in 
MSI-H tumors suggests that this is not the major 
mechanism by which the cells abrogate HLA 
class I expression.
The genome’s coding regions contain multi-
ple microsatellite repeats, which are considered 
hotspots for mutations in mismatch repair-defi-
cient tumors [43]. Such repeats are also pres-
ent within the exons of the APM components, 
β2m, HLA-A and HLA-B genes. In about half of 
the MSI-H cases, loss of expression of HLA class 
I was concordant with the detection of one or 
more mutations in these genes. We have discov-
ered novel mutations in the antigen presenting 
machinery genes; Tapasin, Erp57, Calreticulin and 
Calnexin in colorectal cancer. Previous reports 
associated the loss of HLA class I expression in 
MSI-H tumors with defects on β2m molecule 
[7,9]. However, the authors did not distinguish 
the sporadic/hereditary nature of the tumors 
that were studied. We cannot exclude that the 
MSI-H cases included in these studies were 
mainly HNPCC tumors.
The reason sporadic MSI-H tumors would tar-
get APM members for inactivation and HNPCC 
RST Mutation description
18 TAP2 (341–346)del1 – het
39 HLA-A (621–627)ins1 – het
65 β2m (341–345)del1 – hom; Tapasin (1217–1222)del1 – hom;
 Calreticulin (418–422)ins1 – hom
69 TAP1 (362–366)del1 – hom
78 ERp57 (675–680)del2 – hom; ERp57 (1459–1464)del1 – hom
90 HLA-A (621–627)ins1 – het; Calnexin (1476–1483)del1 – het
94 Tapasin (1217–1222)del1 – het
table 3. Frameshift mutations description in RST
ins – insertion; del – deletion; hom – homozygous; het – heterozygous; the numbers before and after del/
ins indicate the location of the microsatellite repeat containing the frameshift mutation and the number of 
affected nucleotides respectively.
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would target the β2m chaperon is unclear. One 
possibility worth further exploration is that the 
various mutations suggest different immune-
escape mechanisms for thwarting distinct anti-
tumor responses. HNPCC tumors can have an 
age of onset before the 5th decade of life while 
sporadic MSI-H tumors appear generally around 
the 7th decade of life [43]; one would therefore 
predict that the alertness and robustness of 
the immune system would be higher in HNPCC 
patients leading to a stronger, or at least differ-
ent selective pressure on the latter. Furthermore 
it has been recently suggested that the JC poly-
oma virus plays a role in the oncogenicity of 
colon tumors with an identical phenotype to 
sporadic MSI-H tumors [44]. Although specula-
tive, the presence of the JC virus might be impli-
cated in a different immune response between 
sporadic MSI-H and HNPCC tumors.
The advantages of different escape mecha-
nisms (loss of APM members vs. abrogation of 
β2m) are not understood. The only known func-
tion of APM members is facilitating the expres-
sion of HLA classical molecules in complex 
with endogenous peptides. Thus, one would 
expect that only these HLA molecules would 
be affected by failure of the antigen processing 
machinery. On the other hand, it is accepted 
that cell surface expression of non-classical 
HLA molecules (e.g. HLA -G, -E) also depends 
on β2m, so the function of these highly special-
ized molecules would be compromised if β2m 
were mutated or lost. These molecules might 
play an important role in regulation of immune 
cell activity by inhibiting or activating its func-
tion. Therefore, MSI-H sporadic tumors that 
have lost expression of both HLA and an APM 
component and HNPCC tumors with lost β2m 
expression might behave differently or present 
a different kind of interaction with cells from 
the immune system. For instance, Yamamoto 
et al. have described a correlation between 
β2m mutations and unfavorable prognosis in 
colorectal cancer [45].
We separately analyzed the presence of the 
characteristic BRAF V600E somatic mutations in 
the RST cohort (data not shown). Forty-percent 
of MSI-H sporadic tumors presented with this 
mutation which was absent in the MSS tumors. 
It was previously described that this mutation 
is also absent in HNPCC tumors [46]. V600E was 
distributed equally between tumors that lost vs. 
retained expression of HLA class I in the sporadic 
MSI-H cases.
6.  ConClusion
HLA class I aberrations are found at varying 
frequencies in different colorectal tumor types 
and are caused by distinct genetic mechanisms. 
Chiefly, sporadic and hereditary MSI-H tumors 
follow different routes toward HLA class I loss 
of expression supporting the idea that these 
tumors follow different evolutionary pathways 
in tumorigenesis. The resulting variation in 
immune escape mechanisms may have reper-
cussions in tumor progression and behavior.
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1.  towards MoleCular diagnosis, 
treatMent and Prevention oF 
Colon CanCer
Tumours arising from various parts of the colon 
have long been considered and treated as iden-
tical pathological entities. However, accumulat-
ing studies on (molecular) tumour development 
have shown that distinct colon tumour subsets 
differ in important clinical parameters such as 
frequency of dissemination and response to 
adjuvant treatment. Although surgical excision 
will remain inevitably the major step of treat-
ment irrespective of the tumour type, to design 
(customized) therapeutic strategies it is essen-
tial to discriminate distinct tumour subsets by 
molecular analyses in advance [1]. Insight into 
the steps of tumorigenesis may eventually lead 
to cancer prevention by enabling early detec-
tion of precursor lesions, eliminating risk factors, 
or even vaccination [2, 3].
 Concerning the latter, the identification of 
altered HLA class I expression in colon tumours, 
especially in those with mismatch repair (MMR) 
deficiency on a sporadic basis or in the context of 
the Lynch syndrome, has given immune escape 
processes a definite position on the roadmap to 
colon cancer. This observation might support 
the potential of immune-mediated eradication 
as a preventive or therapeutic measure. The vari-
ation in type of HLA alteration among different 
tumour subtypes may suggest as yet unresolved 
differences in immune editing. Such differences 
probably have repercussions on the applicability 
of immune therapy approaches for colon cancer.
2.  tiMing oF Colon CanCer iMMune 
resPonses
The studies presented in this thesis have solely 
focused on the nature of immune escape 
mechanisms in primary colon tumours; we did 
neither study the onset of events during tumour 
progression, nor did we study tumour metas-
tasis. In other words, the position of immune 
escape on the roadmap is, to date, unknown. 
Insight into the position on the timeline may 
reveal essential information on the type and 
the effect of both the immune edit and immune 
escape mechanisms. For instance, the amount 
and type of displayed tumour-antigens will vary 
during stages of tumour development, which 
might determine whether this leads to tumour 
immune tolerance or attack [4, 5].
Another question unanswered is the onset 
of the ‘danger signal’. This signal is normally 
evoked at the earliest start of inflammation 
and is able to define the cascade of follow-
ing immune response. It may even lead to loss 
of systemic tolerance [4]. Inflammation is a 
natural response to any tissue damage and is 
microscopically already visable in adenomas. 
Consequently, the danger signal is evoked dur-
ing the adenoma stage, thus before invasion of 
the surrounding tissue starts. Interestingly, in 
Lynch syndrome-adenomas increased tumour-
infiltration of lymphocytes was found only in 
MMR deficient tumours which suggests that 
this immune response is secondary to the MMR 
knock-out [6].
Finally, the immune response to metastases 
needs to be studied. As discussed previously, 
dissemination is not necessarily a roadblock on 
the roadmap to cancer. Therefore, metastasiz-
ing cancer cells may be challenged by the same 
type of adaptive immune responses, albeit that 
they will additionally be confronted more easily 
by the innate immune system (including natural 
killer cells) as they migrate through the lymph or 
bloodstream. Alternatively, they might evoke a 
second danger signal or give positive-feedback 
to the primal danger signal as a result of tissue 
damage at the site of metastasis [7].
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3.  MisMatCh rePair deFiCient 
tuMour iMMunity
The relation of immune response evocation 
and tumour antigen display is of particular 
interest in DNA repair deficient tumours. We 
identified frequent HLA alterations in both 
sporadic MMR deficient tumours, and in Lynch 
syndrome-related tumours; additionally, it has 
been frequently identified in MUTYH-associated 
polyposis-related tumours [8]. Due to deficient 
DNA repair both of these types of tumours 
accumulate a high amount of DNA errors that 
potentially could lead to an acceleration of 
tumour progression compared to DNA repair 
proficient tumours. Such acceleration has been 
observed in the adenomatous phase of Lynch 
syndrome-tumours [9]. In the case of MMR defi-
ciency, proofreading errors result in frame-shift 
encoded proteins that may be, once processed 
to peptides, loaded on HLA class I molecules and 
transported to the cell surface, presented as ‘for-
eign’ antigens; some have indeed been shown 
to be potentially immunogenic [10-12]. Addi-
tionally, microsatellite mutations are frequently 
found within the untranslated regions (UTR) of 
genes [13]. Such mutations would not lead to 
an altered protein product. Although we did not 
observe it for the IFNGR1, mutations of the UTR 
can affect RNA stability leading to functional 
inactivation as has been shown for the BMPR2 
[14].
The frameshift-mutated antigens need to 
accumulate into a large enough amount of 
protein in order to lead the necessary cross-pre-
sentation of dendritic cells to effector cytotoxic 
T cells. Newly designed protein accumulation 
assays and RNA stability assays have been devel-
oped to predict such [15-17]. The results of these 
pre-screening assays will most likely limit the 
potential pool of MMR tumour-antigens as well 
as the repertoire of applicable immunogenic 
frameshift-mutated antigens for vaccination 
strategies.
The identification of distinct molecular 
mechanisms of HLA alteration between the 
sporadic and hereditary mismatch repair defi-
cient colorectal tumour subsets suggests that 
they are related to distinct anti-tumour immune 
responses. What would cause that difference? 
Patients suffering from the Lynch syndrome may 
display a mild degree of microsatellite instabil-
ity throughout the body due to their inherited 
heterozygous mismatch repair gene mutation 
[18, 19]. The latter would suggest a role of haplo-
insufficiency of MMR defects. In contrast to spo-
radic MMR deficient tumours, in Lynch syndrome 
cases a low level of frameshift-mutated antigens 
may have been displayed to the immune system 
during or even before tumour formation [20]. 
The latter might result in a different danger sig-
nal. Whether it would lead to immune tolerance 
or, oppositely, to a stronger immune response is 
not known.
Active adaptive cell-mediated immune-
response (Th1) as detected by intra-tumour infil-
trate phenotype and gene expression profiles 
have been related to a favourable disease-free 
survival of sporadic colorectal tumours, irre-
spective of tumour type, clinical classification, 
or immune escape mechanisms [21]. The protec-
tive property of the elevated immune response 
may be situated locally in reducing the number 
of disseminating tumour cells, as well as in the 
periphery in controlling occult tumour growth 
from dormant metastasised tumour cells [22, 
23]. The acquisition of HLA alterations may lead 
to opposite effects on clinical behaviour and 
patient survival [24-26]. These studies however 
are limited and show somewhat contradictory 
results. In sporadic colorectal tumours it may be 
associated with a favourable prognosis, whereas 
in Lynch syndrome-tumours it has been associ-
ated with a poor prognosis. Whether this can 
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explained by the type of immune escape mech-
anism itself (e.g. the capacity to escape natural 
killer cell annihilation or not) or by intrinsic co-
existing tumour (or immune-response) features 
could so far not be concluded [27].
Further research is needed to answer these 
intriguing questions. It would not only help us 
to understand why the distinct immune escape 
mechanisms are employed, but would also 
clarify the immune potential already present in 
colon cancer patients. This will lead to important 
clues in designing appropriate adjuvant immu-
notherapy or even preventive vaccination of 
colon cancer.
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This thesis is about colorectal cancer, cancer 
of the large intestine. Colorectal cancer has a 
high prevalence in the Western World includ-
ing the Netherlands. The colon is an abdominal 
organ that consists of multiple regions starting 
with the cecum (including the appendix), turn-
ing into ascending colon, transversing colon, 
descending colon, then sigmoid en finally the 
rectum which ends in the anus. Until a decade 
ago, cancers developing in any of those regions 
were considered identical. However, after the 
introduction of new molecular research tech-
niques we know this is not the case. It is now 
firmly established that colorectal cancer com-
prises different types of cancer. It all starts with 
just one cell escaping the ‘social control’ mecha-
nisms needed to maintain the balance between 
cell proliferation and cell loss and preservation 
of normal tissue architecture and function. This 
cell has gained a growth advantage leading to 
clonal outgrowth of its offspring. To develop into 
a malignant tumour (cancer) these cells need to 
acquire many distinct capacities, but how and 
when these capacities are acquired depends on 
the type of cancer. The driving force in cancer 
development is not unlike Darwinian evolu-
tion viz. ‘survival of the fittest’ on a microscopic 
scale. Newly acquired properties are passed on 
to daughter cells by mutations in DNA as well as 
by stable alterations in the expression of genes 
(epigenetic changes). Eventually the increas-
ingly dysregulated cells are able to invade sur-
rounding tissue increasing the risk of metastasis.
To respond to this the human body may call 
for the immune system. But this is far from easy 
since cancer cells pretty much look like healthy 
cells. They are hard to recognize. Nevertheless, 
accumulating evidence has shown that it is pos-
sible. Unfortunately, cancers develop ways to 
circumvent which leads to immune escape.
In this thesis we study immune escape in 
colon tumours, in particular the alterations 
in molecules enabling the immune system to 
recognize the tumour cells. These are so-called 
Human Leukocyte Antigen class I molecules 
who also play a major role in organ transplant-
rejection. Furthermore we untangled distinct 
colon tumour subsets, in order to study the 
tumour-immune interaction more closely and to 
be able to predict it.
In the general introduction in chapter 1 some 
of the current views on the molecular roads to 
(colon) cancer development relevant for this 
thesis are summarized. Based on the type of 
genomic or DNA alterations two main catego-
ries of colon cancer can be distinguished. The 
first category is characterized by chromosomal 
instability (CIN) which is associated with inher-
ited or acquired mutations of the APC tumour 
suppressor gene. Patients with inherited APC 
mutations suffer from the Familial Adenomatous 
Polyposis (FAP) syndrome that is characterized 
by hundreds to thousands of colorectal polyps 
and a high risk of cancer. The second category 
comprises colon tumours caused by defects 
of DNA mismatch repair leading to instability 
of microsatellite DNA sequences (microsatel-
lite instability or MIN). Germline mutations in 
the mismatch repair genes cause hereditary 
Lynch syndrome, which is characterized by a 
high risk of cancer including colorectal cancer 
and endometrial cancer. Next the interplay 
between tumour cells and the immune system 
summary
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is outlined. A model of the different processes 
involved in the genesis of a specialized adaptive 
anti-tumour immune response is shown. Finally, 
the distinct ways of immune escape, in particu-
lar alterations of the HLA class I molecules are 
discussed.
In the study described in chapter 2 we investi-
gated the value of immunohistochemistry for 
the identification of mismatch repair defects. 
This involves the use of specific antibodies that 
recognize mismatch repair gene products and 
have been labelled with an enzyme producing 
a coloured reaction product. The presence or 
absence of staining in tissue sections can be 
inspected by microscopy and indicates whether 
the mismatch repair genes function normally 
or are defective. Mismatch repair defects cause 
shortening or expansion of repeated DNA 
sequences called microsatellites and microsatel-
lite instability (MSI) which can be demonstrated 
by DNA analysis. We compared the performance 
of immunohistochemistry with that of MSI anal-
ysis for the detection of mismatch repair defects 
on colorectal and endometrial tumours from 
Lynch syndrome patients. Using antibodies for 
three different mismatch repair gene products 
we show that immunohistochemistry reliably 
detects defects in mismatch repair genes.
In chapter 3 we extended the immunohisto-
chemistry approach in a large series of heredi-
tary colon tumours. We constructed a tissue 
micro array using multiple 0.6 mm cores of 
tumour tissue. The information obtained from 
these small tissue samples appeared to be suf-
ficient for identification of mismatch repair 
defects. We now acquired a powerful tool to 
study large series of colon tumours with preser-
vation of essential information on the molecular 
subtype.
Next we studied colon tumour immune escape 
mechanisms. In chapter 4 we describe the iden-
tification of a mutation of the IFNGR1 gene in 
MIN tumours. In up to 59 percent of hereditary 
cases a mutation was found. It concerns a muta-
tion of a microsatellite region within the regula-
tory region of a gene that codes for a receptor 
of interferon-gamma (IFN-γ). IFN-γ is a small 
molecule that immune cells need to prepare 
for attack. It upregulates the expression of HLA 
class I molecules and makes target cells more 
vulnerable to attack by cytotoxic T cells. We were 
curious whether the mutation would protect 
tumour cells against such an assault. We tested 
this on living, cultured cells from both CIN- and 
MIN tumours (the latter all bearing IFNGR1 
mutations). Now we could compare their reac-
tions to IFNγ. We appeared to be wrong. MIN 
colon tumours remained equally sensitive to 
IFNγ, with respect to upregulation of HLA class I 
molecules and vulnerability to one of the attack 
mechanisms used by T cells. The mutations 
seemed to have no functional consequence, 
therefore probably do not contribute to colon 
cancer development, nor immune escape.
In chapter 5 we describe the study of HLA class I 
molecules in colon cancer. HLA class I comprises 
a large family of proteins, which makes it rather 
complicated to study. Each HLA class I molecule 
consists of two chains, a light chain and a heavy 
chain. The former is identical in all cases. How-
ever, the heavy chain is highly variable and is 
represented by 6 isotypes of which the genes 
have distinct locations (loci) on the short arm of 
chromosome 6 and which are indicated HLA-A to 
G. Each locus has many variants, polymorphisms, 
especially HLA-A (over 120) and HLA-B (over 
250). Every human being has two copies of each 
locus, alleles, as we inherit one from our father 
and from our mother. Usually, this concerns two 
distinct polymorphisms. So the number of allele 
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combinations is huge and this abundant vari-
ability has an evolutionary benefit viz. minimiz-
ing the chance of infective pathogens to remain 
unnoticed.
We set out to study the expression of indi-
vidual HLA molecules. The use of 4 colour flow 
cytometry enabled us to study the quantitative 
expression of distinct alleles in freshly isolated 
single tumour cells obtained by dissociation of 
primary tumour tissues. Since tumours consist 
of multiple cell lineages, including various types 
of normal cells, we used three colours of fluores-
cence to discriminate those. The fourth colour 
was used to label the HLA molecules on the cell 
surface. The fluorescent dyes were coupled to 
specific antibodies, of which we needed a large 
panel.
We identified HLA alterations in 38 percent 
of the tumours. Furthermore, we discovered 
that the alterations conferred to either of two 
patterns. Either just one allele was deleted, or 
four alleles jointly showed diminished expres-
sion (although not all HLA class I molecules were 
lost). Finally, the distinct patterns were associ-
ated with distinct tumour subtypes viz. MIN 
tumours and tumours from the proximal colon.
In comparison to the results from immu-
nohistochemistry, those from flow cytometry 
proved to be more consistent. However, the 
four-allele-diminution pattern as observed in 
MIN tumours was also distinguishable with use 
of immunohistochemistry. This opened up the 
opportunity to study larger series using the tis-
sue micro array technique.
The high frequency of HLA alterations in MIN 
tumours is remarkable. It suggests a strong selec-
tive pressure present forcing tumours to escape 
the immune system. Previous studies support 
this hypothesis. MIN tumours are more heavily 
infiltrated by T cells. Possibly, this is related to the 
relative abundance of frameshift- and otherwise 
mutated proteins (even in the absence of any 
benefit as shown in chapter 4). Microsatellite 
instability may have its disadvantages. To see if 
this hypothesis was consistent, we compared 
sporadic MIN cases to hereditary cases. This 
is described in chapter 6. We analysed large 
series of sporadic proximal colon tumours, MIN 
tumours, and Lynch syndrome-tumours. We 
studied the distinct HLA patterns as well as the 
underlying molecular mechanisms. We searched 
for mutations in HLA alleles, in the gene encod-
ing the β2-microglobulin light chain (B2M), and 
in genes encoding proteins of the antigen pro-
cessing machinery (APM). The latter is needed 
for the assembly of HLA molecules, and in 
particular for charging them with small pieces 
of protein, the antigens. These antigens make 
the difference as they determine whether a T 
cell comes into action or not. Without antigens 
HLA molecules are useless and not even trans-
ported to the cell surface. We found mutations 
in several genes viz. B2M, HLA-A, as well as in 
the APM members TAP1, TAP2, tapasin, calnexin, 
calreticulin, and ERP1. In other cases the entire 
chromosomal region encoding the HLA-alleles 
(chromosome 6p21.3) was lost. This is called 
loss of heterozygosity (LOH). Interestingly, dis-
tinct mutations were limited to distinct tumour 
subsets. B2M mutations were found in Lynch 
tumours. In sporadic MIN cases, mutations of 
HLA-A or APM members were observed. LOH of 
6p21.3 was observed in CIN tumours.
What does this tell us? Although the exact reason 
for the distinct HLA alterations is unknown, it is 
evident that colon tumours, in particular in the 
proximal colon are under quite some pressure to 
modulate the immune-tumour dialogue. In chap-
ter 7, this is discussed in more detail. Recent stud-
ies have shown that Lynch tumour cells do bear 
mutation-derived antigens which can give rise 
to specific cytotoxic T cells that are able to attack 
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them. Whether feasible therapeutic or preventive 
immune based modalities can be designed is 
something to be addressed in the future.
In summary, this thesis describes molecular 
methods to distinguish separate colon tumour 
entities. Furthermore, it shows that distinct 
immune escape mechanisms, in particular dis-
tinct mechanisms of corrupting the HLA system, 
are operational in subsets of colon tumours. The 
apparent necessity of some colon tumours to 
circumvent the immune system might under-
score the potential of immune based therapy 
approaches. Alternatively, it may suggest that 
such therapies will only lead to selection of 
tumour cells with HLA alterations, limiting the 
value of these approaches. In general, the iden-
tification of distinct tumour types to be targeted 
by tailor-made therapy is essential study the suc-
cess of any applied strategy.
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Dit proefschrift gaat over dikkedarmkanker. 
Het komt in de westerse wereld (en dus ook in 
Nederland) veel voor. Maar wat is het nu eigen-
lijk?
De dikke darm is een groot orgaan in de 
buik en bestaat uit meerdere delen die elk hun 
eigen anatomische naam hebben. De dikke 
darm begint daar waar de dunne darm ophoudt 
en heet dan achtereenvolgens coecum (met de 
blinde darm), colon ascendens (van rechtsonder 
naar rechtsboven), colon transversum (dwars 
van rechts naar links), colon descendens (van 
linksboven naar onder), sigmoïd en tot slot 
endeldarm (rectum). Dan is de opening van de 
anus bereikt. Het is eigenlijk verbazingwekkend 
dat kwaadaardige gezwellen in al deze verschil-
lende gebieden lange tijd op een hoop werden 
gegooid. Maar door onderzoek met nieuwe, 
moleculaire technieken weten we dat dit niet 
terecht is en dat er wel degelijk verschillende 
subtypen onderscheiden kunnen worden.
Kanker is een gezwel (tumor) van woeke-
rende cellen. Cellen die alsmaar doorgroeien. 
Het ontstaat in eigen cellen en begint met de 
ontsporing van één enkele cel. Er is heel wat 
ontsporing nodig voordat de nakomelingen van 
deze cel zich tot een kwaadaardig gezwel kun-
nen ontwikkelen. Tegenwoordig zijn al een groot 
aantal moleculaire – en celbiologische verande-
ringen die deze ontwikkeling mogelijk maken 
in kaart gebracht. Hoe en wanneer deze veran-
deringen optreden verschilt voor de vele soor-
ten van kanker. Als drijvende factor speelt het-
zelfde mechanisme een rol als in Darwiniaanse 
evolutie, ‘survival of the fittest’, maar dan op 
micro niveau. De meest competitieve kanker-
cellen overleven en geven hun eigenschappen 
door aan dochtercellen via veranderingen in het 
genetisch materiaal, het DNA. Ook wordt daarbij 
de gevreesde eigenschap verkregen van groei in 
het omliggende weefsel dat voor uitzaaiingen 
kan zorgen.
Hoe komt het dat het lichaam daar niets 
tegen doet? Het menselijk lichaam kan reageren 
door het afweersysteem (het immuunsysteem) 
erop af te sturen. Dat is nog niet zo gemak-
kelijk. Kankercellen verschillen namelijk maar 
nauwelijks van gezonde cellen. En dus kan het 
immuunsysteem ze moeilijk herkennen. Toch 
zijn er genoeg aanwijzingen dat het in prin-
cipe wel mogelijk is. Alleen hebben sommige 
kwaadaardige tumoren weer manieren ontwik-
keld om dat te omzeilen. Dat laatste noemen we 
immuunmodulatie.
In dit proefschrift bespreken wij een manier 
van immuunmodulatie in dikkedarmtumoren. 
We bestudeerden veranderingen in bepaalde 
moleculen die nodig zijn om immuuncellen 
(leukocyten, witte bloedlichaampjes) in staat te 
stellen de kankercellen überhaupt te herken-
nen. Dat zijn de zogenaamde klasse-1-humane-
leukocytenantigeen-moleculen (HLA). Deze 
eiwitten zijn ook betrokken bij afstotingsreac-
ties na transplantatie. Ook hebben we gepoogd 
om de binnen de groep van darmtumoren 
verschillende subtypen te onderscheiden op 
moleclair niveau om zo iets meer te kunnen 
zeggen over de processen die betrokken zijn bij 
samenvatting
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immuunmodulatie. En om ze beter te kunnen 
voorspellen.
In het inleidende hoofdstuk 1 wordt een globaal 
overzicht gegeven van de huidige inzichten in 
ontwikkeling van (dikkedarm)kanker die rele-
vant zijn voor ons onderzoek. In het bijzonder 
wordt aandacht besteed aan de fasen in het 
proces waardoor normale cellen zich ontwik-
kelen tot kankercellen en de veranderingen 
in het DNA die hierbij een rol spelen. De twee 
bekendste routes voor het ontstaan van dik-
kedarmkanker worden besproken, nl. die voor 
CIN- en MIN-tumoren. Hoewel deze oorspronke-
lijk geïdentificeerd werden in twee verschillende 
erfelijke vormen van dikkedarmkanker blijken 
ook veel niet-erfelijke tumoren via één van deze 
routes te ontstaan. CIN, voor chromosomale 
instabiliteit, hangt samen met een verstoorde 
functie van het APC-eiwit. Geërfde veranderin-
gen (mutaties) in dit gen veroorzaken familiaire 
adenomateuze polyposis (FAP) dat wordt geken-
merkt door de ontwikkeling van honderden tot 
duizenden darmpoliepen met een hoog risico 
op kanker. MIN, dat staat voor microsatelliet 
instabiliteit, wordt veroorzaakt door defecten in 
de moleculen die betrokken zijn bij de reparatie 
van bepaalde DNA-beschadigingen. Mutaties in 
deze zogeheten ‘mismatch-repair’-genen blijken 
erfelijk te worden overgedragen bij patiënten 
met het syndroom van Lynch. Deze mensen 
hebben een verhoogd risico op de ontwikke-
ling van dikkedarmkanker, maar ook op andere 
soorten kanker waaronder die van het baarmoe-
derslijmvlies.
Vervolgens wordt de wisselwerking tussen 
tumorcellen en het immuunsysteem bespro-
ken. Een vereenvoudigd model laat de beno-
digde processen zien die uiteindelijk leiden tot 
een gerichte aanval van gespecialiseerde witte 
bloedcellen, de cytotoxische T-cellen, tegen 
tumorcellen. Het hoofdstuk wordt afgesloten 
met een beschrijving van de mogelijkheden 
waarmee tumorcellen deze aanval kunnen pare-
ren (immuunmodulatie). In het bijzonder is er 
aandacht voor de manier waarop de samenstel-
ling van HLA-moleculen kan worden veranderd.
Het eerste deel van ons onderzoek (hoofdstuk 
2) had tot doel een methode te ontwikkelen 
waarmee op een efficiënte en betrouwbare 
manier MIN-tumoren kunnen worden onder-
scheiden. Daartoe werden twee verschillende 
technieken, nl. microsatelliet-instabiliteits-
analyse (MSI) en immunohistochemie getest 
op een serie baarmoederslijmvliestumoren 
en dikkedarmtumoren van patiënten met het 
syndroom van Lynch. Bij MSI-analyse wordt 
de instabiliteit van bepaalde DNA-sequenties 
(microsatellieten) onderzocht. Deze micro-
satellieten veranderen van lengte, ze raken 
‘instabiel’, wanneer in tumorcellen het DNA-
mismatch-repairmechanisme niet goed meer 
werkt. Immunohistochemie maakt het mogelijk 
om de aanwezigheid van specifieke eiwitten in 
cellen en weefsels aan te tonen. Daarvoor zijn 
antistoffen gericht tegen deze eiwitten nodig. 
Door de antistoffen te koppelen aan een kleur-
stof kunnen de eiwitten gelokaliseerd worden. 
Wij gebruikten antistoffen die tegen drie van de 
mismatch-repair-eiwitten gericht waren. Door 
dunne plakjes tumorweefsel (weefselcoupes) 
hiermee te behandelen konden we door micros-
copisch onderzoek nagaan of die eiwitten 
verdwenen waren in de tumorcellen. Het bleek 
inderdaad mogelijk om betrouwbaar mismatch-
repair-defecten op te sporen en bovendien het 
gendefect dat hiervoor verantwoordelijk is te 
voorspellen.
Vervolgens onderzochten we of we deze 
methode ook konden toepassen op dikkedarm-
tumoren van patiënten met het syndroom van 
Lynch (hoofdstuk 3). Dat bleek inderdaad het 
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geval. Bovendien testten we de toepassing van 
immunohistochemie op een zogenaamde ‘tis-
sue micro array’, een verzameling van pijpjes 
weefsel van veel verschillende patiënten samen-
gebracht in één blokje. Daarmee is het mogelijk 
om in een keer heel veel (in dit geval 129) darm-
tumoren tegelijk te onderzoeken. De informatie 
uit de pijpjes bleek voldoende om de tumoren 
met mismatch-repair-defecten te onderschei-
den.
Nu konden we overgaan tot het onderzoek van 
mechanismen van immuunmodulatie (hoofd-
stuk 4). Allereerst ontdekten we een veelvoorko-
mende mutatie van het IFNGR1-gen in erfelijke 
MIN-tumoren. In 59 procent van deze tumoren 
werd deze mutatie gevonden. Het gen codeert 
voor de receptor van interferon-gamma (IFN-γ). 
IFN-γ is een signaalstof die door T-cellen wordt 
gebruikt ter voorbereiding op de aanval op 
tumorcellen. Het zorgt ervoor dat tumorcellen 
meer HLA aanmaken (waardoor ze beter herken-
baar zijn voor het immuunsysteem) en het maakt 
tumorcellen gevoeliger voor de aanval zelf. We 
hebben onderzocht of de mutaties hier tegen 
beschermden. Dit deden we door gekweekte 
cellen van CIN-tumoren en van MIN-tumoren 
met IFNGR1-gen-mutaties bloot te stellen aan 
IFN-γ. De CIN- en MIN-tumorcellen bleken in 
gelijke mate een toename van HLA moleculen 
te vertonen. Ook waren de MIN-tumorcellen niet 
meer of minder gevoelig voor één van de door 
cytotoxische T-cellen gebruikte aanvalsmetho-
den. Kortom, de veelvoorkomende mutatie in 
het IFNGR1-gen speelt waarschijnlijk geen rol bij 
immuunmodulatie.
We besloten om de expressie van HLA-klasse-I-
moleculen meer gedetailleerd te onderzoeken 
voor de verschillende typen dikkedarmtumoren 
(hoofdstuk 5). HLA-klasse-I bestaat namelijk uit 
een hele familie van eiwitten en dat maakt het 
behoorlijk ingewikkeld. Ten eerste is elk HLA-
molecuul opgebouwd uit twee ketens, een 
lichte en een zware. De lichte keten is bij alle 
HLA-klasse-I moleculen hetzelfde maar de zware 
HLA-klasse-I-ketens worden verdeeld in 6 typen 
(loci, HLA-A tot en met G). Daarbij zijn er echter 
per locus zeer veel variaties (polymorfismen), 
met name van HLA-A (meer dan 120) en HLA-B 
(meer dan 250). Ieder mens heeft twee versies 
van elk locus, zogeheten allelen, want we krijgen 
er een van onze moeder en een van onze vader. 
Meestal zijn dit twee verschillende polymorfis-
men. Die variatie is van belang want dit bepaalt 
het ‘repertoire’ van eiwitfragmenten dat aan de 
T-cellen gepresenteerd kan worden. Deze vari-
atie is dus ook van groot evolutionair belang om 
allerlei (virale) infectie-ziekten het hoofd te kun-
nen bieden door geïnfecteerde cellen zo snel 
mogelijk te herkennen en op te ruimen. De zeer 
vele combinaties van HLA-moleculen vormen 
dus een essentieel onderdeel van onze afweer 
tegen virale infectieziekten. Om de expressie 
van de verschillende typen HLA-moleculen in 
tumorcellen te onderzoeken hebben we gebruik 
gemaakt van vier-kleuren-multiparameter-flow-
cytometrie. Met behulp van deze gevoelige tech-
niek kan de hoeveelheid van de verschillende 
HLA-moleculen in individuele cellen gemeten 
worden. In korte tijd worden duizenden cel-
len geanalyseerd, waardoor een representatief 
beeld van de tumorcelpopulaties wordt verkre-
gen. De cellen worden losgemaakt uit stukjes 
tumorweefsel en vervolgens worden in verschil-
lende stappen de HLA-moleculen aangekleurd. 
Omdat in tumoren naast tumorcellen ook ver-
schillende soorten normale cellen voorkomen, 
gebruikten we drie kleuren om tumorcellen te 
onderscheiden en een vierde kleur om de hoe-
veelheid HLA-moleculen op het celoppervlak 
te meten. De kleurstoffen werden gekoppeld 
aan specifieke antilichamen die gericht waren 
tegen de verschillende soorten HLA-moleculen. 
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Omdat we afzonderlijk de expressie van HLA-A-
moleculen en HLA-B-moleculen onderzochten 
hadden we vanwege de grote variabiliteit een 
aanzienlijke verscheidenheid aan antilichamen 
nodig.
Allereerst zagen we dat veranderingen in 
HLA bij 38 procent van de dikkedarmtumoren 
voorkomen. Ten tweede ontdekten we dat deze 
veranderingen zich beperkten tot slechts twee 
patronen (in tegenstelling tot de op voorhand 
berekende grote variatie aan mogelijkheden): 
of tumoren schakelden één allel uit, of alle vier 
tegelijk. In de laatste groep was trouwens niet al 
het HLA verdwenen. Tot slot bleek dat de HLA-
veranderingen voorkwamen in twee subtypes 
tumoren: in MIN tumoren en in tumoren uit 
het proximale deel van de dikke darm (caecum, 
colon ascendens en het eerste stuk van de colon 
transversum).
We vergeleken de met flow-cytometrie 
verkregen resultaten met die verkregen met 
immunohistochemie, want die laatste techniek 
is beter toepasbaar op grote series van tumo-
ren en ook op gearchiveerd tumorweefsel. Het 
leerde ons dat immunohistochemie in dit geval 
veel minder betrouwbaar is. Wel konden we er 
één van de patronen van HLA-afwijkingen mee 
onderscheiden, nl. het patroon dat wij in MIN-
tumoren zagen.
Het grote aantal afwijkingen in MIN-tumoren 
suggereert dat deze tumoren meer onder druk 
staan van aanvallen van het immuunsysteem. 
Dat laatste is ook al eerder beschreven. Zo wor-
den er meer T-cellen in die tumoren gezien. 
Bovendien zou het heel goed kunnen samen-
hangen met het feit dat deze tumoren zoveel 
afwijkende eiwitten produceren (zonder dat ze, 
zoals we in hoofdstuk 4 lieten zien, bijdragen 
aan de ontwikkeling van de tumor). Wellicht 
werkt dat dan toch in hun nadeel. Om te kijken 
of deze hypothese juist was besloten we na te 
gaan of er een verschil is tussen spontane-MIN-
darmtumoren en erfelijke-MIN-darmtumoren. 
Dit wordt beschreven in hoofdstuk 6. We onder-
zochten daarvoor een grote groep tumoren. 
Deels tumoren uit het proximale deel van de 
dikke darm, waaronder spontane MIN tumoren 
en deels tumoren van patiënten met het syn-
droom van Lynch. Ditmaal onderzochten we 
niet alleen de patronen van HLA-veranderingen, 
maar zochten we ook naar de mechanismen die 
deze veranderingen veroorzaakten. We zochten 
naar mutaties in het DNA. Daarbij richtten we 
ons niet alleen op de HLA-allelen zelf, maar ook 
op de lichte keten, het β2-microglobuline (B2M) 
en op de kandidaten betrokken bij het bewer-
ken van antigenen. Die laatste worden tezamen 
aangeduid als ‘antigen processing machinery’ 
(APM). Het is een hele batterij van eiwitten die 
betrokken is bij de opbouw van HLA-moleculen 
en in het bijzonder het verwerken van stukjes 
eiwit, antigenen, die op HLA-moleculen worden 
geladen en door deze op het celoppervlak wor-
den ‘gepresenteerd’ aan patrouillerende T-cellen. 
Deze antigenen zijn essentieel, want zij bepalen 
of T-cellen de presenterende cel aanvallen of 
niet. HLA-moleculen die niet beladen zijn met 
antigenen hebben geen functie en worden zelfs 
niet meer naar het celoppervlak toegebracht.
We vonden mutaties in B2M, in HLA-A en in 
de APM-leden TAP1, TAP2, tapasine, calnexine, 
calreticuline en ERP1. Ook zagen we soms dat 
het hele gebied op chromosoom 6 (6p21.3) 
dat codeert voor de verschillende HLA-allelen 
weg was. Dit wordt ‘loss of heterozygosity’ 
(LOH) genoemd. Nog interessanter was dat het 
mutatiespectrum verschillen toonde tussen de 
verschillende typen tumoren. In Lynchtumoren 
vonden we met name B2M-mutaties, terwijl in 
spontane MIN-tumoren mutaties in HLA-allelen 
of in één van de APM-leden de overhand had-
den. Verder zagen we in CIN-tumoren LOH van 
6p21.3.
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Wat de reden is van die verschillen in afwijkin-
gen in HLA is nog onduidelijk. In ieder geval 
vertelt het ons dat er bij de ontwikkeling van 
dikkedarmtumoren, vooral die uit het eerste, 
proximale deel, een grote selectiedruk is om 
het immuunsysteem te ontduiken. Daar wordt 
in hoofdstuk 7 nog een korte beschouwing aan 
gewijd. Recente literatuur komt ter sprake die 
laat zien dat Lynchtumoren inderdaad een hoop 
verschillende antigenen kunnen presenteren 
die voor T-cellen het signaal kunnen geven 
om de tumorcel te doden. De resultaten uit dit 
proefschrift tonen dat een preventieve of thera-
peutische rol van tumorvaccins bij dikkedarm-
kanker verder moeten worden onderzocht.
Kort samengevat beschrijft dit proefschrift 
methoden om verschillende typen dikkedarm-
kanker van elkaar te onderscheiden. Daarnaast 
laat het zien dat deze te onderscheiden typen 
tumoren ook verschillen vertonen in mechanis-
men van immuunmodulatie, in het bijzonder 
in de manier waarop het HLA-systeem wordt 
uitgeschakeld. Deze bevindingen benadruk-
ken de kennelijke noodzaak van tumoren om 
het immuunsysteem te ontduiken en dat geeft 
weer hoop op therapievormen of vormen van 
preventie die gebruik maken van het immuun-
systeem om (beginnende) kankercellen te 
doden. Tegelijkertijd wijst dit proefschrift op het 
belang om bij het ontwikkelen van therapievor-
men rekening te houden met de moleculaire 
variatie tussen de verschillende vormen van 
dikkedarmkanker.
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